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Abstract
Inflammatory diseases and multiple human cancers are associated with increased cyclooxygenase-2
(COX-2) expression together with decreased expression of 15-hydroxyprostaglandin dehydrogenase
(15-PGDH). This has been hypothesized to lead to a milieu of bioactive lipids modulating angiogenesis
and cellular proliferation. Further insight into these processes were gained by traditional cell and
molecular biology approaches, which were combined with cutting edge liquid chromatography mass
spectrometry (LC-MS) methods to elucidate the function, disposition, and metabolism of a major COX-2/
15-PGDH derived metabolite, 11-oxo-eicosatetraenoic acid (11-oxo-ETE). 11-oxo-ETE was found to
possess significant anti-proliferative activity (IC50 2 microM) in human umbilical endothelial cells
(HUVECS), which was 5 times more potent than isomeric 15-oxo-ETE. The corresponding methyl ester
derivatives were even more potently anti-proliferative than the free acids. The gold standard method of
quantification, stable isotope dilution (SID) LC-MS, was applied to determine the absolute intra- and extracellular levels of oxo-ETEs in multiple cell lines. Maximal intracellular concentrations of 11-oxo-ETE were
0.02 ng/4x10^5 cells in human colon adenocarcinoma (LoVo) cells versus 0.58 ng/4x10^5 cells in
HUVECs. Its methyl ester derivative increased the intracellular concentration of free 11-oxo-ETE 3-fold.
Pharmacological inhibition of relevant transporter proteins increased anti-proliferative activity and the
intracellular pool of 11-oxo-ETE. Consistent with an observed structural homology to other bioactive fatty
acids, 11-oxo-ETE reduced canonical nuclear factor-kappa B signaling activity. LC-MS revealed a
mechanistic explanation of this activity via adduction to critical cysteine or histidine residues of the p50
subunit of the p50/p65 transcription factor. LC- high-resolution MS/MS approaches revealed that the oxoETEs underwent substantial intracellular metabolism. Two of the double bonds were reduced and novel
coenzyme A (CoA) thioesters were formed followed by reduction of all four of their double bonds. The
identification of novel CoA thioester metabolites could have important implications to detection and
function of the oxo-ETEs as well as other electrophilic polyunsaturated fatty acids in normal physiology as
well as in inflammation and cancer.
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ABSTRACT

INVESTIGATIONS OF BIOACTIVITY, DISPOSITION, AND METABOLISM OF LIPIDS
THROUGH LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY
Nathaniel W. Snyder
Ian A. Blair
Inflammatory diseases and multiple human cancers are associated with increased
cyclooxygenase-2 (COX-2) expression together with decreased expression of 15hydroxyprostaglandin dehydrogenase (15-PGDH). This has been hypothesized to lead to a
milieu of bioactive lipids modulating angiogenesis and cellular proliferation. Further insight into
these processes were gained by traditional cell and molecular biology approaches, which were
combined with cutting edge liquid chromatography mass spectrometry (LC-MS) methods to
elucidate the function, disposition, and metabolism of a major COX-2/15-PGDH derived
metabolite, 11-oxo-eicosatetraenoic acid (11-oxo-ETE). 11-oxo-ETE was found to possess
significant anti-proliferative activity (IC50 2 μM) in human umbilical endothelial cells (HUVECS),
which was 5 times more potent than isomeric 15-oxo-ETE. The corresponding methyl ester
derivatives were even more potently anti-proliferative than the free acids. The gold standard
method of quantification, stable isotope dilution (SID) LC-MS, was applied to determine the
absolute intra- and extra- cellular levels of oxo-ETEs in multiple cell lines. Maximal intracellular
5

concentrations of 11-oxo-ETE were 0.02 ng/4x10 cells in human colon adenocarcinoma (LoVo)
5

cells versus 0.58 ng/4x10 cells in HUVECs. Its methyl ester derivative increased the intracellular
concentration of free 11-oxo-ETE 3-fold. Pharmacological inhibition of relevant transporter
proteins increased anti-proliferative activity and the intracellular pool of 11-oxo-ETE. Consistent
with an observed structural homology to other bioactive fatty acids, 11-oxo-ETE reduced
canonical nuclear factor-kappa B signaling activity. LC-MS revealed a mechanistic explanation of
this activity via adduction to critical cysteine or histidine residues of the p50 subunit of the
p50/p65 transcription factor. LC- high-resolution MS/MS approaches revealed that the oxo-ETEs

vii
underwent substantial intracellular metabolism. Two of the double bonds were reduced and
novel coenzyme A (CoA) thioesters were formed followed by reduction of all four of their double
bonds. The identification of novel CoA thioester metabolites could have important implications to
detection and function of the oxo-ETEs as well as other electrophilic polyunsaturated fatty acids
in normal physiology as well as in inflammation and cancer.
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Chapter 1: Introduction
This thesis describes the application of liquid chromatography-mass spectrometry (LCMS) to study the bioactivity, disposition, and metabolism of lipids. Thus, a brief introduction to
lipids with a focus on one of the most abundant endogenous lipids, arachidonic acid (AA), is
provided in order to provide a framework for the research presented in this thesis. The relevant
nomenclature, structure, metabolism, roles of AA metabolites in disease, and methods for the
quantification of AA metabolites are discussed. The history of the scientific study of lipids is
storied and important to our understanding of human health and disease. Likewise, a primer on
the analytical methods and technologies used in this thesis provides an introduction to the novel
studies that have been conducted. As a central methodological theme of this thesis, the theory of
LC-MS has also been provided.

1.1 Lipids and Nomenclature
Lipids can be been defined as fatty or waxy organic compounds that are readily soluble in
nonpolar solvents such as ether but poorly in polar solvents such as water. This definition covers
a range of diverse molecules, and can be further refined by a multi-functional nomenclature of
lipids proposed by Fahy, et al. The nomenclature classifies lipids into eight categories; fatty acyls
(FAs), glycerolipids (GLs), glycerophospholipids (GPs), sphingolipids (SPs), sterol lipids, prenol
lipids, saccharolipids, and polyketides (5). This thesis covers mostly investigations into the first
group, the FAs (Chapter 1-7), but GLs, GPs and SLs are also discussed (Chapter 6-7).
FAs are structurally simple lipids that form the building blocks of more complex lipids and
can be classified as unsaturated or saturated based on the presence or absence, respectively, of
double bonds. FAs can be further described by number of carbons, number of double bonds, and
by position of the double bonds.

Subcategories of FAs can be grouped by distinct

physiochemical properties, emergent from chemical moieties present in the structures.

For

example, polyunsaturated fatty acids (PUFAs) are subject to oxidation by reactive oxygen and

2
nitrogen species as well as oxygenase enzymes. The resulting oxidized lipids function as a
diverse array of signaling molecules (6). When more than one double bond is present in a FA,
the connecting group is often a methylene moiety termed a bis-allylic configuration, and the
abstraction of a bis-allylic hydrogen is an important initiating step in enzymatic oxidation and lipid
peroxidation (7).
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Figure 1.1. Struture of AA, 1-stearoyl-2-arachidonoyl phosphatidylinositol, and
arachidonoyl-coenzyme A. (A) The structure of AA. Double bond positions indicated
by carbon number. The omega () and omega (-6) carbons are also labeled. Bis-allylic
hydrogens are indicated. (B) The structure of a glycerophospholipid with stearic acid at the
sn-1 position, AA at the sn-2 position, and a polar phosphoinositol head group at the sn-3
position. (C) The structure of arachidonoyl-Coenzyme A. The arachidonoyl acyl group is
linked to the coenzyme A molecule through a thioester bond in the carbonyl of AA.
As shown in Figure 1.1.A, the application of the above nomenclature can describe many
important elements about the FA being described. AA has 20 carbon atoms and 4 double bonds,
so it can be abbreviated as 20:4-6 or 20:4n-6, where the notation -6 derives from the double
bond at C14-C15 being five carbons away from the terminal carbon at C-20 (which is designated

4
by convention as ). Additionally, the FAs include the subgroup of acyl-coenzyme A (CoA)
thioesters (8), a topic covered in Chapter 7 and 8. In the case of the acyl-CoA species, the FA is
esterified through a thioester linkage to a bulkier CoA molecule.
Another class of lipids, the phospholipids, are ubiquitous and major components of all cell
membranes where they form lipid bilayers (9). Phospholipids can also serve as precursors for
bioactive products, or engage in signaling activities directly (Fig. 1.2).

Phospholipids are a

diverse class of biomolecules, but the structure of a typical GP, 1-stearoyl-2-arachidonoylphosphatidylinositol is shown in Figure 1.1.B. In this representative structure, glycerol is esterified
with stearic acid (18:0) at the sn-1 position, and it is esterified with AA at sn-2 position with a polar
phosphoinositol head group at the sn-3 position. The esterification of AA to yield more complex
lipids is an important part of the regulation of AA metabolism and physiology.

1.2 Arachidonic Acid Metabolism and Disease
Metabolism of AA is an active area of study because it involves the generation of diverse
biologically active lipid mediators, the eicosanoids (10). The eicosanoids derived from AA act via
G-protein coupled receptor (GPCR) agonism or potentially as nuclear transcription factor ligands
(6,11,12). They are involved in inflammation (13), cancer (14), and other physiological processes
by modulating signaling pathways (15), transcription factor activity (16), and gene expression
(17). The diverse roles of various eicosanoids in inflammation, cancer, and other processes are
described in more detail in Chapters 2, 3, 4, and 7.
In most animals, AA is a non-essential fatty acid because it can be synthesized from
linoleic acid (3). Free AA in mammals is tightly regulated and exists primarily as the esterified
form in PLs, GPs, and SLs (Figures 1.1 and 1.2). Release of AA by hydrolysis from esterified
lipid stores is an important step in AA metabolism, and critical in the physiological role of AA
metabolites. Esterified AA at the sn-2 position on phosphatidylinositol can be directly released
through hydrolysis of the PL by phospholipase A2 enzyme (18). Alternatively, phospholipase Cmediated hydrolysis of phospholipids can first occur at the sn-3 position.

The polar
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phosphoinositol head group is thereby removed, forming a diacylglycerol (DAG) which is acted on
by DAG lipase to release free AA (19,20). In the brain, arachidonylethanolamide (AEA) is an
endogenous cannabinoid neurotransmitter, and the substrate for fatty acid amide hydrolase,
which converts AEA into ethanolamine and AA (21). As shown in Figure 1.2, the tight control of
AA directly impacts the generation of eicosanoids in physiologically important pathways.
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1.3 Enzymatic and Non-enzymatic Biotransformation of AA
Transformation of AA through the cyclooxygenases (COXs) is one of the primary routes
of AA metabolism into potent lipid signaling mediators (Figure 1.2).

COX exists as two

isoenzymes, COX-1 and COX-2 (22). COX-1 is constitutively expressed in many cells and is
considered to function as a house-keeping enzyme where its products help to maintain normal
biological processes. COX-2 was identified independently by three groups as a COX isoenzyme
that is induced in response to cytokines, growth factors, bacterial endotoxin, and certain other
stimuli (23-25).
COXs are membrane bound proteins located on the inner and outer membrane of the
nuclear envelope, as well as the surface of the endoplasmic reticulum lumen (26). The enzymes
possess dual catalytic functions, containing both COX and peroxidase (POX) active sites. The
COX site converts AA into PGG2 and 11(R)- and 15-HPETEs, while the peroxidase site reduces
the hydroperoxide groups in PGG2 or HPETEs to the corresponding hydroxyl groups (Figure 1.2).
This results in the generation of PGH2 as well as 11(R)- and 15-HETEs (27).
The generally accepted mechanism of COX action involves a tyrosine protein radical
(10). The COX catalytic cycle begins when an alkyl hydroperoxide binds to heme in the POX site.
The hydroperoxide is reduced to the corresponding alkyl hydroxyl. The heme is thereby oxidized
4+

4+

.

to the oxyferryl Fe =O and a protoporphyrin radical cation (Fe =O ) is formed. This unstable
intermediate abstracts hydrogen from the
radical and an oxyferryl. The
in the COX active site.

385

385

Tyr side chain, resulting in the formation of

385

Tyr

385

Tyr radical then abstracts the pro-S hydrogen at C13 of AA bound

Tyr is adds a proton, while an allylic radical is formed at C13 of AA. The

C11-C12 double bond of AA relocates to C12-C13 and forms a conjugated double bond with
C14-C15 and the C13 radical is transferred to C11. Then oxygen is inserted at the C11 position.
The radical is transferred to oxygen, which rapidly attacks the C8-C9 double bond. This attack
forms a dioxygen (endoperoxide) bridge between C11 and C9, along with a C8 radical. This is
followed by a C8 radical attack of the C12-C13 double bond and formation of a C8-C12 single
bond, together with a C13 radical. After translocation of the C13 radical and C14-C15 double
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bond, a C15 radical is formed and followed by oxygen attachment to C15. Finally, this PGG2
precursor abstracts a hydrogen atom and forms the final PGG 2. PGG2 can then function as the
initial alkyl hydroperoxide and enter the POX site, where it is reduced to PGH 2. After several
cycles, COX will usually lose activity via a mechanism that may be related with the quenching of
tyrosine radicals or damage to the COX protein by free radicals (28). The mechanism leading to
HETE formation is less clear, but notably from the above mechanism, oxygen insertion in the
normal catalytic COX cycle occurs at C11 and C15, which would lead to the formation of 11- and
15-H(P)ETE.
COX is a target for the class of therapeutics known as non-steroidal anti-inflammatory
drugs (NSAIDs). Aspirin was the first described NSAID and differs mechanistically from other
NSAIDs, in that it converts COX-2 into a 15(R)-lipoxygenase (LOX) via covalent modification,
instead of completely inhibiting COX-2 activity. Acetylation of COX-1 via aspirin inactivates the
enzyme.

Other NSAIDs can be referred to as traditional NSAIDs (tNSAIDs) and include

ibuprofen, diclofenac, naproxen, and many others.

These tNSAIDs are usually competitive

inhibitors of COX and ultimately inhibit prostaglandin (PG) biosynthesis with a variety of effects
depending on the drug, dose, timing, co-administration, and selectivity of binding for COX-1/COX2 (29,30). For example, low dose aspirin will selectively inactivate platelet COX-1 for the life of
the platelet, but fail to achieve systemic effects of COX inhibition, resulting in an anti-thrombotic
effect while sparing the irritation of gastric mucosa due to inhibition of PG biosynthesis (31).
COX-2 specific inhibitors have been developed with the hope of reducing the side effect of gastric
irritation, although they have been associated with significant PG/thromboxane dependent
adverse cardiovascular events (29,32).
Aside from COXs, AA can also be metabolized by the lipoxygenase (LOX) family. LOXs
catalyze a dioxygenase type reaction, as opposed to the PG producing di-oxygen insertion and
cyclization of the COXs. The catalytic product of LOXs from AA is a n-6 hydroperoxy fatty acid
with a conjugated Z,E-diene system. Similar to the COX reaction, the unstable hydroperoxy
moiety is then reduced by cellular POXs to the corresponding hydroxyl group. The nomenclature
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for LOXs is based on the specificity of the enzyme for the carbon where molecular oxygen is
inserted. Humans possess at least five lipoxygenases. Of these five, two are pure 15-LOXs.
The other human LOXs, namely 5-LOX, 8-LOX, and 12-LOXs are reviewed elsewhere (33). The
non-human (and non-animal) lipoxygenases are beyond the scope of this thesis.
15-LOX-1 also termed reticulocyte 15-LOX, has been purified from human eosinophils and
leukocytes (34,35). 15-LOX-2 has been isolated and described from human skin. Expression of
15-LOX-2 was also observed in prostate, lung, and cornea (36). The specific reduced products of
15-LOX-1 from AA include 15(S)-HETE and 12(S)-HETE because of some 12-LOX-type activity.
15-LOX-2 produces pure 15(S)-HETE. Unlike COXs, LOXs do not have an absolute requirement
for acting on free AA. Thus, the possibility of oxidation followed by release by phospholipases
must always be considered for lipoxygenase products (33). 15-LOX-1 rapidly inactivates in a
turnover dependent mechanism, but 15-LOX-2 is catalytically stable. The role of 15-LOXs in
humans is complex and animal models give conflicting results, but an excellent review is
available (37). The Brash group at Vanderbilt University describes the possible functions of LOXs
as generators of signaling mediators (directly or through intermediates), peroxidation, or as
enzymes for lipid mobilization. Ongoing research into these roles is discussed in Chapters 2, 3,
4, and 7.
Besides enzymatic pathways, AA is also subject to autoxidation both in vitro and in vivo.
AA has four double bonds and three pairs of bis-allylic hydrogen atoms (Figures 1.1 and 1.2);
therefore, it is readily oxidized when it is exposed to air, free radicals, or heat (38). This instability
requires careful control of parameters to avoid or control for artifact formation during an
experiment.

While enzymatically produced AA metabolites are formed with enantiomeric

specificity, autooxidation of AA results in the formation of racemic products. The use of chiral
chromatography to separate the two enatiomers, discussed below, can differentiate these two
pathways of formation in simple systems (39).

Thus, both enzymatic and non-enzymatic

generation of eicosanoids, can generate a diverse array of products from the parent AA. The
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initial composition of this complex mixture of eicosanoids depends upon the enzymatic machinery
present and the physiochemical environment.

1.4 Further Metabolism of Eicosanoids
Total eicosanoid levels are controlled not only via COX/LOX dependent generation, but
also by eicosanoid catabolism (40).

Among the eicosanoid catabolism enzymes, 15-

hydroxyprostaglandin dehydrogenase (15-PGDH) has been studied the most intensively. 15PGDH is strongly down-regulated in numerous cancer cell lines and human cancers resulting in
the accumulation of pro-proliferative PGs, such as PGE2 (41).

Increasing 15-PGDH levels

reduces PGE2 and results in anti-proliferative effects in cell and mouse models (42,43).
Additionally, COX-2 inhibitor therapy alone fails in some patients who are 15-PGDH deficient,
suggesting that a combination of COX-2 inhibitors and inducers of 15-PGDH provide a better
chemoprevention approach (44).
15-PGDH preferentially converts the 15(S)-hydroxyl group on eicosanoids to a keto group
(45). For example, PGE2 undergoes 15-PGDH-mediated conversion to 15-keto-PGE2 which can
be further metabolized to 13,14-dihydro-15-keto-PGE2 by a specific reductase.
+

The primary

+

cofactor of 15-PGDH is NAD . A different type II 15-PGDH uses NADP as its cofactor, but has a
+

Km value two orders of magnitude higher than NAD dependent 15-PGDH when PGE2 is the
substrate (46). Molecules with a -6 hydroxyl group, such as the LOX-type product 15(S)-HETE,
are also readily oxidized by 15-PGDH (47). This suggests that 15-PGDH could also play an
important role in the metabolism of different oxidized fatty acids, which is a topic explored in
Chapter 2.
After being reduced, these α,β-unsaturated ketone containing fatty acids can undergo
glutathione S-transferase (GST)-mediated conjugation with glutathione (GSH) (48). The GSH
conjugates have higher polarity than their precursors, and they can be excreted out of cells
through relevant transporters (49). The interconnected metabolism and function of 15-PGDH
products are discussed in more detail in Chapters 2, 3, and 4.
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The localization of eicosanoids is also important to their function and metabolism. In the
setting of cancer, the generation, signaling, and metabolism of eicosanoids is partly controlled via
dysregulation of eicosanoid transporters (50).

This is consistent with the intracellular

biotransformation of eicosanoids such as PGE2 and action via GCPRs with binding pockets
facing the extracellular space. The transporters thought to be important to eicosanoids include
members of the family of Organic
Anion Transporters (OATs) and
the Multidrug Resistance Proteins
(MRPs)

of

Cassette

the

ATP-Binding

family

(ABC).

Specifically, the PG transporter

Table 1.1: The van Deemter equation for departure

(PGT) and OATP-D
carrier

mediated

provide

transport

for

from ideal chromatography. Simplified to H = A + B/
efflux of the eicosanoids (51).
+ C* from the original h= 2 dp + (2 Dm / ) + (8/^2)
(/ (1+)

2

2
)(df /D1

) Where A= Eddy diffusion term,

B=coefficient of longitudinal diffusion, C=coefficient of
mass transfer, D= coefficient of molecular diffusion
(m=mobile phase, l=liquid stationary phase), d=
diameter (p=particle, f=film), k=column capacity ratio,
=proportionality factor, h= plate height, =linear
velocity. The C term has been expanded to include
modern chromatographic instrumentation, and some
modern treatments have re-written the fundamental
equation. Adapted from (3,4).
3.

MRP4 has also been shown to
efflux eicosanoids, notably PGE2
(52).

MRP1 mediates efflux of

GSH-conjugates, including LOX
products (49).

Studies into the

effect of eicosanoids may need to
take into account the state and
relevance of transporters to any
bioactivity,

potency,

or

metabolism under investigation
as is further discussed in Chapter
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1.5 Liquid Chromatography-Mass Spectrometry for Metabolite
Measurements
LC uses the differential partition of a molecule of interest to a mobile phase (solvent) and
a stationary phase (column) to separate compounds from a complex sample. Thus, LC adds a
dimension, termed retention time, to the identity of the molecule being studied (an analyte).
Retention time reflects the physical interaction of the liquid chromatography separation (53). The
underlying factors of liquid chromatography can be expressed by the Van Deemter equation
(Table 1.1). In this equation, the resolving power in height equivalents of a theoretical plate is
explained by departure from the ideal chromatography caused by molecular diffusion, eddy
diffusion, and mass transfer coefficient (4). This equation explains how the characteristics of a
liquid chromatography method can be tuned to maximize the number of theoretical plates by
minimizing their theoretical height. This optimization would provide the best separation possible
between any set of molecules.

Driving improved chromatographic performance is thereby

dependent on the ideal packing of the column particle material, low dispersion, fit mass transfer
between phases, and optimum velocity of flow. Approaches to chromatographic performance in
metabolite analysis are further discussed in Chapter 6.
The chemistry of the column can provide varying selectivity for different compounds based on the
characteristics of the compounds being separated (charge, hydrophobicity and chirality) (39).
The nature of the solvents can determine the analyte interactions with the column to provide
reversed phase chromatography, where a polar solvent is transitioned to an increasing non-polar
solvent, or normal chromatography where a non-polar solvent is transitioned to a more polar
solvent. Column chemistries and solvent selection can be optimized to provide differing retention
times to even closely related compounds, including structural isomers difficult to resolve by other
methods (54). However, retention time is often an insufficiently specific dimension for accurate
analysis of related molecules or complex mixtures, thus additional terms are required for
identification and quantitation of a given analyte. This leads to the necessity of coupling LC to
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another instrument in order to provide additional data to describe molecules from a complex
mixture.
A powerful instrument called a mass spectrometer can be attached after the LC to
provide additional information about an analyte. The fundamental output of a mass spectrometer
is the determination of signal intensity for a given mass to charge ratio (m/z). The m/z is derived
from the mass of the molecule as well as the number of charges imparted to the molecule. By
definition a mass spectrometer must analyze a charged molecule so; mass spectrometers
actually measure the ions (charged species) of a given analyte.
A mass spectrometer operates on the principles of: generation of an ion (at the source),
separation of the ion (via a mass analyzer), and detection (at the detector). Each of these
segments of the mass spectrometer will be discussed sequentially in the following paragraphs,
starting with the ion source. The source of the mass spectrometer determines the type of ions
generated, and influences the resulting analysis.

Ion polarity can be either positive (+) or
negative (-), with the polarity
mode of detection imparting some
properties to the resulting data
based on the specifics of the
analyte (55). When coupled with
LC, the most widely used source
utilizes

atmospheric

pressure

ionization (API) (56). Analytes in

Table 1.2: The mass spectrometers employed in

the

this thesis. Mode of detection in terms of ion

desolvated by charged droplet

destruction through analysis for each instrument is
given. Separation in-time or in-space is given for

liquid

mobile

phase

are

collapse (electrospray ionization,
ESI) (57) or by applying a current
to a conducting needle under

each instrument for better understanding of the
atmospheric

discussion below and experimental design.
Operating resolutions used in this thesis are listed.
R=Resolution, t=time of detection, T= period of

pressure
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(atmospheric pressure chemical ionization, APCI) (58). Analytes are charged in solution for ESI
by adjusting the pH of the mobile phase, or by other techniques (e.g. derivatization).

High

temperature, nitrogen gas, a spray/source voltage, and/or vacuum at the source of the instrument
may also assist the desolvation process. Flow rates from the LC into the source can drastically
affect the nature and output of the source, and the resulting analysis and detection of ions (59).
Different analytes are often differentially compatible with ionization by distinct source types; often
a chemical knowledge or empirical approach is needed to determine the ideal conditions for
ionization, taking into account prior knowledge of matrix effects, solvent effects, thermal stability,
propensity for adduction, and stability holding charge (60).
The mass analyzer is the primary instrument used to distinguish ions with different m/zs,
given the resolving power of the mass spectrometer. A functional definition of resolution is the
m/z divided by the minimum m/z peak separation of ions with the same nominal mass expressed
in Da. (61). A larger value of resolution means better separation of peaks, or an isolated peak
with a smaller width as measured from the full width of the peak at half maximum of the peak
height (FWHM). Mass spectrometers featuring different analyzers are highlighted in Table 1.2.
Low resolution instruments, which typically operate at unit mass resolution, can only distinguish
two ions that differ in mass by 1 Da.

The TSQ, API4000, and LTQ are the low resolution

instruments used in this thesis. High resolution by contrast, could be up to 2,000,000 FWHM (or
higher) (62), giving neutron encoded mass defect specific information, but more practically runs a
range of 30,000 to 240,000 FWHM. An LTQ-Orbitrap XL and a FT-ICR are high resolution
instruments used in this thesis.

High resolution instruments confer much higher analytical

specificity than the corresponding low resolution instruments.
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Figure 1.4: Schematic of tandem MS experiments. (A) Product ion scan for
generation of a fragment ion spectra. (B) Precursor ion scan for detection of the set of
parent ions giving rise to a particular fragment. (C) Neutral loss scan for synchronized
detection of the set of ions that lose a given m/z upon fragmentation. (D) Ion
monitoring (Single/Multiple Reaction) for detection of a precursor/fragment pair.
Adapted from (2).
The interplay of the analyzer and detector results in different characteristics of the
resulting data acquired, such as scan rate (expressed in Hz), dynamic range, instrument specific
strengths and weaknesses, and an increasing requirement for data management strategies as file
size increases exponentially. The detector on mass spectrometers also plays an independent
role in analysis.

Amplification and interpretation of the signal is an important component of

detection due to the inherently weak signal generated by a low abundance ion. For induction
based detectors, such as utilized in the Orbitrap, Fourier transform is used to convert amplitude to
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a useable m/z. Characteristics, utilization, and the future applications of mass analyzers are
discussed in greater detail in Chapter 6 and the Conclusion.
n

Aside from resolution of a mass analyzer, tandem mass analysis (MS/MS or MS ) can be used to
improve sensitivity (increased signal/noise) and specificity and increase the information gained
from a mass spectrometry experiment (63). Tandem mass spectrometry can be tandem in space
where the elements are physically separated across analysis as in a transmission quadrupole
(e.g. triple quadrupole (64)) or time-of-flight instrument.

Alternatively, tandem in time based

analysis involves trapping the ions in a confined physical space, with separations occurring over
time, as in an ion trap (65,66). The type of analysis determines the type of experiment which can
be performed on the ions of interest. Analysis in space allows true precursor ion and neutral loss
scanning, where the ions are scanned through the first mass analyzer and a product ion is
scanned through the last mass analyzer. In the case of the neutral loss scan, the first and last
mass analyzers are operated at a given offset, so only an ion losing a certain value of m/z is
detected. Both analysis in time and analysis in space can perform product ion scans, where a
given ion is selected in the first stage, fragmented, and then the resulting product ions are
analyzed in the last stage.

The final type of tandem MS experiments is selected reaction

monitoring, where the first and last stages are set to a given mass range so a distinct precursor
and product ion are selected for. This type of analysis can be used to improve performance for a
given experiment by tuning sensitivity, specificity, and information gained. This thesis features
experiments conducted in all of these analysis modes, where specific instrumentation used for
such analysis is indicated in Table 1.2.
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Figure 1.5: ECAPCI with a PFB derivative of AA. The

and
derivatization and ECAPCI of AA with PFB resulting in the

improved
formation of a negative ion of AA is shown. This process improves
chromatographic
sensitivity and specificity by increasing the efficiency of ion
characteristics, including
formation for a molecule of interest.
retention

and

peak

shape, can be attained through simple derivatization schemes (54,58). The application of specific
derivatization techniques to analytical challenges are discussed in chapters 2 and 3. In particular,
this thesis takes advantage of liquid chromatography- electron capture atmospheric pressure
chemical

ionization-

mass

spectrometry

pentafluorobenzyl bromide (PFB) (58).

(LC/ECAPCI/MS)

via

derivatization

with

This technique can provide increased sensitivity and

specificity via increasing the ionization efficiency of a target analyte by tagging an electron
capturing group (PFB in this case) to the analyte of interest. The process of derivatization and
ECAPCI is shown in Figure 1.5.
Ultimately, LC-MS provides a highly sensitive and specific platform to measure a range of
analytes even from complex matrices (67). Advancements in high resolution and accurate mass
MS (68,69) coupled with bioinformatics and software platforms (70-72) have made MS the
optimal methodology for robust, sensitive, high-throughput metabolomic and proteomic analyses
(73,74).

Regardless of these advances, a LC-MS system is not truly quantitative, even for

relative measurements, without the application of additional analytical methodologies.
Appropriate internal standards are especially critical when measuring analytes in complex and/or
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biological samples, due to possibly systemic bias introduced by matrix effects on analyte stability,
extraction, and ionization efficiency (75-80).

Internal standards that faithfully reproduce the
15

13

properties of the analytes of interest are ideal. Stable isotope analogs containing [ Nn] [ Cn], or
both isotopes, represent the best internal standards because they have the same chemical
properties as the analyte of interest, but can still be uniquely distinguished by a mass
2

spectrometer (81). [ Hn]-containing stable isotope analogs are much easier to synthesize and
2

tend to be used even though there is usually a slight separation between the [ Hn]-analog and the
2

endogenous analyte. Therefore the use of [ Hn]-containing stable isotope analogs is not quite as
15

13

rigorous as the corresponding [ Nn]- or [ Cn]-containing stable isotope analogs. Applying stable
isotope analogs to a LC-MS experiment allows for quantification based on the observed ratio of
analyte to internal standard. This approach is termed stable isotope dilution (SID) LC-MS, and
represents the gold standard method of analysis because it corrects for many potential sources of
bias and error introduced by the experimenter and instrumentation (82).
The power of LC-MS, especially when coupled to other techniques including but not
limited to derivatization and SID-LC-MS, can be applied to quantitatively and qualitatively study
metabolism in a rigorous and sensitive manner. This thesis will apply LC-MS as explained in the
above paragraphs to the problem of human metabolism, in particular lipid metabolism. The lipid
subset of the human metabolic system is particularly interesting because of the incredible
diversity of known and potential pathways and products. Lipids are an important element of
metabolism because of their involvement in a wide variety of disease states.
Notably, in inflammatory diseases and multiple human cancers, increased COX-2 and
decreased 15-PGDH are hypothesized to lead to a milieu of bioactive lipids promoting
angiogenesis and cellular proliferation. I hypothesized that this pro-proliferative switch is also
dependent on the loss of generation of anti-proliferative homeostatic lipids. In chapter 2, through
LC-MS and other analytical techniques, it has been established that 11-oxo-eicosatetraenoic acid
(11-oxo-ETE) is a major COX-2/15-PGDH derived metabolite with anti-proliferative function.
Based on the observation that a cancer model system rapidly exported 11-oxo-ETE, I sought to
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understand the disposition of 11-oxo-ETE and the related 15-oxo-ETE. I hypothesize that the
potency of endogenous anti-proliferative lipids is mediated by the decreased availability of those
molecules to the intracellular space of cancer cells. The inadequacies of the available chemical
tools in this sphere led to a search for new chemical entities to use as probes for future studies.
In chapter 3, methyl-ester derivatives of both 11-oxo and 15-oxo-ETE were tested. Using SIDLC-MS, it was possible to show that the methyl esters potently deliver the oxo-ETE to the
intracellular space. In chapters 3 and 4, the signaling and disposition of the oxo-ETEs were
explored, using the tools that I developed, which are described in chapters 2 and 3.
In my early work, it was observed that the oxo-ETEs were highly transient. This led to
the hypothesis that 11-oxo- and 15-oxo-ETE are subject to further metabolic transformation inside
the cellular space.

To explore the metabolism of the oxo-ETEs untargeted and targeted

approaches to biomolecule analysis were developed as described in chapters 5 and 6. Using
these untargeted and targeted approaches, limited saturation of the free acids was observed, as
well as the formation and saturation up to all four double bonds of a novel coenzyme A thioester
of oxo-ETEs. The identification of novel metabolites was supported through LC-MS/MS, time
course studies, stable isotope labeling, and treatments with the methyl-esters of the oxo-ETEs as
well as isotope labeled 15-oxo-ETE.
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Chapter 2: 11-Oxo-eicosatetraenoic Acid is a Cyclooxygenase2/15-Hydroxyprostaglandin Dehydrogenase-Derived AntiProliferative Eicosanoid

Published as: Liu X, Zhang S, Arora JS, Snyder NW, Shah SJ, Blair IA. 11-Oxoeicosatetraenoic
acid is a cyclooxygenase-2/15-hydroxyprostaglandin dehydrogenase-derived antiproliferative
eicosanoid. Chem Res Toxicol. 2011 Dec 19;24(12):2227-36. Epub 2011 Sep 30. PubMed PMID:
21916491; PubMed Central PMCID: PMC3242474. NWS contributed to cell proliferation
studies and elucidation of oxo-ETE-GSH structure, as well as preparation of the manuscript.

2.1 Abstract
Previously, we established that 11(R)-hydroxy-5,8,12,14-(Z,Z,E,Z)-eicosatetraenoic acid
(HETE) was a significant cyclooxygenase (COX) -2-derived arachidonic acid (AA) metabolite in
epithelial cells. Stable isotope dilution chiral liquid chromatography (LC)-electron capture
atmospheric pressure chemical ionization (ECAPCI)/mass spectrometry (MS) was used to
quantify COX-2-derived eicosanoids in the human colorectal adenocarcinoma (LoVo) epithelial
cell line, which expresses both COX-2 and 15-hydroxy prostaglandin dehydrogenase (15-PGDH).
11(R)-HETE secretion reached peak concentrations within minutes after AA addition before
rapidly diminishing, suggesting further metabolism had occurred. Surprisingly, 15-PGDH, which
is normally specific for oxidation of eicosanoid 15(S)-hydroxyl groups, was found to convert
11(R)-HETE to 11-oxo-5,8,12,14-(Z,Z,E,Z)-eicosatetraenoic acid (ETE). Furthermore, LoVo cell
lysates converted 11(R)-HETE to 11-oxo-ETE and inhibition of 15-PGDH with 5-[[4-
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ethoxycarbonyl) phenyl]azo]-2-hydroxy-benzeneacetic acid (CAY 10397) (50 M) significantly
suppressed endogenous 11-oxo-ETE production with a corresponding increase in 11(R)-HETE.
These data confirmed COX-2 and 15-PGDH as enzymes responsible for 11-oxo-ETE
biosynthesis. Finally, addition of AA to the LoVo cells resulted in rapid secretion of 11-oxo-ETE
into the media, reaching peak levels within 20 min of starting the incubation. This was followed
by a sharp decrease in 11-oxo-ETE levels. Glutathione (GSH)-S-transferase (GST) was found to
metabolize 11-oxo-ETE to the 11-oxo-ETE-GSH (OEG)-adduct in LoVo cells, as confirmed by
LC-MS/MS analysis. Bromodeoxyuridine (BrdU)-based cell proliferation assays in human
umbilical vein endothelial cells (HUVECs) revealed that the half-maximal inhibitory
concentration (IC50) of 11-oxo-ETE for inhibition of HUVEC proliferation was 2.1 M. These
results show that 11-oxo-ETE is a novel COX-2/15-PGDH-derived eicosanoid, which inhibits
endothelial cell proliferation with a potency that is similar to that observed for 15d-PGJ2.

2.2 Introduction
In a previous study, we established that 11(R)-HETE was a significant COX-2-derived AA
metabolite in epithelial cells.(83) However, the consequences of this finding were not clear at
that time. A number of toxic substances including arsenite,(84) dioxin,(85) benz[a]pyrene-diolepoxide,(86) and cigarette smoke(87) up-regulate COX-2 expression, which in turn regulates
numerous intracellular biochemical pathways. This occurs primarily through the biosynthesis of
COX-2-derived AA metabolites, which can exert cell-specific effects on inflammation, cell
growth, and proliferation. For example COX-2-derived prostaglandin (PG) E2 increases tumor
proliferation through multiple mechanisms including activation of plasma membrane G-proteincoupled receptors and the nuclear peroxisome proliferator-activated receptor (PPAR).(13)
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Steady-state levels of PGE2 are maintained by PGE-synthase-mediated biosynthesis from
COX-2-derived PGH2 and catabolism by 15-PGDH-mediated inactivation to 15-oxo-PGE2
(Figure 1).(88,89) The 15-oxo-PGE2 is then converted to 13,14-dihydro-15-oxo-PGE2 by 15oxo-prostaglandin-13 reductase.(90) Loss of 15-PGDH expression is associated with tumor
formation in bladder, breast, colon, intestine, kidney, lung, pancreas, stomach, and skin
cancer.(41,91-96) Thus, up-regulation of COX-2(13) and down-regulation of 15-PGDH(41)
provides a switch towards endogenous mediators that are significant contributors to cancer
progression.(97)
PGD2, another COX-2-derived metabolite is also metabolized by 15-PGDH to form 15-oxoPGD2, which is then converted to the corresponding inactive 13,14-dihydro-derivative (Figure
1).(98) Alternatively, PGD2 undergoes albumin-mediated dehydration to give PGJ2, followed by
a further dehydration to give 15-deoxy-12,14-prostaglandin J2; (15d-PGJ2) (Figure 2).(99)
Previous studies have shown that 15d-PGJ2 is a PPAR agonist,(100) which inhibits HUVEC
proliferation in culture.(101) In addition, 15d-PGJ2 can induce caspase-mediated endothelial cell
apoptosis(102) and inhibit the nuclear factor B (NFB) pathway.(103,104) It can also increase
levels of p53 in HUVECs, activate p53 phosphorylation, and induce p21.(105)
Studies of purified COX enzymes have shown that 11(R)-HETE, 15(S)-hydroxy-5,8,11,13(Z,Z,Z,E)-eicosatetraenoic acid (15(S)-HETE), and 15(R)-HETE are the major HETEs that are
formed.(106) The HETEs arise from reduction of the corresponding hydroperoxyeicosatetraenoic
acids (HPETEs) primarily through the peroxidase (POX) activity of COXs (Figure 1).(107)
11(R)-HETE was a significant eicosanoid secreted by AA-treated rat intestinal epithelial cells that
stably express COX-2 (RIES cells) but it was rapidly metabolized.(83) 15(S)-HETE was formed
in lower abundance and metabolized to 15-oxo-ETE,(54,108) as expected from its 15(S)configuration and the substrate specificity of 15-PGDH. 15-Oxo-ETE was also found to inhibit
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endothelial cell proliferation, although at concentrations higher than 15d-PGJ2.(108) However,
there is little evidence that 15d-PGJ2 can be formed in vivo at concentrations commensurate with
an endogenous anti-proliferative role.(109) In our earlier study,(110) the metabolic fate of 11(R)HETE secreted by the RIES cells was not established. 11-Oxo-ETE has now been synthesized
and a LC-selected reaction monitoring (SRM)/MS method for its analysis has been developed.
This has made it possible to determine whether 11-oxo-ETE is secreted by human epithelial cell
lines with up-regulated COX-2 expression and to identify the dehydrogenase responsible. The
ability of 11-oxo-ETE to modulate HUVEC proliferation has also been examined.

2.3 Experimental Procedures
Chemicals and Reagents. AA (peroxide-free), 11(R,S)-HETE, 15(R,S)-HETE, [2H8]-15(S)HETE, [13C20]-15-oxo-ETE, 15-oxo-ETE, PGE2, [2H4]-PGE2, 13,14-dihydro-15-keto-PGE2, [2H4]13,14-dihydro-15-keto-PGE2, 15d-PGJ2, CAY10397, protease inhibitor cocktail and recombinant
human 15-PGDH were purchased from Cayman (Ann Harbor, MI). The Dess-Martin reagent
[1,1,1-Tris(acetyloxy)-1,1-dihydro-1,2-benziodoxol-3-(1H)-one],

2,3,4,5,6-pentafluorobenzyl

(PFB) bromide, Trizma-HCl, lipoxidase from Glycine max (soybean), sodium borohydride, and
NAD+ were purchased from Sigma-Aldrich (St. Louis, MO). Fetal bovine serum (FBS) was from
Gemini Bioproducts (West Sacramento, CA). F12K medium, DMEM medium, Medium 200
(M200), D-glucose, L-glutamine, low-serum growth supplement (LSGS) kit, penicillin, and
streptomycin were supplied by Invitrogen (Carlsbad, CA).

LC-MS grade water, hexane,

methanol, isopropanol, acetonitrile and dichloromethane were obtained from Fisher Scientific
(Pittsburgh, PA). Gases were supplied by The Linde Group (Munich, Germany). [ 13C20]-AA was
obtained from Spectra Stable Isotopes (Columbia, MD).
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Cell Culture. Human colorectal adenocarcinoma LoVo cells (ATCC, Manassas, VA) were
cultured in F12K medium supplemented with 10% FBS, 2 mM L-glutamine, 100,000 units/l
penicillin and 100 mg/l streptomycin. Human colonic adenocarcinoma HCA-7 Colony 29 cells
(Sigma-Aldrich, St. Louis, MO) were grown in DMEM supplemented with 10% FBS, 2 mM Lglutamine, 110 mg/L sodium pyruvate, 100,000 units/l penicillin and 100 mg/l streptomycin. For
lipidomics analysis, the culture media was replaced with serum-free F12K or DMEM media
before the treatment. HUVECs were obtained from Invitrogen (Carlsbad, CA), and cultured on
collagen I-coated tissue culture dishes in Medium 200 supplemented with LSGS kit.

Cell

proliferation assays were performed using HUVECs from passage 4.
Mass Spectrometry. A triple stage quadrupole (TSQ Quantum) mass spectrometer (Thermo
Electron, San Jose, CA) equipped with an APCI source was used for the quantitative lipidomics
analyses. Targeted chiral LC-ECAPCI/SRM/MS analysis was conducted using PFB derivatives
of 7 lipids and 4 heavy isotope analog internal standards.

For the lipidomics profile, the

instrument was operated in the negative ion mode, and unit resolution was maintained for both
precursor and fragment ions.

Operating conditions for the TSQ Quantum were: vaporizer

temperature at 450°C; heated capillary temperature at 250 °C with the corona discharge needle
set at 30 µA; nitrogen as sheath (25 psi) and auxiliary (5 arbitrary units) gas. Collision-induced
dissociation (CID) was performed using argon as the collision gas at 2.7 mtorr in the RF-only
quadrupole. The following SRM transitions were used: 11-oxo-ETE-PFB, m/z 317 → 165
(collision energy (CE), 25 eV), 15-oxo-ETE-PFB, m/z 317 → 113 (CE, 18 eV), [13C20]-15-oxoETE-PFB, m/z 337 → 120 (CE, 18 eV), 11(R)-HETE-PFB, m/z 319 → 167 (CE, 16 eV), [2H8]15(S)-HETE-PFB, m/z 327 → 226 (CE, 13 eV), PGE2-PFB, m/z 351 → 271 (CE, 18 eV), [2H4]PGE2-PFB, m/z 355 → 275 (CE, 18 eV). 13,14-dihydro-15-keto-PGE2-PFB, m/z 351 → 235 (CE,
22 eV), [2H4]-13,14-dihydro-15-keto-PGE2-PFB, m/z 355 → 239 (CE, 22 eV).
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For GSH adduct analysis, the mass spectrometer was operated in the positive ion mode with
an electrospray ionization (ESI) source. The operating conditions were: spray voltage at 4 kV;
capillary temperature at 350°C; nitrogen as sheath (35 psi) and auxiliary (13 arbitrary units) gas.
CID was performed using argon as the collision gas at 2.7 mtorr in the Rf-only quadrupole. The
following SRM transition (m/z 626 → 497) was monitored for 11-oxo-ETE-GSH (CE, 18 eV).
Liquid Chromatography. LC separations were conducted using a Waters® Alliance 2690
HPLC system. A Chiralpak AD-H column (250 × 4.6 mm inner diameter, 5 µm; Daicel) was
employed for normal phase separation (flow-rate 1 ml/min) of PFB-derivatives of eicosanoids.
Gradient 1 was used for separating PFB-derivatives of HETEs and PGE2, whereas gradient 2 was
used for PFB derivatives of oxo-ETEs. For gradient 1, solvent A was hexane, and solvent B was
methanol/isopropanol (1:1; v/v). Gradient 1 was as follows: 2% B at 0 min, 2% B at 3 min, 3.6%
B at 11 min, 8% B at 15 min, 8% B at 27 min, 50% B at 30 min, 50% at 35 min, and 2% B at 37
min. Separations were performed at 30°C using a linear gradient. For gradient 2, solvent A was
hexane, and solvent B was isopropanol/hexane (6:4; v/v). Gradient 2 was as follows: 2% B at 0
min, 2% B at 14.5 min, 12% B at 15 min, 23% B at 19 min, 90% B at 19.5 min, 90% B at 23.5
min, and 2% B at 24 min.
A Chiralpak AD-RH column (150 × 4.6 mm inner diameter, 5 µm; Daicel) was used for
reverse phase (isocratic method 1, flow-rate 0.5 ml/min) separation of the un-derivatized 11-oxoETE. The mobile phase for isocratic separations was methanol/water/formic acid (95:5:0.1; v/v).
Chemically synthesized 11-oxo-ETE was purified by normal-phase (isocratic method 2)
preparative LC (Ultrasphere™ 250 × 10 mm, inner diameter, 5 µm; Beckman) using Waters®
Alliance 2690 HPLC system by monitoring the UV absorbance at 236 nm. The mobile phase for
isocratic method 2 (flow-rate 2.5 ml/min) was hexane/isopropanol/acetic acid (98.5:1.5:0.1 ; v/v).
GSH adducts were separated by reverse phase using gradient 3 on Waters® Alliance 2690
HPLC system. The separation employed a Phenomenex Synergi Hydro-RP column (150 × 4.6
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mm inner diameters, 5 µm). Solvent A was 0.1% aqueous formic acid, and solvent B was
methanol/acetonitrile (50:50; v/v). Gradient 3 was as follows: 2% B at 0 min, 2% B at 14 min,
30% B at 20 min, 42% B at 21 min, 65% B at 27 min, 80% B at 29 min, 90% B at 33 min, 90% B
at 34 min, 2% B at 35 min. The flow rate was 0.4 ml/min. The separation was performed at
ambient temperature using a linear gradient.
PFB Derivatization. Eicosanoids were dissolved in 100 µl of acetonitrile, and then reacted
with 100 µl of PFB bromide in acetonitrile (1:19; v/v) and 100 µl of diisopropylethylamine in
acetonitrile (1:9; v/v) at room temperature for 30 min. The derivatives were evaporated to
dryness, dissolved in 100 µl of hexane/ethanol (95:5; v/v) and analyzed by chiral LCECAPCI/SRM/MS.
Enzymatic Conversion of 11(R)-HETE by 15-PGDH. Various concentrations of 11(R)HETE (0, 2.3 M, 4.6 M, 6.9 M, 9.2 M and 23 M) were incubated with 4 nM of
recombinant human 15-PGDH (50 ng, 1.8 pmol) and cofactor NAD+ (400 M) in 50 mM Tris-Cl
(pH 7.9) for 3.5 min at 37 oC. Each total reaction volume was 200 l. After a 3.5 min
incubation, the enzymatic reaction was quenched with 400 l of ice cold methanol and [13C20]-15oxo-ETE (8 ng) added as the internal standard. Eicosanoids were extracted with 1.2 ml of
dichloromethane/methanol (8:1; v/v). The lower organic layer was then evaporated to dryness
under nitrogen and reconstituted in methanol (100 l). An aliquot (25 µl) was separated using
isocratic method 1 and analyzed by LC-ESI/MS as described above. The retention time for 11oxo-ETE was 8.7 min. In separate experiments, the formation of 11-oxo-ETE was found to be
linear for the first 5 min. Eicosanoids were quantified by interpolation from a standard curve
prepared with 11-oxo-ETE using [13C20]-15-oxo-ETE as the internal standard.
Chemical Synthesis and Purification of 11-Oxo-ETE. The Dess-Martin reagent (5 mg, 12.0
mol) was added to a solution of 11(R,S)-HETE (10 mg, 31.0 µmol) in dichloromethane (0.5 ml)
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and stirred for 2 h at room temperature. The reaction was monitored by LC-MS using gradient 1
as described above, after PFB derivatization until there was no starting material left. There was
only one major product, which corresponded to 11-oxo-ETE.

The reaction mixture was

centrifuged twice at 3,400 rpm (10 min) and the supernatant was evaporated. The residue was
dissolved in the mobile phase (800 l) and purified by isocratic method 2 as described above.
The retention time for 11-oxo-ETE was 13.1 min. High resolution accurate mass measurements
were obtained using electrospray ionization on a Thermo LTQ-FT mass spectrometer at a
resolution of 100,000 (data not shown). NMR spectra were obtained on a Bruker 500 MHz NMR
instrument.
15-PGDH inhibition in LoVo or HCA-7 Cell Lysates by CAY10397.LoVo or HCA-7 cells
were grown to 90% confluence, washed with 10 ml of phosphate-buffered saline (PBS) buffer (2
times), and then gently scraped in 600 µl of lysis buffer containing 0.1 M Tris-HCl (pH 7.9) and
the protease inhibitor. Cell suspension was transferred to 2 ml Eppendorf tubes, and sonicated for
60 seconds on ice (power 5). Cell lysate was then incubated with or without the selective 15PGDH inhibitor (CAY10397, 50 M) and its co-factor (NAD+, 500 µM) for 10 min at 37°C. The
pH was then adjusted to 4 with 10% aqueous acetic acid (10 µl) followed by addition of the
internal standard mix, [13C20]-15-oxo-ETE, [2H8]-15(S)-HETE and [2H4]-PGE2 (50 pg/µl, 20 µl).
Diethyl ether (600 µl) was added, and samples were vortex-mixed and centrifuged (15000 rpm×2
min).

The organic layer was evaporated under nitrogen, and then the eicosanoids were

derivatized with PFB bromide as mentioned above.

Finally, samples were re-dissolved in

hexane/ethanol (95:5; v/v, 100 µl), and analyzed (20 µl) by normal phase LC-ECAPCI/MS. The
amounts of eicosanoids were normalized by protein concentrations of each lysate, which were
determined by BCA assay.
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Metabolism of AA by LoVo or HCA-7 Cells. LoVo or HCA-7 cells were grown to 90%
confluence in 6-well plates as described above, and then fed fresh serum-free F-12K or DMEM
medium. Cells were then incubated with AA (10 µM) for 0, 5, 10 and 30 min, 1 and 2.5 h at
37°C. At each time point, 0.6 ml medium was taken out, 20 µl 10% aqueous acetic acid was
added to adjust pH to 3-4, together with 20 µl internal standards mixture (50 pg/ µl [12C20]-15oxo-ETE, [2H8]-15(S)-HETE, [2H4]-PGE2 and [2H4]-13,14-dihydro-15-keto-PGE2-PFB). Then
diethyl ether (1 ml) was added, and the mixture was vortex-mixed and centrifuged (15000 rpm ×
2 min).

The upper ether layer was evaporated under nitrogen, and PFB derivatives were

synthesized as described above and analyzed by normal phase LC-ECAPCI/MS.
Standard curves for Eicosanoid Quantification. To quantify eicosanoids excreted in the
medium, Eppendorf tubes containing 0.6 ml F12K medium were spiked with lipid standards,
together with internal standards for ([12C20]-15-oxo-ETE, [2H8]-15(S)-HETE ,[2H4]-PGE2 and
[2H4]-13,14-dihydro-15-keto-PGE2-PFB 1 ng each). To quantify eicosanoids in the cell lysate,
lipids standards and internal standards mixture were spiked into 0.2 ml Tris-HCl buffer. The
extraction and PFB derivatization methods are the same as mentioned above.
Analysis of 11-OEG adducts in LoVo cell lysate. LoVo cells were grown to 90% confluence
and then washed with PBS (10 ml). Cells were gently scraped in 600 µl Tris-HCl buffer (0.1 M,
pH=7.9), containing protease inhibitor. Cell lysates were transferred to 2 ml Eppendorf tubes,
and sonicated for 60 seconds on ice (power 5). 11-oxo-ETE (20 ng in ethanol) was added to the
lysate together with 1 mM GSH. After incubation for 25 min at 37°C, 10 µl of 10% acetic acid
was added, and the sample was loaded onto SPE column (oasis HLB, 30 mg) pre-conditioned
with methanol and then 0.1% formic acid. The column was washed with 1 ml water and eluted
with 250 µl methanol, and then 20 µl was analyzed by reverse phase LC-ESI/MS using gradient
3, as described above.
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Cell proliferation assay. BrdU incorporation in HUVECs was used to assess the effects of
11-oxo-ETE on cell proliferation. The BrdU assay was performed in a 96-well format using a
commercially available colorimetric enzyme-linked immunosorbent assay (ELISA) kit (Roche),
and also by immunofluorescence microscopy. Equal numbers of HUVECs in passage 4 were
plated in either, collagen-I coated 96-well plates (2000 cells/well), or collagen-I coated 8chamber tissue culture glass slides (10000 cells/chamber). Cells were allowed to attach overnight
in 0.25% DMSO containing media. Eicosanoids were dissolved in DMSO, such that the final
concentration of DMSO in cell media was always 0.25% or lower. Cells were then treated for 24
h with either vehicle (0.25% DMSO), 11-oxo-ETE (1 nM-100 M), or 15d-PGJ2 (1 nM-100 M).
After 18 h of treatment, BrdU (final concentration, 10 M in 0.25% DMSO) was added to each
treatment group for an additional 6 h.
For the colorimetric ELISA, the manufacturer’s protocol was followed to perform the assay.
The absorbance at λ = 370 nm obtained from the assay was transformed to the cell numbers using
a standard curve constructed by plating known number of HUVECs in triplicate. The IC50 values
for eicosanoid inhibition of HUVEC proliferation were defined as the half maximal inhibitory
concentration for endothelial cell proliferation over 24 h when compared with vehicle-treated
cells. They were determined from the regression lines of the log inhibitor vs. response curves
using a least squares fit.
For the immunofluorescence staining, cells were fixed with neutral buffered formalin for 10
min, permeabilized with methanol for 20 min, and then DNA was denatured by pressure cooking
the slides in 10 mM citric acid buffer, pH 6 for 1 h. Cells were then incubated overnight with rat
anti-BrdU antibody (1:1000, Accurate Chemical & Scientific Corp.) at 4°C, followed by 30 min
incubation at 37 °C with Cy3-conjugated donkey anti-rat secondary antibody (1:600, Jackson
Immuno Research).

Cells were counterstained with 4',6-diamidino-2-phenylindole (DAPI,
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Invitrogen) and visualized using a Nikon E600 microscope equipped with differential interference
contrast (Nomarski) optics and photographed (x200 magnification) with a Fast 1394 QICam
(QImaging). Positive BrdU staining was quantified by image analysis using IVision Analysis
Software (Biovision). The percentage of proliferating cells was determined by counting the
BrdU-positive cells versus the total number of cells in randomly selected microscopic fields
(10/replicate) for each treatment group.
Statistical Analyses. All experiments were conducted in triplicate, unless otherwise indicated.
Statistical significance (p value < 0.05) was determined using a two-tailed unpaired t-test
employing GraphPad® Prism software (v 5.01).

2.4 Results
Biosynthesis of 11-oxo-ETE by 15-PGDH. Various concentrations of 11(R)-HETE were
incubated with recombinant human 15-PGDH and NAD+ at 37oC. A Michaelis-Menton kinetic
analysis of 11-oxo-ETE formation revealed that the Vmax (296 nmol/min/mg), Km (3.42 M), and
kcat (8.6 min-1) values for oxidation of 11(R)-HETE (Figure 3) were similar to those for 15(S)HETE (Km = 1.65 M, kcat =8.6 min-1; Supplementary Figure 1).

Therefore, the catalytic

efficiency (Kcat/Km) for 15-PGDH-mediated oxidation of 11(R)-HETE (2513 min-1mM-1, Figure
3) was similar to that for 15(S)-HETE (7091 min-1mM-1; Supplementary Figure 1).
Chemical Synthesis of Authentic 11-Oxo-ETE. 11-Oxo-ETE was synthesized chemically
by oxidizing racemic 11(R,S)-HETE using the Dess-Martin reagent, and then purified using
chromatographic separation. A combined total of 10 mg of the racemic 11(R,S)-HETE resulted in
the isolation of 4.9 mg of pure 11-oxo-ETE (overall yield of 49%). High resolution electrospray
ionization-MS of 11-oxo-ETE revealed accurate masses of m/z 319.2263 and m/z 341.2079 for
the protonated and sodiated molecules, respectively [calculated accurate mass for protonated
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(C20H31O3) and sodiated (C20H30O3Na) molecules, m/z 319.2273 and m/z 341.2093, respectively].
500 MHz 1H-NMR (H, CDCl3; Supplementary Figure 2) 7.55 (dd, J1 = 11.5 Hz, J2 =15.5, 1H),
6.21(d, J =15.5Hz, 1H), 6.15-6.11 (m, 1H), 5.97-5.92 (m, 1H), 5.60-5.58 (m, 2H), 5.41-5.38 (m,
2H), 3.35 (d, J =4.5Hz , 2H), 2.83-2.81 (m, 2H), 2.38-2.31 (m, 4H), 2.17-2.12 (m, 2H), 1.74-1.25
(m, 8H), 0.89 (t, J = 7.0 Hz, 3H). Analysis of purified 11-oxo-ETE as its PFB derivative by LCECAPCI/MS (Figure 4a) revealed an intense negative ion at m/z 317 corresponding to [M-PFB]-.
CID of [M-PFB]- (m/z 317) and MS/MS analysis revealed major product ions at m/z 273, 219,
165, 149, and 123. The UV spectrum was consistent with the presence of a conjugated dienone
with a UV max at 279 nm and molecular extinction coefficient () of 18,985 M-1cm-1.
Confirmation of 11-oxo-ETE Identity by LC-MS and MS/MS Analyses. The LoVo cell
line is known to express both COX-2 and 15-PGDH and only trace amounts of COX-1,(41,111)
this was confirmed by Western blot analysis (data not shown). Cell lysates were incubated with
100 nM 11(R)-HETE in the presence of 500 M NAD+ for 10 min. LC-MS analysis of PFB
derivatives of eicosanoids extracted from the LoVo cell lysate showed that there was a single
major metabolite, which eluted at 12.8 min (data not shown). The full scan mass spectrum of this
metabolite had only one major ion at m/z 317 corresponding to [M-PFB]- (Figure 4b). CID and
MS/MS analysis revealed the formation of intense product ions at m/z 123, 149, 165, 219, and
273 (Figure 4b). The product ion spectrum was identical with that obtained from authentic
synthetic 11-oxo-ETE-PFB (Fig. 4a), which confirmed the identity of 11-oxo-ETE from LoVo
cells.

The product ion at m/z 165 in LoVo cell-derived and synthetic 11-oxo-ETE-PFB

corresponded to cleavage between C-9 and C-10 and m/z 123 was formed from cleavage between
C-11 and C-12 (Fig. 4).
Separation of Eicosanoids by Chiral LC-ECAPCI/SRM/MS. Lysates from LoVo cells
were extracted for the eicosanoids, which were then analyzed (after PFB derivatization) by LC-

32
ECAPCI/SRM/MS. A representative chromatogram (Figure 5) reveals the separation of 11-oxoETE (retention time 12.8 min) and 15-oxo-ETE (retention time 12.0 min) that were formed in the
LoVo cell lysate. Additional eicosanoids that were observed (Figure 5) include, 13,14-dihydro15-keto-PGE2 (retention time, 33.6 min), 11(R)-HETE (retention time, 10.0 min), and PGE2
(retention time, 29.4 min).
Inhibition of 15-PGDH by CAY10397 in LoVo and HCA-7 cell lysates. In contrast to
LoVo cells, the HCA-7 cell line is known to express COX-2 and only trace amounts of COX-1
and 15-PGDH.(41,112) This was confirmed by Western blot analysis (data not shown). LoVo
(Figure 6a) or HCA-7 (Figure 6b) cell lysates were incubated with 500 mM NAD+, with or
without the 15-PGDH-inhibitor, CAY10397 (50 µM) for 10 min.

Inhibition of 15-PGDH

significantly abolished the formation of endogenous 11-oxo-ETE (Figure 6a) by 92%, along with
the diminished formation of 15-oxo-ETE as well as 13,14-dihydro-15-oxo-PGE2 (Figure 6a) in
the LoVo cell lysate.

However, since the oxo-ETEs and 13,14-dihydro-15-oxo-PGE2 were

undetectable in HCA-7 cell lysate, their precursors were quantified instead, and CAY10397 had
no effect on their levels (Figure 6b).
Secretion of eicosanoids from LoVo and HCA-7 cells following AA addition. Time-course
analyses for the amount of different eicosanoids secreted by LoVo and HCA-7 cells following
AA incubation for 0-2.5 h are shown in Figure 7a and Figure 7b, respectively. 11-Oxo-ETE was
secreted into the cell media by LoVo cells along with 15-oxo-ETE and 13,14-dihydro-15-oxoPGE2 (Figure 7a).

Interestingly, both 11-oxo-ETE and 15-oxo-ETE reached maximum

concentrations 10 min after the addition of AA to the cells. This was followed by a decline of
both eicosanoids to steady-state levels after 2.5 h (Figure 7a) in LoVo cells. In contrast, 13,14dihydro-15-oxo-PGE2 levels did not peak until 1 h after the addition of AA (Figure 7a) and
remained constant throughout the remainder of the incubation period. In contrast, none of the
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eicosanoids resulting from 15-PGDH-mediated metabolism were detected in the media of HCA-7
cells incubated with AA (Figure 7b).
Formation of 11-OEG in LoVo Cell Lysates. Biosynthesis of 11-OEG was monitored in the
cell lysate after the addition of 100 nM 11-oxo-ETE and 1 mM GSH to the LoVo cell lysate. 11OEG formation was detected and confirmed by LC-MS/MS monitoring of the major metabolite
formed after a 30 min incubation. OEG (retention time, 32.2 min, data not shown) was observed
as an intense peak in the LC-ESI/MS chromatogram when analyzed by gradient 3 (as described
above). CID and MS/MS analysis revealed the formation of intense product ions at m/z 497, 319,
308, and 179 (Figure 8).
Effects of Eicosanoids on HUVEC Proliferation. Proliferation by HUVECs was assessed by
quantifying the BrdU incorporation into the cells actively synthesizing new DNA. The BrdU
assay was performed using a quantitative colorimetric 96-well format ELISA as well as by
immunofluorescence microscopy for observing the morphological effects of eicosanoids in
HUVECs. For the BrdU ELISA, HUVECs (2000 cells/well) were treated with different doses (0100 M) of 11-oxo-ETE and 15d-PGJ2 for a period of 24h. The cell numbers corresponding to
each treatment dose were computed and used to calculate cell proliferation (%) as compared to
the vehicle-treated controls. 11-Oxo-ETE (IC50 = 2.1 M) was equipotent with 15d-PGJ2 (IC50 =
2.3 M), a known potent inhibitor of endothelial cell proliferation (Figure 9a).

For the

immunofluorescence analysis, HUVECs (8000 cells/chamber) were treated with 2 M of either
11-oxo-ETE or 15d-PGJ2 for 24 h. BrdU incorporation was assessed by counting the BrdUpositive cells as compared to the total number of cells counted in randomly selected microscopic
fields (10 fields/treatment). The photomicrographs clearly show that treatment with 11-oxo-ETE
as well as 15d-PGJ2 remarkably reduced the total number of BrdU-positive cells (stained red) as
compared to vehicle-treated controls (Figure 9b). Moreover, there was a distinct change in the
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morphological appearance of the DAPI-stained (stained blue) cells in the eicosanoid-treated
slides that failed to incorporate BrdU (Figure 9b).

2.5 Discussion
15-PGDH catalyzes NAD+-mediated oxidation of the 15(S)-hydroxyl moiety of PGs and other
eicosanoids (Fig 1).(41,98,108) Our previous studies had established that 15-PGDH is also
responsible for metabolizing the 15-lipoxygenase-derived 15(S)-HETE in macrophages and
monocytes to 15-oxo-ETE.(108) Surprisingly, we have now found that 11(R)-HETE is also
metabolized by 15-PGDH to a novel eicosanoid, that was identified as 11-oxo-ETE (Fig 2).
Moreover, the catalytic activity of human 15-PGDH for oxidation of 11(R)-HETE (Figure 2) was
very similar to that observed for 15(S)-HETE (Supplementary Figure 1). These results were very
surprising in view of the lack of a 15(S)-hydroxyl group on 11(R)-HETE as well as the incorrect
11(R)-stereochemistry. The structure of 11-oxo-ETE metabolite was established by chemically
synthesizing authentic 11-oxo-ETE from racemic 11-HETE. 11-Oxo-ETE was formed in both
LoVo cell lysates (Figure 6a) and secreted from intact cells (Figure 7a); whereas 11-oxo-ETE was
not formed by HCA-7 cell lysates (Figure 6b) or secreted from intact cells (Figure 7b). Since
LoVo cells express COX-2 as well as 15-PGDH, whereas HCA-7 cells express COX-2 but not
15-PGDH,(41,111,112) these data convincingly prove that 11-oxo-ETE is an endogenous product
formed enzymatically by a combination of COX-2 and 15-PGDH.
11-oxo-ETE is isomeric with 15-oxo-ETE (Figure 2) and also has very similar LC properties.
Therefore, a reversed phase LC-SRM/MS method was developed to separate the un-derivatized
oxo-ETEs, and normal phase was implemented to separate their PFB derivatives. This made it
possible to readily analyze the two oxo-ETEs. Endogenous eicosanoids formed by LoVo and
HCA-7 epithelial cells and cell lysates as well as those formed after the addition of AA were
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analyzed

as

PFB

derivatives

by

chiral

LC-ECAPCI/MS.(110,113)

Representative

chromatograms of the eicosanoids produced endogenously in the LoVo cell lysates are shown in
Figure 5. Inhibition of 15-PGDH enzyme by CAY10397 significantly diminished the formation
of endogenous 11-oxo-ETE in LoVo cell lysates (Figure 6a). In addition, the formation of 15oxo-ETE as well as 13,14-dihydro-15-oxo-PGE2, the other two 15-PGDH-dependent metabolites,
were also significantly reduced in LoVo cell lysates treated with CAY10397 (Figure 6a). In
contrast, the three 15-PGDH products, namely, 11-, 15-oxo-ETE and 13,14-dihydro-15-oxoPGE2, were undetectable in HCA-7 cells as these cells do not express any 15-PGDH.(41,111)
Instead, the corresponding precursors for these three metabolites were observed in the lysates.
Furthermore, treatment with CAY10397 had no effect on levels of 11(R)-HETE, 15(S)-HETE or
PGE2 (Figure 6b). Intact LoVo cells also secreted 11-oxo-ETE, 15-oxo-ETE as well as 13,14dihydro-15-oxo-PGE2.

However, the 11-oxo-ETE was cleared very rapidly (Figure 7a),

suggesting that further metabolism was occurring. Subsequently, it was observed that 11-oxoETE underwent GST-mediated metabolism to 11-OEG, similar to the formation of 15-OEG in
RIES cells (Figure 8).(110)
We realized that 11-oxo-ETE, is very similar in structure to 15d-PGJ2. It only differs in the
lack of a C-8 to C-12 bond, in having a cis-8,9- rather than cis-9,10-double bond, and a cis- rather
than trans-14,15-double bond (Figure 2). This suggested that 11-oxo-ETE might be a more
effective inhibitor of HUVEC proliferation than 15-oxo-ETE(108) with a potency similar to that
observed for 15d-PGJ2.(101) In fact, 11-oxo-ETE was six times more potent than 15-oxo-ETE
(data not shown) and equipotent with 15d-PGJ2 at inhibition of HUVEC proliferation (Figure 9).
Dose-response studies revealed that its IC50 was 2.1 M compared to an IC50 value of 2.3 M for
15d-PGJ2 (Figure 9a). Moreover, immunofluorescence microscopy revealed that 11-oxo-ETE not
only inhibited BrdU incorporation into the HUVECs but it also caused a dramatic change in the
shape and morphology of these cells (Figure 9b). Although the total number of cells counted in
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the eicosanoid-treated groups were quite similar to the vehicle-treated group, the BrdU-negative
cells were significantly distorted (Figure 9b). Typically, if the cells are undergoing death by
apoptosis, they would appear more compact and round. However, 11-oxo-treated cells were
elongated and stretched (Figure 9b), which could be indicative of extensive cytoskeletal
remodeling, cell cycle arrest and/or differentiation. Interestingly, 11-oxo-ETE formation could
not be detected in HUVEC lysate that was incubated with 11(R)-HETE (data not shown).
Finally, immunoblot analysis of HUVEC cell lysate failed to detect COX-2 protein (data not
shown). Taken together, these data suggest a paracrine role for 11-oxo-ETE on endothelial cell
proliferation.
As noted above, inhibition of 15-PGDH resulted in significant decreases in 11-oxo-ETE
formation in LoVo cells (Figure 6).

15-PGDH is down-regulated in numerous cancers

types,(41,91,92,94-96) which would cause a decrease in 11-oxo-ETE biosynthesis by preventing
the in vivo conversion of 11(R)-HETE to 11-oxo-ETE (Figure 1). This could be particularly
devastating as COX-2 becomes up-regulated during tumorigenesis, which would result in
elevated PGE2 biosynthesis along with decreased 15-PGDH-mediated inactivation to 15-oxoPGE2 (Figure 1). Ultimately, this would result in an increase in PGE2-mediated pro-proliferative
activity(13,97) without the counter effect of anti-proliferative oxo-ETEs. Increased PGE2 activity
can also arise through down-regulation of the influx PG transporter - the organic anion transporter
polypeptide (OATP) 2A1 (Figure 1).(50,114)
There is some evidence that 11-oxo-ETE can activate nuclear PPAR.(16) PPAR is a liganddependent transcription factor responsible for the regulation of a number of cellular events
ranging from lipid metabolism to apoptosis.(115) 15d-PGJ2 is a PPAR agonist, which might
account for its ability to inhibit endothelial cell proliferation.(100,101) However, this effect is
only observed with pharmacological amounts of 15d-PGJ2 rather than endogenous
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concentrations.(109)

Besides PPAR agonistic activity, 15d-PGJ2 is also known to be an

inhibitor of NFB signaling, a pathway critical to cell proliferation as well as
tumorigenesis.(116,117) In view of the ability of COX-2/15-PGDH to rapidly metabolize AA to
nM amounts of oxo-ETEs, together with the structural similarity of oxo-ETEs and 15d-PGJ2
(Figure 2), it will be important to determine which of these activities are shared by both classes of
eicosanoids. It is noteworthy that docosahexaenoic acid and docosapentaenoic acid can be
metabolized by the sequential action of COX-2 and dehydrogenises into oxo-eicosanoids that
modulate the antioxidant response.(118)

Similarly 5-lipoxygenase-drived 5(S)-HETE is

metabolized by 5-hydroxyeicosanoid dehydrogenase into the chemoattractant 5-oxo-ETE.39
(119)(118)(118)(117)(117)(116)(116)(116) Therefore, the oxo-eicosanoids represent a family of
oxidized lipids with diverse biological activities.
In summary, our studies have revealed that down-regulation of 15-PGDH inhibits the
formation of endogenous anti-proliferative eicosanoid, 11-oxo-ETE. Therefore, 15-PGDH has
two quite distinct properties; it can either inactivate PGs or activate HETEs to oxo-ETEs that
exert a paracrine effect on endothelial cells (Figure 1). 11-Oxo-ETE, a member of the oxo-ETE
family,(119-121) was observed previously as an endogenously-derived lipid in human
atherosclerotic plaques.(122)

However, the biosynthesis of 11-oxo-ETE and its biological

activity were not evaluated in that study.

Furthermore, there does not appear to be any

subsequent report of its formation either, in vitro or in vivo. We have now shown that in fact 11oxo-ETE is derived from COX-2/15-PGDH-mediated AA metabolism and that it inhibits
endothelial cell proliferation with an IC50 that is very similar to that of 15d-PGJ2.

ACKNOWLEDGEMENT

38
This work was supported by the National Institutes of Health [RO1CA091016, UO1ES016004,
and P30ES013508]. The authors would like to acknowledge Gary P. Swain at The Morphology
Core of the Center for the Molecular Studies of Liver and Digestive Diseases (P30 DK50306), for
his assistance with the BrdU immunofluorescence staining.

15d-PGD2
PGJ2
15d-PGJ2
albumin

epithelial cell membrane
15-oxoPGD2

PGD2

13,14,-dihydro15-oxo-PGD2

15-PGDH

Ca2+

PGD2

CPLA 2

PGDS

PGES

15-PGDH

PGE2

15-oxoPGE2

AA
COX-2

Nucleus

15(R)-HPETE
POX

OATP
2A1

PGE2

PGG2

POX

15(R)-HETE

ABC
C4
PGE2

Tumor
Increased
proliferation

15(S)-HPETE

13,14,-dihydro15-oxo-PGE2

11(R)-HPETE
POX

15(S)-HETE

11(R)-HETE

15-PGDH
GST

15-oxo-ETE

11-OEG

GST

11-oxo-ETE

15-OEG

Pro-angiogenic
factors

Decreased proliferation

Blood vessel

PGH2

Figure 2.1. Formation and action of COX-2-derived eicosanoids in epithelial cell
models.
AA is released from membrane phospholipids by calcium-dependent cytosolic phospholipase A2
(cPLA2). The released AA undergoes COX-2-medaited metabolism to PGs or forms the lipid
hydroperoxides, 15(S)-hydroperoxyeicosatetraenoic acid; (HPETE), 15(R)-HPETE and 11(R)HPETE, which are reduced to the corresponding HETEs. PGD2 and PGE2 are inactivated by 15PGDH-mediated conversion to their 15-oxo-metabolites. Both 15-oxo-PGD2 and 15-oxo-PGE2
are converted to 13,14-dihydro-5-oxo-PG metabolites. Intact PGD2 secreted by the epithelial
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cells can undergo albumin-mediated dehydration to 15d-PGJ2. PGE2 secreted from the epithelial
cells by the ABCC4 transporter is pro-proliferative for tumor cells. Re-uptake of PGE2 by
OATP2A1 into the epithelial cells leads to further 15-PGDH-mediated inactivation. In contrast to
PGE2 and PGD2, 15(S)-HETE and 11(R)-HETE are activated by 15-PGDH-mediated oxidation to
15-oxo-ETE and 11-oxo-ETE, respectively. The oxo-ETEs are further conjugated to form OEGs.
Secreted 15- and 11-oxo-ETE that escape further metabolism can then inhibit endothelial cell
proliferation. Therefore, down-regulation of 15-PGDH and OATP2A1 would result in increased
PGE2-mediated tumor and endothelial cell proliferation.
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Figure 2.2. Chemical structures of COX-2 derived eicosanoids.
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Figure 2.3. Kinetic plot of the formation of 11-oxo-ETE by 15-PGDH. Various
concentrations of 11(R)-HETE (0-

-PGDH and cofactor NAD+.

Determinations for 11-oxo-ETE were conducted in triplicate (means ± S.E.M.) by stable isotope
dilution LC-ESI/MS analyses.
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Figure 2.4. Confirmation of 11-oxo-ETE formation by LC-MS/MS analysis.
Specific product ions observed by CID and MS/MS analysis of [M-PFB]∙ (m/z 317), corresponding
to 11-oxo-ETE are shown on the relevant chemical structures. (a) Synthetic 11-oxo-ETE-PFB
standard; (b) 15-PGDH-derived 11-oxo-ETE-PFB from LoVo cell lysate to which 100 nM 11(R)HETE had been added.
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Figure 2.5. Targeted chiral lipidomics of COX-2 derived eicosanoids from LoVo
cells.
LoVo cells were lysed; eicosanoids were extracted, derivatized with PFB bromide, and analyzed by
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LC-ECAPCI/SRM/MS. LoVo cell lysates were pre-treated with 50 µM CAY10397 to inhibit 15PGDH to be able to detect the 11-, 15-HETEs and PGE2. Representative chromatograms are shown
for (a) 11(R)-HETE-PFB (m/z 319  167), (b) [2H8]-15(S)-HETE-PFB internal standard (m/z 327 
226), (c) 11-oxo-ETE-PFB (m/z 317  165), (c) 15-oxo-ETE-PFB (m/z 317  165), (d) [13C20]- 15oxo-ETE-PFB internal standard (m/z 337  120), (e) PGE2-PFB (m/z 351  271), (f) [2H4]-PGE2PFB (m/z 355  275), (g) 13,14-dihydro-15-oxo-PGE2-PFB (m/z 351  235), (h) [2H4]-13,14dihydro-15-oxo-PGE2-PFB (m/z 355  239).
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Figure 2.6. Inhibition of 15-PGDH in LoVo and HCA-7 cell lysates by CAY10397. (a)
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LoVo or (b) HCA-7 cell lysate (1x106 cells/treatment group) was incubated with or without
CAY10397 (50 µM, to inhibit 15-PGDH). Eicosanoids were extracted from the lysates and their
levels were determined by chiral LC-ECAPCI/SRM/MS. Analyses were performed in triplicates,
and error bars show S.E.M.
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Figure 2.7. Time course for eicosanoids secreted from LoVo and HCA-7 cells.
(a) LoVo or (b) HCA-7 cells were incubated with 10 M AA for 0-6 h. The different eicosanoids
secreted into the media at various time-points were extracted and their levels were determined by
stable isotope dilution LC-ECAPCI/SRM/MS analysis of their PFB derivatives. Determinations
were conducted in triplicate (means + S.E.M.), and the quantitation was performed using the
standard curves generated for these eicosanoids.
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Figure 2.9. Effect of eicosanoids on cell proliferation of HUVECs. (a) For BrdU ELISA,
HUVECs (2000 cells/well) were treated with various doses of 11-oxo-ETE and 15d-PGJ2 for a
period of 24 h. Cell proliferation (means + S.E.M.) was assessed by measuring absorbance at 370
nm and converting it to cell numbers using a standard curve and thereby used to construct the IC50
plots. All experiments were conducted three times in triplicate. Representative data from one
experiment conducted in triplicate are shown as means ± S.E.M. (b) For immunofluorescence,
HUVECs (8000/chamber) were treated with 2 M of 15d-PGJ2 or 11-oxo-ETE for 24 h and then
stained for BrdU and counterstained with DAPI (cells stained blue). Photomicrographs were taken at
x200 magnification, and BrdU-positive (stained purple) cells were counted in randomly selected
microscopic fields (10/replicate) as compared to the total number of cells in these fields. All
experiments were conducted in triplicate. Representative photomicrographs from one set of
replicates are shown.
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Figure 2.10. Kinetic plot of the formation of 15-oxo-ETE by 15-PGDH. Various
concentrations of 15(S)-HETE were incubated with 4 nM 15-PGDH and cofactor NAD+.
Determinations were conducted in triplicate (means ± S.E.M.) by stable isotope dilution LC-ESISRM/MS analyses.

Figure 2.11. 500 MHz 1H NMR spectrum of 11-oxo-ETE in CDCl3.
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Chapter 3: Cellular Uptake and Anti-proliferative Effects of 11oxo-eicosatetraenoic Acid

Published as: Snyder, Nathaniel W., et al. "Cellular uptake and anti-proliferative effects of 11oxo-eicosatetraenoic acid." Journal of lipid research (2013).

3.1 Abstract
Cyclooxygenases

(COXs)

metabolize

arachidonic

acid

(AA)

to

hydroxyeicosatetraenoic acids (HETEs), which can then be oxidized by dehydrogenases
such as 15-hydroxyprostaglandin dehydrogenase (15-PGDH) to oxo-eicosatetraenoic
acids (ETEs). We have previously established that 11-oxo-eicosatetraenoic acid (oxoETE) and 15-oxo-ETE are COX-2/15-PGDH-derived metabolites. Stable isotope dilution
chiral liquid chromatography coupled with electron capture atmospheric pressure
chemical ionization/mass spectrometry has now been used to quantify uptake of 11-oxoETE and 15-oxo-ETE in both and LoVo cells and human umbilical vein endothelial cells
(HUVECs).

Intracellular 11-oxo- and 15-oxo-ETE concentrations reached maximum

levels within 1 h and declined rapidly, with significant quantitative differences in uptake
between the LoVo cells and the HUVECs. Maximal intracellular concentrations of 11oxo-ETE were 0.02 ng/4x105 cells in the LoVo cells and 0.58 ng/4x105 cells in the
HUVECs. Conversely, maximal levels of 15-oxo-ETE were 0.21 ng/4x105 in the LoVo
cells and 0.01 ng/4x105 in the HUVECs. The methyl-esters of both 11-oxo- and 15-oxoETE increased the intracellular concentrations of the corresponding free oxo-ETEs by 38-fold. 11-oxo-ETE, 15-oxo-ETE, and their methyl esters inhibited proliferation in both
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HUVECs and LoVo cells at concentrations of 2-10 M, with 11-oxo-ETE methyl ester
being the most potent inhibitor. Co-treatment with probenecid, an inhibitor of multiple
drug resistance transporters (MRPs) 1 and 4, increased anti-proliferative effect of 11oxo-ETE methyl ester in LoVo cells and increased the intracellular concentrations of 11oxo-ETE from 0.05 ng/4x105 cells to 0.18 ng/4x105 cells. Therefore, the present study
has established that the COX-2/15-PGDH derived eicosanoids 11-oxo- and 15-oxo-ETE
enter target cells, that they inhibit cellular proliferation, and that their inhibitory effects are
modulated by MRP exporters.

3.2 Introduction
AA metabolism is implicated in cellular and physiologic regulation, inflammatory
diseases, and cancer (123).

In colon cancers, COX-2 expression is increased and

conversely 15-PGDH is down-regulated (41). There is also evidence for COX-2/15PGDH counter-regulation in gastric, breast, and lung cancers (88,95,124).

The

magnitude of the up-regulation/down-regulation may even serve as an independent
predictor of progression and survival (125,126).

This “proliferative switch” is

hypothesized to increase tumorigenesis and angiogenesis via increased prostaglandin
(PG) E2 formation (Fig. 1A) and a feed forward loop for COX-2 (127,128). However,
COX-2 mediated AA metabolism also generates other eicosanoids including 11- and 15hydroperoxyeicosatetraenoic acids (HPETEs) and after reductive metabolism, the more
stable 11- and 15-HETEs (27,83) (Figs. 1A, 1B). 15-HPETE is also a major product of
the lipoxygenase pathway, through various 15- or 12/15-lipoxygenases (LOXs; Fig. 1B)
(33). 15-PGDH then oxidizes 11- or 15-HETE to the ,-unsaturated ketone-containing
oxo-ETEs (108,129). Confirmation of the dehydrogenase pathway has been obtained
using numerous experimental paradigms. 15-oxo-ETE was found as a major product of
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15-PGDH-mediated oxidation of 15(S)-HETE in rabbit lung, as a major product of AA
from mast cells, and as a major product of stenosed canine coronary arteries (130-132).
In addition, either COX/15-PGDH or LOX/15-PGDH mediated metabolic pathways are
involved in the formation of 15-oxo-ETE (Fig. 1B) (83,108). Furthermore, 11-oxo- and
15-oxo-ETE have been detected in advanced human atherosclerotic lesions, although its
route of formation was not examined in that study (122). Finally, we have demonstrated
recently that 11-oxo-ETE is generated by COX/15-PGDH mediated metabolism (129).
In spite of significant evidence for the formation of 11- and 15-oxo-ETEs in vivo,
the pharmacology of these endogenous metabolites has not been examined in detail. In
contrast, the structurally related PG analog, 15-deoxy-12,14-PGJ2 (15d-PGJ2; Fig. 1A)
has been very extensively studied as an endogenous PPAR ligand, NF-B modulator,
and redox signaling mediator (12,133,134).

Anti-proliferative and anti-inflammatory

properties have also been examined for similar bioactive lipids including: 15-oxo-ETE
(108), linoleic acid metabolites (135), a series of long-chain electrophilic fatty acids
termed the EFOXs (118), and nitro-fatty acids (136). In the absence of a known Gprotein coupled receptor, such as that activated by 5-oxo-ETE,(121) these bioactive
lipids are hypothesized to rely on intra-cellular targets. Therefore, understanding the
availability of these compounds to the cytoplasmic space is of critical importance. This
study was designed to test the cellular uptake, metabolism, and anti-proliferative effects
of 11-oxo-ETE in multiple cell models. We examined differential uptake of both 11-oxoand 15-oxo-ETE between HUVECs and the LoVo colon cancer cell line. Using methylester derivatives of 11-oxo-ETE and 15-oxo-ETE, we studied targeted intracellular
delivery to HUVECs and LoVo cells. Finally, we investigated whether there was
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potentiation of the anti-proliferative action of oxo-ETEs through targeted delivery or by
pharmacological blockade of MRP exporters.

3.3 Materials and Methods
Chemicals and Reagents.

LC-MS Optima grade hexanes, methanol, acetonitrile,

isopropanol, protease inhibitor, and BCA protein quantification kit were obtained from
Fisher Scientific (San Jose, CA). Dichloromethane, N,N-diisopropylethylamine (DIPEA),
dimethyl sulfoxide (DMSO), and pentafluorobenzyl bromide (PFB) were from SigmaAldrich (St. Louis, MI). Probenecid was obtained from Enzo Life Sciences (Farmingdale,
NY). Phosphate buffered saline (PBS) and 3-(N-morpholino) propanesulfonic acid
(MOPS) were from Invitrogen (Carlsbad, CA). 11-oxo-ETE, 15-oxo-ETE, [13C20]-15-oxoETE, as well as the methyl esters of 11-oxo-ETE (11-oxo-ETE-ME) and 15-oxo-ETE (15oxo-ETE-ME) were prepared in house with standard procedures (129).

Western

Lightning ECL was obtained from Perkin Elmer (Waltham, MA). Fetal bovine serum
(FBS) was obtained from Gemini Bioproducts (West Sacramento, CA).

HUVECs,

human arterial endothelial cells (HAECs), Medium 200, Low Serum Growth Supplement
(LSGS), penicillin, streptomycin, F-12K media, and DMEM media were obtained from
Invitrogen (Carlsbad, CA). LoVo, MCF-7, A549, and HCA-7 cell lines were obtained
from American Type Culture Collection (ATCC) (Manassas, VA).
Cell culture. LoVo and adenocarcinoma human alveolar epithelial (A549) cells were
maintained in F-12K media supplemented with 2% FBS and 100,000 units/L penicillin
and 100mg/L streptomycin.

HUVECs and human arterial endothelial cells (HAECs)

were maintained in Medium 200 (Invitrogen, Carlsbad, CA ) supplemented with the
LSGS Kit on Collagen I-coated tissue culture dishes (Becton Dickinson, Bedford, MA).
Human colonic adenocarcinoma (HCA-7) cells and the MCF-7 breast cancer cells were
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maintained in DMEM supplemented with 2% FBS and 100,000 units/L penicillin and
100mg/L streptomycin. The relevant maintenance media was used for treatment unless
otherwise indicated.
Quantification of cellular uptake. LoVo cells and HUVECs were plated at 4x105 cells /
well in a 6-well tissue culture plate (Corning, Corning, NY) or a 6-well collagen coated 6well plate (Becton Dickinson, Bedford, MA) and allowed to attach for 12 h. 11-oxo-ETE,
15-oxo-ETE, or the respective methyl ester stocks were re-suspended in media
containing 0.25% DMSO at indicated concentrations. Either LoVo cells or HUVECs
were treated for indicated time-points with indicated compounds. Media was pipetted
off; a 3 mL aliquot was spiked with 1 ng [13C20]-15-oxo-ETE internal standard, and taken
for analysis. The cells were rinsed 4 times with cold PBS, gently scraped into 3 mL of
cold PBS, and spiked with 1 ng [13C20]-15-oxo-ETE internal standard. The final rinse of
cold PBS was taken and sampled as a control for residual 11-oxo- or 15-oxo-ETE.
Extraction and derivatization has been described in detail elsewhere (137).

Briefly,

media was extracted with diethyl ether with 0.5% acetic acid with vigorous shaking and
the organic phase was separated and evaporated under nitrogen gas.

Cells were

extracted with dichloromethane/methanol (2:1,v/v, with 0.5% acetic acid) with vigorous
shaking and one freeze-thaw cycle, the organic phase was then removed and
evaporated under nitrogen gas. After evaporation of the organic phases to dryness,
samples were suspended in 100 µL DIPEA in acetonitrile (1:9; v/v) and 200 µL of PFB
bromide in acetonitrile (1:19; v/v) and kept at room temperature for 30 min.

The

derivatized samples were dried down again under nitrogen, and then re-suspended in
100 µL of hexane/ethanol (95:5; v/v) for stable isotope dilution chiral LC-selected
reaction monitoring (SRM)/ECAPCI/MS analysis.
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Treatment of cells with [13C20]-15-oxo-ETE. LoVo cells (5x106) were cultured as
described above and then treated with 10 mM [13C20]-15-oxo-ETE.

Cell and media

fractions were pooled, and derivatization and analysis were performed as described
above except the internal standard was omitted.
Liquid Chromatography. A Water’s Alliance 2690 HPLC system (Waters Ltd, Watford,
Hertfordshire, UK) was used for liquid chromatography separations. The PFB derivatives
of 11-oxo-ETE and 15-oxo-ETE were separated using normal phase Chiralpak AD-H
column (250x4.6mm, 5µm; Daicel Chiral Technologies, Westchester, PA) with a 1
mL/min flow rate. Solvent A was hexanes and solvent B was isopropanol/hexane (6:4;
v/v). Gradient composition was: 2% B at 0 min, 2% B at 14.5 min, 12% B at 15 min, 90%
B at 17 min, 90% B at 22 min, 2% B at 22.5 min, and 2% B at 29 min.
Mass Spectrometry.

A Thermo Triple Stage Quadrupole (TSQ Quantum) mass

spectrometer (Thermo Scientific) with an APCI source was operated in negative ion
mode. The following transitions corresponding to each compound were monitored; 11oxo-ETE-PFB, m/z 317165 [collision energy (CE), 25 eV] 15-oxo-ETE-PFB, m/z
317113 (CE, 18 eV); [13C20]-15-oxo-ETE-PFB, m/z 337120 (CE, 18 eV).

For

absolute quantification of 15-oxo-ETE and 11-oxo-ETE, standard curves ranging from 0
to 2 ng and 0 to 4 ng, respectively, were generated in the same matrix under identical
extraction conditions with pure compounds. Data analysis was performed using Xcalibur
software (Thermo Scientific).
BrdU Incorporation Assays. HUVECs, LoVo, HCA-7, and A549 cells were plated at
2000 cells/well and allowed to attach for 12 h.

Treatment media was prepared at

indicated concentrations by serial dilution from the most concentrated stock, keeping
constant 0.25% DMSO. Cells were treated for 24 h, and then spiked with BrdU for 6 h to
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allow incorporation into newly synthesized DNA. The assay was developed using a
BrdU cell proliferation kit (Roche Diagnostics) according to the manufacturer’s directions,
and a UV-Vis plate reader (BioRad).
Western Blots. Cells were collected from pre-confluent cultures and lysed in RIPA
buffer containing 1x protease inhibitor cocktail. Protein was quantified with a BCA kit.
30 g of protein lysate in reducing conditions was loaded into 4-12% gradient gel and
ran in MOPS buffer for 50 min at 200V. Proteins were transferred onto a nitrocellulose
membrane overnight on ice at 30V. After blocking with 5% BSA in TBS/T, primary
antibody was incubated overnight in blocking buffer.

Primary antibodies for MRP1,

MRP4, and GAPDH were respectively, Abcam (ab32574-100), (ab56675), and (ab8245).
Secondary antibody was HRP-conjugated sheep anti-mouse from GE Life Sciences
(NA9310). All antibodies were diluted in blocking buffer at 1:1000. Visualization was
accomplished with Western Lightning ECL in a digital developer (GE Healthcare).
MTT Proliferation Assays. LoVo cells were plated at 2000 cells/well and allowed to
attach for 12 h. Treatment media was prepared at indicated concentrations by serial
dilution from the most concentrated stock, keeping constant 0.25% DMSO. Probenecid
was added from a concentrated stock to 1mM treatment concentration. After indicated
time-points, media was replaced with fresh base media containing no FBS or Pen/Strep,
and MTT was added to a final concentration of 2 mg/mL and allowed to incubate for 4 h.
After incubation, all of the media was removed and the MTT was eluted using pure
isopropanol. The resulting absorbance was read at 565 nm in a 96-well plate using a
UV-Vis plate reader (BioRad).
Statistical analysis. All statistical analyses were carried out using the GraphPad Prism
(5) software package.
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3.4 Results
Intracellular 11-oxo-ETE was reduced in LoVo colon cancer cells versus human
umbilical vein endothelial cells. To study the uptake and metabolism of 11-oxo-ETE,
LoVo cells or HUVECs were incubated with 10 M of 11-oxo-ETE, 10 M of 15-oxoETE, or media with 0.25% DMSO vehicle for 4 h. Media and cells were collected at
various time-points. Quantification of the free 11-oxo- and 15-oxo-ETE was performed
by stable isotope dilution chiral LC-SRM/ECAPI/MS with [13C20]-15-oxo-ETE as the
internal standard. Cells were carefully normalized to cell count used in the experiments,
and only allowed a minimum of time to attach in order to avoid excess growth. Cell
volume determination would require lifting of the cells which, especially in the case of the
collagen attached, elongated HUVECs, could result in a cell volume change.
Intracellular concentrations of 11-oxo-ETE were reduced in the LoVo cells (Fig.
2A) as when compared with the HUVECs (Fig. 2B) at all time-points examined. 15-oxoETE demonstrated the opposite trend, with greater intracellular amounts in LoVo cells
(Fig. 2A) versus HUVECs (Fig. 2B). Maximal uptake of 11-oxo-ETE was achieved for
LoVo cells and HUVECs at 30 min and 60 min, respectively. 15-oxo-ETE maximal
uptake occurred at 30 min for both cell types.

Clearance of the free 11-oxo-ETE

occurred completely in both cell lines by 4 h, whereas 15-oxo-ETE was still detectable at
that time.

Treatment of the LoVo cells with [13C20]-15-oxo-ETE did not cause the

generation of endogenous 11-oxo-ETE or 15-oxo ETE as judged by comparison of the
LC-MS chromatogram that was obtained from the cell suspension (Supplementary Fig.
3) with that obtained from the internal standard alone (Supplementary Fig. 1). This
conclusively demonstrated that 11-oxo-ETE uptake and metabolism was significantly
different between the LoVo cells (Fig. 2A) and HUVECs (Fig. 2B).
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11-oxo-ETE inhibited BrdU incorporation across multiple cell lines with varying
potency. BrdU incorporation assays were used to measure the anti-proliferative effects
of treatments with increasing doses of 11-oxo-ETE. The value obtained for vehicle
treatment 0.25% DMSO was arbitrarily set at 100%. Multiple cancer cell lines were used
including LoVo, HCA-7 and A549 from colon, colon, and lung cancer respectively. The
same assay was conducted with HUVECs to allow comparison to our earlier work on 11oxo- and 15-oxo-ETE (108,129). Increasing doses showed a dose-dependent reduction
in proliferation. HUVECs were the most sensitive to treatment (Fig. 3A) followed by the
colon cancer lines LoVo (Fig. 3B) and HCA-7 (Fig. 3C). A549 lung cancer cells showed
no significant response to treatment until higher doses of 11-oxo-ETE were used (Fig.
3D).
11-oxo-ETE-ME and 15-oxo-ETE-ME preferentially target the intracellular space. In
order to test the targeting of oxo-ETEs to the intracellular environment, 11-oxo-ETE-ME,
15-oxo-ETE-ME, 11-oxo-ETE, 15-oxo-ETE, and a vehicle control were incubated with
LoVo cells and HUVECs for 60 min. Media and cells were then extracted and free oxoETEs were quantified by LC-MS. The methyl esters significantly increased the levels of
free oxo-ETEs in the cell over the amount in the media in both LoVo cells (Fig. 4A) and
HUVECs (Fig. 4B). The free 15-oxo-ETE reached a higher intracellular concentration in
the LoVo cell (Fig 4A). In contrast the 11-oxo-ETE was higher in the HUVECs (Fig. 4B).
Essentially no 11-oxo-ETE or 15-oxo-ETE was detected in the LC-MS chromatogram
from the fourth wash of the LoVo cells treated with 11-oxo-ETE, 15-oxo-ETE, 11-oxoETE-ME or 15-oxo-ETE-ME (Supplementary Fig. 3) when compared with a control
internal standard alone (Supplementary Fig. 2).

Similar results were obtained from

HUVECs (data not shown). Furthermore, there was no detectable 11-oxo-ETE-ME or
15-oxo-ETE-ME in the fourth wash of the cells (data not shown). This confirmed that
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none of the 11-oxo-ETE or 15-oxo-ETE could have arisen from material left on the cell
surface and suggested that the methyl ester derivatives could provide a useful delivery
strategy to target the intracellular environment for both 11-oxo- and 15-oxo-ETE.
MTT assays over multiple days demonstrate anti-proliferative effects for 11-oxoETE and 11-oxo-ETE-ME. To observe the anti-proliferative effects of 11-oxo-ETE, 15oxo-ETE and their methyl esters, MTT assays were carried out over 72 h. Every 24 h,
samples were collected, and the media was refreshed. Values obtained for vehicle
treatment 0.25% DMSO was arbitrarily set at 100%.

15d-PGJ2 was included as a

reference compound. 11-oxo-ETE dose dependently inhibited growth over multiple days
(Fig. 5A). Furthermore, 11-oxo-ETE-ME reached significance for inhibition before the
free 11-oxo-ETE (Fig. 5A). In all cases, by 72 h, significant anti-proliferative effects were
observed versus the vehicle control (Figs. 5A, 5B). Interestingly, 11-oxo-ETE-ME (Fig.
5B) was more potent than 11-oxo-ETE (Fig. 5A), causing a significant antiproliferative
effect at all three time points.
The transporter proteins MRP1/MRP4 were expressed in the more resistant cell
lines. In order to help understand why there were differences in the intracellular 11-oxoETE concentrations the expression of MRP1 and MRP4 membrane transporters was
examined. MRP4 expression was robust in the A549 lung cells and significant in the two
endothelial lines tested (HUVEC, HAEC); whereas expression of MRP 1 was robust in
all cancer lines (LoVo, HCA-7, MCF-7, and A549) when compared with the two
endothelial lines (Fig. 6). This suggested that increased MRP1 expression could have
been a major determinant of the reduced cellular 11-oxo-ETE levels in LoVo cells (Fig.
2A) when compared with the HUVECs (Fig. 2B). MRP1 has previously been implicated
in PG export, especially in the context of cancer cell dependent up-regulation of tumor
microenvironment PGE2 (138).
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Anti-proliferative effects of 11-oxo-ETE-ME are increased with co-treatment of the
drug transport inhibitor probenecid.

To test the possibility of blocking the drug

transporters to increase anti-proliferative effects, a MTT assay over multiple days using
the LoVo cell line was carried out. Treatments with probenecid, 11-oxo-ETE-ME, or the
combination of both were compared to vehicle control arbitrarily set at 100%. At both 48
and 72 h, significantly increased anti-proliferative effects were observed for the
combination treatment versus either treatment alone (Fig. 7).

Pretreatment with

probenecid increased the recovery of 11-oxo-ETE from the 11-oxo-ETE-ME treated
LoVo cells (Fig. 8).

This suggests that increased intracellular 11-oxo-ETE was the

mechanism for the synergistic action of probenecid on 11-oxo-ETE-ME anti-proliferative
action.

3.5 Discussion
The involvement of COX-2 and 15-PGDH in cancer progression has been well
documented (14,40,41,139-142). Pro-proliferative AA metabolites derived from COX-2,
such as PGE2 acting via the G-protein coupled PGE receptors (EP)1, EP2, and EP4,
induce proliferation and angiogenesis (15,143,144). Autocrine and paracrine signaling
of PGE2 in cancer leads to a feed forward loop modulating local immune responses and
increasing angiogenesis and proliferation (139,141). A decrease in catabolic 15-PGDH
leads to increased activity of PGE2 due to its reduced metabolic clearance (41).
However, AA metabolism leads to a plethora of metabolites with distinct and sometimes
opposing functions (6).

Considerable work on the anti-proliferative effects of AA

metabolites have focused primarily on 15d-PGJ2 (17).

These studies have been

complicated by contradictory results (118,145,146), uncertainty over the actual
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physiological relevance of the tested compounds (109), and a lack of dysregulation in
disease states(11). Other cyclopentenone PGs such as PGA2 have been linked to antiproliferative action via inhibition of the cell cycle through cyclin D1 at 100M (147).
11-oxo-ETE and 15-oxo-ETE are known endogenous compounds isolated from
clinical

specimens,

and

major

metabolites

of

AA

via

COX/15-PGDH

(83,108,122,129,132). In this study, measurable anti-proliferative effects were seen in
three of four tested cell lines at 2 M and all four cell lines at 10 M (Fig. 4). Although
11-oxo-ETE was clearly more potent than 15-oxo-ETE, the effect of both eicosanoids
was significant, and their effects could be modulated by targeted intracellular delivery or
pharmacological blockade of transporters (Figs. 5, 6, 7). The amounts of 11-oxo-ETE
and 15-oxo-ETE that were detected in the LoVo cells and HUVECs represented only a
small fraction of the total amount of each oxo-ETE or oxo-ETE-ME that was added to the
cells. From our previous work, we suspect that major amounts of the oxo-ETEs are
conjugated to GSH, exported, and cleaved to the cysteinyl-glycine adduct (83). We are
also actively investigating other biotransformation pathways that contribute to metabolic
clearance.

The finding that intracellular delivery of 11-oxo-ETE through use of the

methyl ester derivative increased the anti-proliferative effects in LoVo cells (Figs. 4, 5, 7)
lends support to the hypothesis that a plausible mechanism of action may be through
intracellular targets.

This was particularly evident in the increased anti-proliferative

activity of 11-oxo-ETE-ME (Fig. 5B) when compared with the free 11-oxo-ETE (Fig. 5A).
The amplification of anti-proliferative effects and increased recovery of 11-oxo-ETE with
probenecid co-treatment (Fig. 7) also supports this hypothesis. This is in agreement
with an expanding body of work supporting a hypothesis for the mechanism of action for
certain bioactive lipids through intracellular signaling mediators (12,118,135,136). These
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findings, along with our previous work on the GSH-mediated metabolism of 11-oxo- and
15-oxo-ETE may implicate intracellular uptake as a rate-limiting factor in bioactivity and
metabolism of these compounds (83).
During tumorigenesis, significant up-regualtion of COX-2 occurs, which would
increase the production of pro-proliferative PGE2, (13,141) as well as the antiproliferative
oxo-ETEs.

However, there is also signficant down-regualtion of 15-PGDH,

(41,92,95,96,148) which would result in increased activity of PGE2 due to its decreased
catobolism coupled with a decrease in the formation of the oxo-ETEs (Fig. 1B) (129).
Increased expression of MRP4, (138,149,150) the transporter involved in the efflux of
PGE2 (151,152) also occurs during tumorigenesis. This would further prevent the 15PGDH-mediated metabolism of PGE2 in epithelial cells and so further facilitate an
increase in its activity at relevant membrane EPs. In contrast, increased efflux of oxoETEs mediated by MRP4 would result in reduced activity because (as described above)
they have intracelluar targets. Finally, the up-regulation of glutathione biosynthesis and
increased glutathione-S-transferase expression (153-155) would result in increased
conversion of oxo-ETEs into their corresponding inactive glutathione adducts (83).
Therefore, tumor progression is associated with substantial activation of pro-proliferative
PGE2 and metabolic inactivation of the the oxo-ETEs.
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Figure 3.1. Oxo-ETE chemical structures and metabolic pathways. (A) Chemical
structures of compounds used in this study, with PGE2 provided for comparison. (B) The
currently elucidated COX-2/15-LOX and 15-PGDH dependent pathway for generation of
11-oxo-ETE and 15-oxo-ETE. AA, Arachidonic Acid, COX, Cyclooxygenase, 15-LOX,
15-Lipoxygenase, cPLA2, cytosolic phospholipase A2, PGH2, prostaglandin H2, HPETE,
hydroperoxyeicosatetraenoic acid, HETE, hydroxyeicosatetraenoic acid, 15-PGDH, 15hydroxyprostaglandin dehydrogenase, POX, peroxidase, DH, dehydrogenase, oxo-ETE,
oxo-eicosatetraenoic acid.
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Figure 3.2. Disposition of oxo-ETEs in LoVo cells and HUVECs. Stable isotope
dilution LC-SRM/ECAPCI/MS quantification of uptake and distribution of 15-oxo-ETE
and 11-oxo-ETE by (A) LoVo cells and (B) HUVECs over time. Cells were incubated at
37°C with 15-oxo-ETE (2µM) or 11-oxo-ETE (2µM) for 5, 30, 60, and 240 min. For each
time point, cellular fractions were collected, extracted and spiked with [13C20]-15-oxoETE, and derivatized with PFB. Each time point is plotted as the mean of triplicates with
SEM.
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Figure 3.3. Anti-proliferative action of 11-oxo-ETE. BrdU incorporation measured by
ELISA in (A) HUVECs, (B) LoVo cells, (C) HCA-7 cells, (D) A549 cells, following 24h
treatment with indicated dose of 11-oxo-ETE in 0.25% DMSO compared to vehicle
control. 1-way ANOVA with post-hoc Dunnett’s Multiple Comparison test versus vehicle
control was used to access statistical significance (* p< 0.05, ** p< 0.01, ***p < 0.001).
Data are plotted as the means (n=3-8) with SEM bars, representative of at least two
independent experiments.
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Figure 3.4. Intracellular oxo-ETEs after methyl ester derivative treatment. Stable
isotope dilution chiral LC-SRM/ECAPCI-MS quantification of the ratio of cellular/ media
11-oxo- and 15-oxo-ETE in (A) LoVo cells and (B) HUVECs. Cells were incubated with
15-oxo-ETE (10 µM), 15-oxo-ME (10 µM), 11-oxo-ETE (10 µM), 11-oxo-ME (10 µM), or
0.25% DMSO vehicle control for 60 min. Cellular and media fractions were collected,
extracted, and spiked with [13C20]-15-oxo-ETE, and derivatized with PFB. Data are
plotted as the means of triplicates with SEMs of the ratio of analytes in the cellular over
media fractions. Statistical significance was assessed by 1-way ANOVA with post-hoc
Bonferroni Multiple Comparison test (* = p<0.05).
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Figure 3.5. Anti-proliferative action of oxo-ETEs and their methyl esters.

Cell

proliferation measured by MTT assay with LoVo cells over multiple days with the
indicated compounds in 0.25% DMSO compared to vehicle control. Treatments with the
free acids are shown in (A), the methyl-esters are shown in (B). Data are plotted as the
means (n=4) with SEMs, representative of at least two independent experiments.
Statistical significance was assessed by 1-way ANOVA with post-hoc Bonferroni Multiple
Comparison test against the respective vehicle control (* p < 0.05, ** p < 0.01, *** p <
0.001).
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Figure 3.6. MRP1 and MRP4 expression. Western blots of HAEC, HUVEC, MCF-7
cells, HCA-7 cells, LoVo cells, and A549 cells for transporters MRP 4 and MRP 1,
together with the loading control GAPDH. Increased expression of MRP1 was observed
in the cancer cells lines (MCF-7, HCA-7, LoVo, A549) versus the endothelial cells
(HAEC, HUVEC).

MRP4 expression was detectable in all cell lines, with robust

expression in A549 cells.
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Figure 3.7. Potentiation of 11-oxo-ETE by probenacid. Cell proliferation of LoVos
measured by MTT assay over multiple days with 2 M 11-oxo-ETE-ME and/or 1 mM
probenecid in 0.25% DMSO compared to vehicle control. Data are plotted as the means
(n=4) with SEMs, representative of at least two independent experiments. Statistical
significance was assessed by 1-way ANOVA with post-hoc Bonferroni multiple
comparison test (* p <0.05).

Figure 3.8. Increased recovery of 11-oxo-ETE with probenacid treatment. Stable
isotope dilution chiral LC-SRM/ECAPCI-MS quantification of the recovery of 11-oxo-ETE
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in LoVo cells. Cells were incubated with either 0.25% DMSO or 1mM probenecid for 30
min before incubation with 11-oxo-ME (10 µM) in 0.25% DMSO vehicle control for 60
min. Cellular and media fractions were collected, extracted, and spiked with [ 13C20]-15oxo-ETE, and derivatized with PFB. Data are plotted as the means of triplicates with
SEMs. Statistical significance was assessed by 2-way student’s t-test (** = p<0.01).

Figure 3.9. LC-ECAPCI–MS of 15-oxo-ETE internal standard. 10ng PFB-derivatized
13

C20-15-oxo-ETE internal standard analyzed by normal phase ECAPCI-MS. Noise levels in the

11-oxo-ETE and 15-oxo-ETE channels are shown to establish a baseline.
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Figure 3.10. Lack of residual oxo-ETEs after washing of the cells. The 4th wash of the
cellular fraction was pooled for a 11-oxo-ETE and a 15-oxo-ETE treatment, derivatized, and
analyzed as indicated for the media fractions. 11-oxo-ETE and 15-oxo-ETE channels
demonstrate noise levels of signal, indicating that the wash steps were sufficient to remove
detectable 11-oxo- or 15-oxo-ETE.

Figure 3.11. Lack of induction of oxo-ETEs by treatment with 13C20-15-oxo-ETE.
LoVo cells were cultured and treated as indicated in the methods section, and then treated with
13

10M C20-15-oxo-ETE. Cell and media fractions were pooled, and derivitization and analysis
were performed as indicated except the internal standard was ommitted. No detectable 11-oxo13

ETE of 15-oxo-ETE was found, indicating that the C20-15-oxo-ETE did not induce generation
of 11-oxo-ETE or 15-oxo-ETE.
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Chapter 4. A Covalently Modifying Endogenous Canonical NF-B
Inhibitor from Arachidonic Acid Metabolism

In preparation for submission as: A covalently modifying endogenous canonical NF-B inhibitor
from arachidonic acid metabolism. Nathaniel W. Snyder, Guang Yang, Xiaojing Liu, Suhong
Zhang, Phyllis A. Dennery, and Ian A. Blair.

Background: Arachidonic acid (AA) metabolism results in the formation of eicosanoids
including 11-oxo-eicosatetraenoic acid (11-oxo-ETE).
Results: 11-oxo-eicosatetraenoic acid was found to inhibit canonical p50/p65 NF-B
signaling via a covalent modification.
Conclusion: 11-oxo-ETE is a feedback mediator for arachidonic acid metabolism and
NF-B signaling.
Significance: Inflammatory states involved in normal physiology and disease are
regulated by a diverse set of mediators.

Summary
α,β-unsaturated ketone containing molecules have been shown to bind to critical
cysteine residues of proteins. Metabolism of arachidonic acid (AA) via
Cyclooxygenase/15-hydroxyprostaglandin dehydrogenase (COX/15-PGDH) leads to the
formation of 11-oxo-eicosatetraenoic acid (oxo-ETE), an α,β-unsaturated ketone
containing eicosanoid with structural similarity to other bioactive lipids. 11-oxo-ETE has
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no known receptor or function, but has been detected in human samples. Here, we
show that pre-treatment of human umbilical vein endothelial cells (HUVECs) by 11-oxoETE reduced p50/p65 binding to consensus sequence DNA when activated by TNF-
and Kdo2-Lipid A. Inhibition of canonical NF-B signaling was confirmed through
electrophoretic mobility shift assays, western blot for manganese super oxide dismutase
from TNF- challenged HUVECs, and a stably expressed firefly luciferase NF-B
reporter assay in HEK293 cells. Western blots of phosphorylated inhibitor of kappa B
(IkB) α and inhibitor of kappa B kinase (IKK) β revealed a decrease in phosphorylation of
IBα, with no change in phosphorylation of IKK. This finding was confirmed by in vitro
kinase studies of IKK. LC-MS/MS of tryptic peptides from the DNA binding domain of
p50/p65 revealed a Michael addition adduct of 11-oxo-ETE to a critical cysteine residue,
as well as a histidine adduct. These experiments demonstrate that products of AA
through COX/15-PGDH metabolism may serve as a negative feedback loop via a redox
sensitive lipid mediator, 11-oxo-ETE. Therefore, it may be of interest to design stable
11-oxo-ETE mimetics or modulators of AA metabolism to induce 15-PGDH.

Introduction
Initiation, control, and resolution of inflammation are all regulated, in part, by
arachidonic acid (AA) metabolism, and thus by the enzymes responsible for transforming the AAderived bioactive lipids (6). However, the roles of several of these major downstream products
remain to be elucidated.
AA metabolism by the cyclooxygenase enzymes (COX) begins with abstraction of the 13
pro-S hydrogen (26). Formation of prostaglandin (PG) G2 occurs through insertion of molecular
oxygen, followed by a second insertion and a cyclization reaction. A monoxygenase type reaction
may also occur, with insertion of molecular oxygen at either C11 or C15 resulting in 11(R)-
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hydroperoxyeicoatetaenoic acid (HPETE) or a mixture of 15(S) and 15(R)-HPETEs (156). The
C15 monoxygenase reaction to 15(R)-HPETE is a major pathway after acetylation by aspirin.
The HPETEs are then reduced by peroxidases yielding stable hydroxyeicosatetraenoic acids
(HETEs) (157).

15-HPETE can also be generated from arachidonic acid by various

lipoxygenases (LO) with specificity for the carbon where the oxygen insertion occurs, including a
12/15-LO and a 15-LO (33). 11- or 15-HETEs are then transformed into oxo-ETEs via a second
level of metabolism involving 15-hydroxyprostaglandin dehydrogenase (15-PGDH), converting
the hydroxyl group to a carbonyl (83,108,129). This creates an electrophilic -unsaturated
ketone that could react via a Michael addition with a nucleophilic cysteine or histidine residue.
The metabolic pathway for generation of the 11-oxo- and 15-oxo-ETE has been
demonstrated in cell lines expressing both COX-2 and 15-PGDH (83,108,129). 11-oxo-ETE has
been detected in advanced human atherosclerotic plaques (122). Despite our understanding of the
metabolism and a demonstration of the endogenous presence of 11-oxo-ETE, there is no known
G-protein coupled receptor, or any well described signaling pathway for this molecule. However,
similar molecules such as the electrophilic oxo-derivatives (EFOXs) (118) and 15-deoxy-12,14PGJ2 (15d-PGJ2) (12), also contain -unsaturated ketones, and have been shown to inhibit NFB signaling. Therefore, we hypothesized that 11-oxo-ETE may act via a similar mechanism.
This study was aimed at investigating the effects of 11-oxo-ETE on the canonical signaling
pathway of NF-B mediated by the transcription factors p50/p65, and test a plausible mechanism
based on covalent adduction to explain the inhibitory effects observed in a cell model system.

Experimental Procedures
Chemicals and Reagents–Protease inhibitor cocktail (100x), phosphatase inhibitor
(100x) Trizma-HCl, ethacrynic acid, pentafluorobenzyl bromide (PFB), and clear flat-
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bottom streptavidin coated 96-well plates were purchased from Sigma-Aldrich (St. Louis,
MO). Medium 200 and low serum growth supplement (LSGS) were supplied by
Invitrogen (Carlsbad, CA). RIPA and MOPS buffers, LC-MS grade (Optima) formic acid,
water, and acetonitrile were obtained from Fisher Scientific (Pittsburgh, PA). Gases were
supplied by The Linde Group (Munich, Germany). Electrophoretic mobility shift assay
(EMSA) probes were purchased from Integrated DNA Technologies (Coralville, IA).
Unless otherwise noted, antibodies were purchased from Cell Signaling Technologies
(Danvers, MA). Recombinant IKK, biotin-tagged IkB- substrate peptide, ATP, and
kinase buffer were also from Cell Signaling Technologies.
Cell Culture–Human umbilical vein endothelial cells (HUVECs) were obtained from
Invitrogen (Carlsbad, CA) and were cultured in Medium 200 with low serum growth
supplement on Collagen IV coated tissue culture plates from Becton Dickinson (Bedford,
MA). HEK293 cells stably expressing firefly luciferase driven by a 5x-B reporter were a
kind gift of the Hogenesch lab at University of Pennsylvania and were maintained in
DMEM with 2% FBS and 100,000 units/L penicillin and 100 mg/L streptomycin.
Transcription Factor Binding Assays–HUVECs were treated with 2 M 11-oxo-ETE, 2
M 15d-PGJ2, or vehicle control 0.25% DMSO in maintenance media. After 15 minutes
the cells were then challenged with 0.5 mg/mL Kdo2-Lipid A and 40 ng/mL TNF- or
vehicle control for 45 minutes without changing the media. Nuclear fractions were taken
from cells using a nuclear extraction kit from Cayman Chemical (Ann Arbor, MI) and
p50/p65 binding was assayed using a p50/p65 binding EIA based detection kit from
Cayman Chemical.
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Electrophoretic Mobility Shift Assay–HUVECs were treated with 0.2 M 11-oxo-ETE, 2
M 11-oxo-ETE, the NF-B inhibitor BAY 11-7085, or vehicle control 0.25% DMSO.
After 15 minutes the cells were then challenged with 40 ng/mL TNF- or vehicle control
for 45 minutes without changing the media.

Nuclear extracts were taken as described

above. Duplexes of oligonucleotide containing the consensus sequence (5’-GCC TGG
GAA AGT CCC CTC AAC T-3’) or mutated sequence (5’-GCC TGG GAA ACT CGC
CTC AAC T-3’) of NF-B were synthesized by Integrated DNA Technologies. EMSA
assay was performed as described previously (158) with minor modification. Briefly, a
32

P-labeled consensus NF-B was used as a probe to evaluate NF-B binding ability.

To identify nonspecific binding of the nuclear proteins, competition reactions were
performed by addition of either 50-fold excess of non-radiolabeled NF-B or 50-fold
excess of non-radiolabeled mutated NF-B to the reaction mixtures prior to
electrophoresis. In order to identify the NF-κB subunit proteins in the complex, 1 µL of
p50 or p65 antibody, ab7971 or ab7970, respectively, from Abcam (Cambridge, MA)
was incubated with the nuclear protein prior to addition of the radiolabeled probe to
visualize any supershift-retarded bands in the NF-B complex (11). A loading control
oligomer SP-1 (5’-ATT CGA TCG GGG CGG GGC GAG C-3’) was obtained from
Promega (Madison, WI) (12). An AP-1 oligomer (5’-TTC CGG CTG AGT CAT CAA GCG
C-3’) from IDT was used as an additional control. Purity of all oligomers was checked by
gel electrophoresis prior to use (data not shown).
Superoxide Dismutase Western Blotting– HUVECs were treated with 2 M 11-oxo-ETE,
2 M 11-oxo-ETE-methyl ester (11-oxo-ETE-ME), or vehicle control 0.25% DMSO in
maintenance media. After 15 minutes the cells were challenged with 40 ng/mL TNF- or
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vehicle control for 6 hours without changing the media. Cells were lysed in RIPA buffer
with protease inhibitor cocktail and flash frozen in dry ice/ethanol then stored at -80°C
until analysis. Protein was quantified with a micro-BCA kit from Thermo-Pierce, and 30
g of protein/well was loaded in a 4-12% gradient Bis-Tris gel and ran for 50 minutes at
200 V in MOPS buffer. Proteins were transferred to a nitrocellulose membrane in
transfer buffer with 10% methanol at 30 V overnight at 4°C and blocked for an hour in
5% skim milk in TBS/T. The membrane was cut and incubated overnight at 4°C with the
primary antibody. After washing, the membrane was incubated for 2 hours at room
temperature with the secondary antibody. Visualization was performed in a digital
analyzer (GE healthcare) with Western Lightning ECL reagent (Perkin Elmer).
Phospho-protein Western Blotting–HUVECs were treated with 2 M 11-oxo-ETE, 2 M
11-oxo-ETE-ME, or vehicle control 0.25% DMSO in maintenance media. After either 5
minutes or 6 hours the cells were challenged with 40 ng/mL TNF- or vehicle control for
45 minutes without changing the media. Cells were lysed in RIPA buffer with 1x
protease and 1x phosphatase inhibitor cocktail and flash frozen in dry ice/ethanol then
stored at -80°C until analysis. Blotting and visualization were performed as above.
IKK Kinase Assay–HTScan IKK Kinase assay kit (Cell Signaling) was used as
directed with minor modification to screen for IKK inhibition. Briefly, recombinant IKK
was incubated with indicated compounds at the indicated concentrations for 15 minutes
in 1x kinase buffer prepared separately from the kit using the reducing agent TCEP
instead of DTT. Biotin-tagged IB- and ATP were added to a final concentration of
1.5M and 200 M respectively, and the mix was incubated for 30 minutes at room
temperature. The reaction was quenched with addition of 50 mM EDTA pH 8. The
cocktail was loaded into strepavidin coated clear 96-well plates, allowed to bind for 2
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hours at room temperature, washed with PBS/T three times. The plate was incubated
with 100 mL 1:1000 anti-phospho-IB- antibody in TBS/T with 5% BSA for 2 hours,
then washed three times with 200 mL PBS/T. The plate was incubated with 100 mL
1:1000 secondary anti-rabbit antibody coupled to HRP for an hour at room temperature.
The plate was developed and read in a UV-Vis spectrometer (BioRad).
Adduct Formation and Analysis–A synthetic peptide with a tryptic overhang of two
residues on each terminus (FRYVCEGPSHGGLPGASSEKNK) corresponding to the
human and mouse p50 DNA binding domain (Supplemental Fig. 1) was obtained from
AnaSpec (Freemont, CA). The peptide was incubated overnight with 10 m 11-oxo-ETE
in 1 mM ammonium bicarbonate buffer pH 7.5 then digested with sequencing grade
trypsin (Promega) for 16 hours at 37°C. The sample was then desalted on a C18 spin
column from The Nest Group (Southborough, MA), evaporated in a vacuum dessicator,
and dissolved in mobile phase A for LC-MS analysis. LC separations were conducted
using a Waters nano-ACQUITY UPLC system (Waters Corp., Milford, MA, USA). A
Waters BEH130 C18 column (100 m × 150 mm inner diameter, 1.7 µm pore size;
Waters Corp) was employed for reversed phase separation (flow-rate 1.8 L/min).
Solvent A was 98% water/2% acetonitrile with 0.1% formic acid, and solvent B was
99.5% acetonitrile/0.5% water with 0.1% formic acid. The gradient was as follows: 5% B
at 0 min, 5% B at 3 min, 60% B at 35 min, 95% B at 37 min, 95% B at 43 min, 5% B at
44 min, and 5% at 60 min. Separations were performed at 30°C. A LTQ XL-Orbitrap
hybrid mass spectrometer (Thermo Fisher) was used in positive ion mode with a
Michrom captive spray electrospray ionization (ESI) source. The operating conditions
were: spray voltage at 4 kV; capillary temperature at 250°C; capillary voltage at 35 V;
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collision induced dissociation (CID) was performed using helium as the collision gas in
the ion trap (normalized collision energy [CE], 30%).
NF-B reporter assay–HEK293 cells stably expressing firefly luciferase driven by
a 5x-B reporter were incubated with increasing concentrations of 11-oxo-ETE for 5
minutes before treatment with 40 ng/mL TNF- for 6 hours. Treatment media was the
same as maintenance media with 0.25% DMSO.
LC-MS Quantification of Cellular Uptake–HEK293s as above were plated at 4x105 cells /
well in a 6-well tissue culture plate (Corning, Corning, NY) and allowed to attach for 12
hours. 11-oxo-ETE was re-suspended in media containing 0.25% DMSO at indicated
concentrations by serial dilution from the most concentrated treatment. After 90
minutes, the cells were gently scraped in the media; an aliquot of 250 L of the cell
suspension was taken and spiked with 1 ng [13C20]-15-oxo-ETE internal standard.
Extraction and derivatization has been described in detail elsewhere (159). Briefly, the
samples were extracted with dichloromethane/methanol (2:1,v/v) containing 0.5% by
volume acetic acid with vigorous shaking, the organic phase was then removed and
evaporated under nitrogen gas. After evaporation of the organic phases to dryness,
samples were suspended in 100 µL DIPEA in acetonitrile (1:9; v/v) and 200 µL of PFB
bromide in acetonitrile (1:19; v/v) and kept at room temperature for 30 minutes. The
derivatized samples were dried down again under nitrogen, and then re-suspended in
100 µL of hexane/ethanol (95:5; v/v) for stable isotope dilution chiral LC-selected
reaction monitoring (SRM)/electron capture atmospheric pressure chemical ionization
(ECAPCI)/MS analysis. A Water’s Alliance 2690 HPLC system (Waters Corp.) was used
for liquid chromatography separations. The PFB derivatives of 11-oxo-ETE and 15-oxoETE were separated using normal phase Chiralpak AD-H column (250 x 4.6 mm, 5 µm;
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Daicel Chiral Technologies, Westchester, PA) with a 1 mL/min flow rate. Solvent A was
hexanes and solvent B was isopropanol/hexane (6:4; v/v). Gradient composition was:
2% B at 0-14.5 min, 12% B at 15 min, 90% B at 17 min, 90% B at 22 min, 2% B at 22.5
min, and 2% B at 29 min. Seperations were performed at 30°C. A Thermo Triple Stage
Quadrupole (TSQ Quantum) mass spectrometer (Thermo Scientific) with an APCI
source was operated in negative ion mode as previously described (129). The following
transitions corresponding to each compound were monitored; 11-oxo-ETE-PFB, m/z
317165 (CE, 25 eV) and [13C20]-15-oxo-ETE-PFB, m/z 337120 (CE, 18 eV). For
absolute quantification of 11-oxo-ETE, a standard curve ranging from 0 to 2 ng was
generated in the same matrix under identical extraction conditions with pure compound.
Data analysis was performed using Xcalibur software (Thermo Scientific).

Results
11-oxo-ETE inhibits p50/p65 DNA Binding in HUVECs–Pretreatment of the HUVECs
with 11-oxo-ETE or 15d-PGJ2 significantly reduced the additional p50 (Figs. 2A, 2C) and
p65 (Figs. 2B, 2D) binding induced by treatment with Kdo2/TNF-. These results were
confirmed by EMSA. Either 2 M 11-oxo-ETE (Fig. 3, lane 6) or the NF-B inhibitor BAY
11-7085 (Fig. 3, lane 4) abolished the induced NF-B signaling in the TNF- treated
HUVECs. Competition assays revealed that the induced factor was in fact NF-B, and
predominantly p65 (Fig. 3, lane 9).
11-oxo-ETE Dose-Dependently Inhibits NF-B Driven Luciferase Activity– HEK293 cells
stably expressing firefly luciferase driven by a 5x-B reporter were incubated with
increasing concentrations of 11-oxo-ETE for 5 minutes before treatment of 40 ng/mL
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TNF- for 6 h. 11-oxo-ETE reduced firefly luciferase activity in a dose-dependent
manner versus the vehicle control (Fig. 4A). With a 30 minute pretreatment of 100 M of
the GST inhibitor ethacrynic acid the effect of 11-oxo-ETE on NF-B inhibition was more
evident (Fig. 4B), and recovery of 11-oxo-ETE from the treated cells was higher at 90
minutes (Fig 4B, 4C).
11-oxo-ETE Inhibits Downstream of IKK in HUVECs–Pretreatment of 11-oxo-ETE for 5
minutes before TNF- challenge for 45 minutes caused a modest reduction in TNF-mediated elevation of phospho-IkB-α levels. The methyl ester of 11-oxo-ETE, which
targets the intracellular space, also caused a modest reduction in phospho-IkB-α levels
(Fig. 5A). However, a 6 hour pretreatment with 11-oxo-ETE or 11-oxo-ETE-ME, caused
no inhibition of TNF--mediated phospho-IkB-α elevation (Fig. 5B).
To exclude the possibility of effects on upstream kinases, levels of phospho-IKK
were surveyed by Western blotting from the same cell extracts. No reduction in
phosphor-IKK was observed in either time point. In no cases did the 11-oxo-ETE or 11oxo-ETE-ME alone induce significant phosphorylation of IKK or IkB-α (Fig. 5A, 5B).
In vitro screening of IKK activity with recombinant IKK, a biotin linked substrate,
capture on a streptavidin coated plate, and HRP-based visualization was used to study
the effects of ,-unsaturated ketone containing eicosanoids on IKK kinase activity.
This experiment demonstrated dose dependent inhibition of IKK by 15d-PGJ2 and 11oxo-ETE (Fig. 5C). 15-oxo-ETE was much less potent (data not shown).
11-oxo-ETE Treatment in HUVECs Inhibits the Induction of Manganese Superoxide
Dismutase–Treatment of HUVECs with 11-oxo-ETE and 11-oxo-ETE-ME before TNF-
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challenge strongly inhibited the induction of the NF-B target manganese superoxide
dismutase after 6 h (Fig. 6).
11-oxo-ETE Forms a Covalent Adduct with Amino Acids within the p50 DNA Binding
Domain–In order to mechanistically explain the reduction in p50/p65 activity, we
investigated the possible formation of a covalent adduct forming between the
electrophilic ,-unsaturated ketone of 11-oxo-ETE and the nucleophilic residues of
p50/p65. The tryptic peptide corresponding to the cysteine and histidine containing
DNA-binding domain of p50 was chosen because it would offer the most structural
information for complete elucidation of the adduct (Supplemental Fig. 1A).
The synthetic peptide with a tryptic overhang of 2 residues on each terminus was
obtained from AnaSpec, incubated overnight with 10 M 11-oxo-ETE then digested with
trypsin for 16 h. The sample was then desalted using a C18 spin column (The Nest
Group), evaporated in a vacuum desiccator, and dissolved in mobile phase A for
chromatographic separation and mass spectrometry.
Reversed LC-MS/MS revealed two putative covalent adducts that were isomeric.
Positive ion mode charge state determination and high-resolution accurate mass
determination in the Orbitrap showed that the unmodified and modified peptide was
primarily triply charged (MH33+) (Supplemental Fig. 2A, 2B). The LC retention time of the
unmodified peptide (17.4 min; Fig 7A) was shorter than the two modified peptides (24.8
min, 28.3 min; Fig. 7B). This was consistent with the increased hydrophobicity derived
from the addition of a fatty acid. MS/MS analysis of MH43+ (m/z 698.35) from the later
eluting adduct, suggested that 11-oxo-ETE had added to the peptide residue
corresponding to cysteine-61 (Supplementary Fig. 4) of the p50 protein (Supplementary
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Fig. 1). Three relatively high abundance y11+2, y13+2, y14+2 ions were observed containing
an unmodified histidine residue provided compelling evidence for a covalent modification
on cysteine (Fig. 8, Supplemental Fig. 4). The presence of the oxo-ETE moiety was
confirmed by the ion at m/z 319.2258 (Calculated m/z for C20H36O3 = 319.2268).
The earlier eluting adduct had a product ion spectrum that was consistent with
addition of 11-oxo-ETE to the histidine moiety (Fig. 8, Supplemental Fig. 3). The
spectrum was quite different from that observed for the cysteine adduct. In particular,
there was a relatively intense y16 ion containing the oxo-ETE moiety. Additional minor
product ions confirmed that the attachment of oxo-ETE was at the peptide residue
corresponding to histidine-64 (Fig. 8) of the p50 DNA binding domain.

Discussion
The specific identity and mechanism for lipid mediators of resolution remain
controversial. Anti-inflammatory lipids with a mechanism of action through a GPCR,
such as the lipoxins, may constitute one family of signaling molecules. Other molecules
such

as

15d-PGJ2,

the

EFOXs

derived

from

eicosapentaenoic

acid

and

docosahexaenoic acid, nitro-fatty acids, and now 11-oxo-ETE have non-G proteincoupled receptor mechanisms of action (12,118,135,136,145,160).
-unsaturated ketone containing fatty acids can form covalent adducts to cysteine
and histidine residues of proteins (161). In the case of adduction to signaling proteins,
such as Keap1-Nrf2 (135), PPAR(12), NF-B (12), or IKK(133) this may mediate a
cellular response as a redox sensor. Such a system of redox-mediated feedback has
been hypothesized to be important in the control and resolution of inflammatory
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responses. Alternatively, other adduct forming entities such as 4-hydroxynonenal have
been implicated in pathological oxidative stress (162).
The present study has unequivocally shown that 11-oxo-ETE is directly analogous to
(and slightly more potent than) the widely studied PGD2 degradation product 15-d-PGJ2
in its ability to inhibit the activity of NF-κB (Fig. 2). This occurs through a pathway that
did not appear to involve diminished phosphorylation of IKKβ (Fig. 5A) or IkB-α (Fig. 5B).
In spite of a very modest change in the phosphorylation status of IKKβ there was a clear
dose-dependent decrease in the activity of NF-κB (Fig. 5C).
The structure/function relationship of electrophiles to inhibition of NF-κB is likely
complex, especially within the wider pathological context. This may be attributable to the
structural properties of targets for electrophiles, as has been suggested by studies with
PPAR (16,163). Available structural data on the NF-κB family members examined in
our study points to the critical nature of the contact of the cysteine binding domain
(Supplementary Fig. 1) with the target consensus sequence DNA (164,165).
Interactions may also be a property of the contextually dependent metabolism of the
electrophile (166).
Identifying 11-oxo-ETE-mediated covalent modifications to NF-κB components such
as p50 or p65 in a cellular context would be extremely challenging because of the trace
amounts that are present.

Furthermore, the purified proteins require substantial

amounts of free thiols to maintain their activity.

This would prevent the covalent

attachment of any electrophilic Michael acceptors such as 11-oxo-ETE. Therefore, we
used a potential tryptic peptide (with two amino acid overhangs at the trypsin sites)
derived from the p50 component of NF-κB (Supplementary Figure 1A). After treatment
of the peptide with 11-oxo-ETE and trypsin digestion, an adduct was identified with a
structure that was consistent with covalent attachment of 11-oxo-ETE to cysteine-61
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(Fig. 8, Supplementary Fig. 4) and an adduct at histidine-66 (Fig. 8, Supplementary Fig.
3).

Availability of these covalently modified peptides show that the 11-oxo-ETE

modifications were a plausible hypothesis to explain the cellular responses observed
earlier. However, current LC-MS methodology does not have sufficient sensitivity to
determine whether the 11-oxo-ETE modifications can also occur on the endogenous p50
protein.
Interestingly, 15d-PGJ2, 15-oxo-ETE, and 11-oxo-ETE also exhibit anti-proliferative
effects (108,129). In inflammatory states and in multiple cancers, COX-2 is up-regulated
and 15-PDGH is down-regulated (88,115,127,167,168). This metabolic dysregulation,
as well as perturbation of cellular eicosanoid transporters, is hypothesized to contribute
to a pro-inflammatory, pro-proliferative, and pro-angiogenic environment. Therefore, the
oxo-ETEs could potentially exert both anti-inflammatory and anti-proliferative effects that
would be abolished by down regulation of 15-PGDH, which is required for their
biosynthesis (83,108,129).
Our findings indicate that therapies designed to modulate, rather than completely
inhibit, AA metabolism into downstream products might be a more effective therapy for
chronic inflammatory conditions and cancer. Thus, increased COX-2 activity can be
compensated by increased 15-PGDH activity through inactivation of pro-inflammatory
eicosanoids such as PGE2 and increased formation of eicosanoids that can modulate
the activity of NF-κB such as 11-oxo-ETE. Research into the metabolism and signaling
of other polyunsaturated lipid products, or via other signaling pathways may also provide
valuable insight into electrophiles with therapeutic or diagnostic implications.
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Figure 4.1. Chemical structures examined in this study. -unsaturated ketone
containing eicosanoids used in this study and the Michael addition adduct of 11-oxo-ETE to a
cysteine residue.
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Figure 4.2. Inhibition of induced p50/p65 transcription factor binding in activated
endothelial cells. (A) NF-κB p50 binding in nuclear extracts from HUVECs pre-treated with 2
M 11-oxo-ETE. (B) p65 binding in nuclear extracts from HUVECs pre-treated with 2 M 11oxo-ETE. (C) p50 binding in nuclear extracts from HUVECs pre-treated with 2 M 15d-PGJ2.
(D) p65 binding in nuclear extracts from HUVECs pre-treated with 2 M 15d-PGJ2. Cells were
first treated with 0.5 mg/mL Kdo2-Lipid A and 40 ng/mL TNF- for 45 minutes. 0.25 % DMS
was used as control.
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Figure 4.3. EMSAs from HUVEC nuclear extracts after various treatments. (1) Free
probe for NF-kB. (2) 0.25 % DMSO control. (3) TNF-α. (4) BAY 11-7085 + TNF-α. (5) 0.2 µM
11-oxo-ETE + TNF-α. (6) 2 µM 11-oxo-ETE + TNF-α. (7) 50-fold excess of cold NF-kB (8)
Mutated NF-B cold competition. (9) p50 antibody supershift. (10) p65 antibody supershift. (11)
SP-1 cold competition. (12) AP-1 cold competition.
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Figure 4.4. NF-B driven firefly luciferase activity with 11-oxo-ETE treatment. (A)
Firefly luciferase activity versus vehicle control in HEK293 cells stably transfected with a
5x-B reporter driving firefly luciferase with pretreatment of 11-oxo-ETE for 5 minutes
before treatment with 40 ng/mL TNF-. B) Following an additional pre-treatment of the

88
cells with 100 M ethacrynic acid. C) LC-ECAPI/SRM/MS quantification of 11-oxo-ETE
from HEK293 cells with or without ethacrynic acid pre-treatment.
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Figure 4.5. IKKβ and IkBα phosphorylation in HUVECs. (A) Pretreatment with 11oxo-ETE or 11-oxo-ETE–ME for 5 minutes before TNF-α challenge for 45 minutes. (B)
Pretreatment with 11-oxo-ETE or 11-oxo-ETE–ME for 6 hours before TNF-α challenge
for 45 minutes. (C) In vitro IKKβ inhibition with 15d-PGJ2 (2 or 10 µM) and 11-oxo-ETE
(2 or 10 µM).

Figure 4.6. Inhibition of induced manganese superoxide dismutase by 11-oxo-ETE
in activated endothelial cells. Western blot of manganese superoxide dismutase from
HUVECs pre-treated with 0.25% DMSO vehicle control, 2 M 11-oxo-ETE, or 2 M 11oxo-ETE-ME, and then challenged with 40 ng/mL TNF- as indicated.
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Figure 4.7. LC-MS analysis of tryptic peptides. The LC-MS chromatogram of (A) Unmodified peptide from binding pocket of p50. (B) 11-oxo-ETE adducts of peptides from
the DNA binding pocket of p50.
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Figure 4.8. Peptide fragments detected in MS2 analysis of the 698.3468 m/z
precursor ion corresponding to the adduct of the tryptic peptide of the p50 DNA
binding domain. (A) Cys-61 adduct (B) His-66 adduct. Ions in bold provide differential
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site localization of the adduct to Cys-61 versus His-66.

Figure 4.9. DNA binding domain of p50 showing cysteine-61 and hsitidine-66. (A)
Sequence homology of mammalian p50s (NFKB1) and p65. (B) Predicted protonated
molecules from un-modified and modified tryptic peptides.
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Figure 4.10. Protonated molecules with charge states from high resolution LC-MS
analysis. (A) 11-oxo-ETE-modifed peptide from DNA binding region of p50. (B)
Unmodified peptide from DNA binding region of p50.
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2

FIGURE 4.11. MS analysis of the 11-oxo-ETE modification on histidine-66 residue
of the peptide from the binding pocket of p50.

FIGURE 4.12. MS2 analysis of the 11-oxo-ETE modification on cysteine-61 residue
of the peptide from the binding pocket of p50.
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Chapter 5: Stable Isotope Labeling in Cell Culture for Liquid
Chromatography-Mass Spectrometry of Mixed Length Acylcoenzyme A Thioesters.

In preparation for submission as: Stable isotope labeling in cell culture for liquid
chromatography mass spectrometry of mixed length acyl-coenzyme A thioesters.
Nathaniel W. Snyder, Sankha S. Basu, Zinan Zhou, Andrew J. Worth, Ian A. Blair

Abstract
Rationale: Coenzyme A (CoA) thioesters are a critical component of cellular metabolism.
Therefore, the measurement of CoA species is an important analytical task, and can be
accomplished with high sensitivity, specificity, and reproducibility by the gold standard
method of stable isotope dilution-liquid chromatography-single reaction monitoring-mass
spectrometry (SID-LC-SRM/MS).
Methods: Previously, we developed a strategy for producing the required array of short
chain acyl-CoA heavy isotopic standards for SID analysis. Here we expand our
procedure for producing isotopically labeled CoA thioesters to include lower abundance
medium and long chain acyl-CoAs. A fatty acid treatment and solid phase extraction
were adapted for acyl-CoA recovery from cell culture. Reversed phase LC-MS/MS with
an API4000 mass spectrometer operating in positive ion mode was used for analysis.
Results: We demonstrate induction, recovery, and analysis of low abundance medium
and long chain acyl-CoAs. The isotopic purity of our labeling was confirmed to be above
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99%. Chromatographic separation of isobaric mixed length chain acyl-CoAs was
confirmed against commercial standards. Using SID-LC-SRM/MS, we measure murine
liver acyl-CoA levels, and absolutely quantify the induction of arachidonoyl-CoA in cell
culture.
Conclusions: This method should further the rigorous quantitative study of acyl-CoA
species. This procedure provides a simple cost-effective means of preparing acyl-CoA
stable isotope labeled standards.

Introduction
In prokaryotes and eukaryotes, coenzyme A is an essential cofactor for energetic
and synthetic metabolic pathways. CoA species are perturbed in a wide variety of
diseases with high mortality and morbidity including metabolic dysfunction (169),
toxicological insult (170), and a spectrum of genetic disorders (171,172). Fatty acid
synthesis, catabolic breakdown of long chain fatty acids, xenobiotic biotransformation,
and post-translational modification of proteins rely on acyl-CoA intermediates (8,173175). However, mammalian cells are incapable of synthesizing the essential CoA
precursor pantothenate (vitamin B5) from precursors (176). Previously, we have taken
advantage of this incomplete metabolism by replacing pantothenate in cell media with a
[13C3 15N1]-pantothenate heavy isotope labeled analog, which is then incorporated into
CoA, and thus, any CoA thioester (177). We termed this methodology stable isotope
labeling by essential nutrients in cell culture (SILEC), after the similarity to the stable
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isotope labeling by amino acids in cell culture (SILAC) methods employed for proteins
(178). For acyl-CoA molecules, this imparts a +4 m/z shift to the internal standard,
allowing distinction between the analyte and the internal standard in a mass
spectrometer, without significant isotopic overlap or interference from biological matrices
(179).
A major limitation of our earlier work was that our extraction and analysis
methods only encompassed short chain CoA thioesters, failed to include naturally
transient medium chain acyl-CoAs and more hydrophobic longer chain acyl-CoA
species. In this study we have adapted a previously reported extraction to encompass a
wider range of CoA species (180), and demonstrate recovery of short, medium, and long
chain CoA thioesters after an optimized induction of lower abundance species. We
further demonstrate a successful application of our SILEC method to create a panel of
internal standards. To demonstrate the utility of this method we absolutely quantify
induction of arachidonoyl-CoA after treatment with the parent fatty acid in a cell culture
system, and measure absolute levels of acyl-CoA species in mouse liver tissue.

Materials and Methods
Reagents
Arachidonoyl-CoA, 5-sulfosalicilic acid (SSA), ammonium formate solution,
glacial acetic acid, and dimethyl sulfoxide (DMSO) were purchased from Sigma-Aldrich
(St. Louis, MO). Optima LC-MS grade methanol, acetonitrile (ACN), 2-propanol (IPA)
and water were purchased from Fisher Scientific (Pittsburgh, PA). 2-(2-pyridyl) ethyl
functionalized silica gel 100 mg/1 mL tubes were obtained from Supelco Analytical
(Bellefonte, PA). F-12K media, DMEM, medium 200, low serum growth supplement
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(LSGS) kit, streptomycin, and penicillin were purchased from Invitrogen (Carlsbad, CA).
Charcoal stripped fetal bovine serum (csFBS) was from Gemini Bioproducts (West
Sacramento, CA). [13C3 15N1] calcium pantothenate was purchased from Isosciences
(King of Prussia, PA). Peroxide free arachidonic acid (AA) was purchased from Cayman
Chemical (Ann Arbor, MI). Human colorectal adenocarcinoma cells (LoVo) and human
colon adenocarcinoma (HCA7) cells were obtained from ATCC (Manassas, VA).
Cell Culture
For SILEC labeling, Hepa1c1c7s were passaged at least 7 times in custom RPMI
1640 media without calcium pantothenate (AthenaES, Baltimore, MD) and containing
10% charcoal stripped-FBS, 100 units/mL penicillin, 100 mg/L streptomycin, and 2 mg/L
[13C3 15N1]-calcium pantothenate. 24 hours before extraction, “ultra-labeling” with media
as above, but omitting csFBS, was carried out for to ensure optimal CoA heavy isotopic
labeling. For unlabeled cell culture, HCA7 cells were grown in DMEM media with 2%
FBS and 100 units/mL penicillin and 100 mg/L streptomycin. LoVos were grown in F-12K
media with 2% FBS and 100 units/mL penicillin and 100 mg/L streptomycin.
Sample preparation
For SILEC internal standards, batches were grown as above. Upon completion
of labeling method, cells were gently lifted, centrifuged at 500 rcf for 5 minutes and
resuspended in 750 µL / 10cm2 plate of 3:1 ACN:IPA. Samples were sonicated with a
probe tip sonicator on ice 30 times for 0.5 s. 250 µL of 100 mM KH2PO4 (pH 6.7) were
added to the samples, then vortexed and spun down for 10 min at 16,000 rcf at 4°C.
The supernatant was pooled and stored in -80°C until use.
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For cellular acyl-CoA analysis, cells were gently lifted, centrifuged at 500 rcf for 5
minutes and resuspended in 750 µL / 10 cm2 plate of 3:1 ACN:IPA for extraction as
previously described (180). Samples were pulse sonicated with a probe tip sonicator on
ice 30 times for 0.5 s. 250 µL of 100 mM KH2PO4 (pH 6.7) were added to the samples,
then vortexed and spun down for 10 min at 16,000 rcf at 4°C. The supernatant was
transferred to a glass tube and acidified with 125 µL of glacial acetic acid. SPE columns
were equilibrated with 1 mL 9:3:4:4 ACN:IPA:H2O:acetic acid. The samples were
transferred to the column and filtrated. The column was washed two times with 1 mL of
the 9:3:4:4 mix. The columns were eluted two times with 500 µL 4:1 methanol:250 mM
ammonium formate into glass tubes. Filtrate was evaporated to dryness under nitrogen
gas. The filtrate was then re-dissolved in 50 µL of 70:30 H2O:ACN with 5% SSA (w/v)
and transferred to HPLC vials.
Induction of arachidonoyl-CoA and measurement of mouse liver acyl-CoA
HCA7 and LoVo cells were grown until 80% confluence as above. 25 µM
arachidonic acid with 0.25% DMSO in DMEM media was added and at 30 min, 60 min,
90 min and 4 h, the cells were gently scraped and collected in plastic tubes. Tubes were
centrifuged for 5 min at 500 rcf. Media was removed and the cell pellet was dissolved in
550 µL 3:1 ACN:IPA and 200 µL of the internal standard mix was added to each sample.
Then the samples were extracted and prepared as above.
For the arachidonoyl-CoA quantification, six standard solutions of arachidonoylCoA in methanol were made corresponding to 20 pmol, 2 pmol, 0.2 pmol, 20 fmol, 2 fmol
and 0 fmol on column. The standards were dried and then re-dissolved in 800 µL 3:1
ACN:IPA and 200 µL of ISTD were added to each sample. 250 µL of 100 mM KH2PO4
(pH 6.7) were added to the samples, then vortexed and spun down for 10 min. at 16,000
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rcf. The supernatant was transferred to a glass tube and acidified with 125 µL of glacial
acetic acid. Then, the samples were extracted using SPE column and the samples were
prepared as above. Analysis of the standard curve was performed with Excel.
LC-MS/MS
Samples were kept at 4°C in a Leap CTC autosampler (CTC Analytics,
Switzerland) with 20 μL injections used for LC-MS analysis. Chromatographic
separation was performed using reversed phase Waters XBridge C18 column (2.1 x 150
mm, pore size 3.5 μm) on an Agilent 1100 HPLC system using a three solvent system:
(A) 5 mM ammonium acetate in water, (B) 5 mM ammonium acetate in 95/5
acetonitrile/water (v/v), and (C) 80/20/0.1 (v/v/v) acetonitrile/water/formic acid, with a
constant flow rate of 0.2 mL/min. Gradient elution was performed as follows: 2% B
(isocratic) for 1.5 min, 2% to 20% (linear gradient) over 3.5 min, 20% to 100% B (linear
gradient) B over 0.5 min, 100% B (isocratic) for 8 min, 100% C for 5 min, before
equilibration at initial conditions for 5 min.
Samples were analyzed using an API 4000 triple quadrupole mass spectrometer
(Applied Biosystems, Foster City, CA) in positive electrospray ionization (ESI) mode and
data was analyzed using Analyst software as previously described (179). The mass
spectrometer operating conditions were as follows: ion spray voltage (5.0 kV),
compressed air as curtain gas (15 psi) and nitrogen as nebulizing gas (8 psi), heater (15
psi), and collision-induced dissociation (CID) gas (5 psi). The ESI probe temperature
was 450°C, the declustering potential was 105 V, the entrance potential was 10 V, the
collision energy was 45 eV, and the collision exit potential was 15 V. CoA thioesters
were monitored using the transitions described in Table 2.
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Results
Mixed Acyl-CoA Extraction
Extracts of LoVo cells at 80% confluence were analyzed by the LC-MS method
described above. The neutral loss scans of 507.1 m/z are shown in Figure 2 for the
mixed CoA solid phase extraction (Figure 2A), the short chain CoA solid phase
extraction (Figure 2B), and a biphasic liquid-liquid Folch extraction (Figure 2C). In our
hands, the mixed extraction recovered the broadest range of acyl-CoA species as
evidenced by the peaks corresponding to acyl-CoA species in the short, medium, and
long chain range. The short chain extraction we have previously used gave intense
CoASH and acetyl-CoA peaks, and overall higher signal intensity, but did not recover
significant middle or long chain CoA species. Recovered species appeared less
abundant in the Folch extract versus the mixed CoA SPE (Figure 2A, 2C).
Generation of a SILEC standard
Hepa1c1c7 mouse hepatocellular carcinoma cells were grown in RPMI media
with pantothenate omitted, 2% charcoal stripped FBS, and 2 mg/L [13C4 15N1] calcium
pantothenate added for 7 passages. Cells were “ultra-labled” for 24 hours in the same
media with 0% FBS. The cells were harvested using the mixed CoA solid phase
extraction method. Labeling for oleoyl-CoA was determined using integration of the
peak area for the 1032  525 and 1036  529 m/z transitions corresponding
respectively to the unlabeled and labeled oleoyl-CoA (Figure 3A). Commercial standards
were matched with SILEC internal standards for the following acyl-CoA species; acetyl,
butyryl, hexanoyl, octanoyl, decanoyl, lauroyl, tetradecanoyl, palmitoyl, palmitoeloyl,
lineolyl, steareolyl, oleoyl, and arachidonoyl-CoA (Figure 3B). Importantly, the M2
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isotopomers for overlapping species, such as oleoyl-CoA M2 and steareoyl-CoA, are
shown to achieve baseline separation with our liquid chromatography method (Figure
3B). Consistent with our previous work on short-chain acyl-CoAs (170,177,179) we find
that the distribution of species is unequal, such that certain molecules of interest may be
insufficiently synthesized in the internal standard mix for analytical use. To address this
problem, we tested induction of acyl-CoAs in Hepa1c1c7 cells with various doses of fatty
acid mixtures. A fatty acid mix sodium butyrate, sodium hexanoate, sodium octanoate,
sodium decanoate, and sodium dodecanoate at 100 M was found to be ideal, where
above that concentration cellular toxicity was observed (data not shown). A time course
study revealed that 3 hour incubation at 100 M produced the best distribution of acylCoA species (Figure 5).
Arachidonoyl-CoA time course
To demonstrate the use of this method for cellular studies, we quantified the
levels of arachidonoyl-CoA in a cell system treated with free arachidonic acid. A special
SILEC standard was generated by treating the SILEC cells with 25 µM arachidonic acid
for one hour before extraction. This provided increased arachidonoyl-CoA internal
standard, and shows the applicability of this method for targeted long chain acyl-CoA
quantitation. LoVo and HCA-7 colon adenocarcinoma cells were treated with 25 µM
arachidonic acid, and the cells were extracted and analyzed by our method at various
time points. The resulting standard curve was linear over 4 orders of magnitude from 20
fmol to 20 pmol on column and allowed us to capture the entire concentration range of
cellular induction of arachidonoyl-CoA levels in the treated cells with absolute
quantification (Figure 4A).
Tissue acyl-CoA quantitation
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A set of three mouse liver tissue samples were analyzed by our method, and
absolute quantification of select acyl-CoA species is given. We describe pmol/mg of
protein levels of long chain CoA thioesters in the mouse liver tissue (Figure 4B). This
demonstrates the use of this method for quantitative analysis of acyl-CoA species from
tissue samples.

Conclusion
Acyl-coenzyme A species are important to cell bioenergetics metabolism, and
play critical roles in lipid generation, cell signaling, post-translational modification of
proteins, and metabolism of xenobiotics (170,175). However, the variety of individual
chemical entities making up the acyl-CoA family poses a challenge to the analytical task
of their measurement. LC-UV strategies for analysis of CoA species may be
insufficiently specific due to co-eluting peaks (181). Excellent LC-MS/MS strategies for
the analysis of acyl-CoAs have been employed by other groups, including validated
methods by Magnes, et al. (182) and Mauriala et al. (183). However, these
measurements used no internal standards.
In this study, we expand our previous method to generate stable isotope labeled
internal standards for short chain acyl-CoAs to include medium and long chain acylCoAs. We were able to generate standards of even the low abundance acyl-CoA
species and demonstrate the utility of this method in measuring induction of an acyl-CoA
species and measuring absolute levels of CoAs from mouse liver tissue.
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Figure 5.1. A) Biosynthesis of long chain acyl-coenzyme A thioesters B)
Coenzyme A MS fragmentation for neutral loss of 507 amu
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Figure 5.2. Neutral loss 507 scans of LoVo cells. Cells were extracted by A) mixed
acyl-CoA SPE B) Folch extraction C) short chain acyl-CoA SPE.
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Figure 5.3. LC-SRM/MS chromatograms of acyl-CoA thioesters. Chromatograms of
A) labeling efficiency of unlabeled and [13C3,15N1] labeled oleoyl-CoA from Hepa1c1c7
SILEC extracts, B) labeled SILEC acyl-CoAs and unlabeled authentic standard acylCoAs. Where isotopic overlap is observed, chromatographic separation is shown (e.g.
the M2 of oleoyl-CoA and M0 stearoyl-CoA).
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Figure 5.4. Application of SID-LC-MS/MS of mixed length CoAs to biological
systems. A) Absolute quantitation of the induction of arachidonoyl-CoA in two different
colon carcinoma cells lines from 0.5 to 4 hours. B) Absolute quantitation of acyl-CoA
species from three different mouse liver samples taken from different animals.

109

Figure 5.5. Neutral loss of 507 amu scans of [13C3, 15N1] Hepa1c1c7 cells
extracted at various time points. Spectra from extracted cells of (A) baseline, (B) 30
minutes, (C) 3 hours, (D) 6 hours, (E) 12 hours, (F) 24 hours after treatment with a 100
M mix of fatty acids as indicated in materials and methods.
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Chapter 6: Untargeted Metabolomics from Biological Sources
Using Ultraperformance Liquid Chromatography- High
Resolution Mass Spectrometry (UPLC-HRMS)
Published as: Snyder, N. W., Khezam, M., Mesaros, C. A., Worth, A., Blair, I. A. Untargeted
Metabolomics from Biological Sources Using Ultraperformance Liquid Chromatography-High
Resolution Mass Spectrometry (UPLC-HRMS). J. Vis. Exp. (75), e50433, doi:10.3791/50433
(2013).

6.1 Abstract
Here we present a workflow to analyze the metabolic profiles for biological
samples of interest including; cells, serum, or tissue. The sample is first separated into
polar and non-polar fractions by a liquid-liquid phase extraction, and partially purified to
facilitate downstream analysis. Both aqueous (polar metabolites) and organic (nonpolar metabolites) phases of the initial extraction are processed to survey a broad range
of metabolites. Metabolites are separated by different liquid chromatography methods
based upon their partition properties. In this method, we present microflow ultraperformance (UP)LC methods, but the protocol is scalable to higher flows and lower
pressures. Introduction into the mass spectrometer can be through either general or
compound optimized source conditions. Detection of a broad range of ions is carried
out in full scan mode in both positive and negative mode over a broad m/z range using
high resolution on a recently calibrated instrument. Label-free differential analysis is

111

carried out on bioinformatics platforms. Applications of this approach include metabolic
pathway screening, biomarker discovery, and drug development.

6.2 Introduction
Due to recent technological advances in the field of HRMS, untargeted,
hypothesis-generating metabolomics approaches have become a feasible approach to
analysis of complex samples.(184) Mass spectrometers capable of 100,000 resolution
facilitating routine low part per million (ppm) mass accuracy have become widely
available from multiple vendors.(185,186) This mass accuracy allows greater specificity
and confidence in a preliminary assignment of analyte identity, isotopic pattern
recognition, and adduct identification.(187) When coupled with an appropriate
extraction procedure and high-performance LC or UPLC, complex mixtures can be
analyzed with additional specificity derived from retention time data.(188) UPLC
possesses greater chromatographic efficiency and allows greater sensitivity, resolution
and analysis time making a greater coverage of the metabolome possible.(189) The
resulting large datasets can be integrated into any of multiple differential analysis
software and mined for useful patterns or individual analytes of interest.(190-194)
Putative hits can be initially identified using a combination of peak detection algorithms,
accurate mass based chemical formula prediction, fragmentation prediction, and
chemical database searching. This approach allows prioritization of targets for timeconsuming complete structural identification or for development of more sensitive and
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more specific stable isotope dilution UPLC/selected or multiple reaction monitoring/MS
studies that are the current gold standard methods for quantification.(159)
The varying nature of biological samples has led to optimization of extraction
protocols for urine(195), cells(196), serum(197), or tissue(198). This protocol features
extractions for cells, serum, and tissue. Where appropriate, comments and additional
references have been included for modifications of the procedure to address inclusion
of stable isotopes, or for inclusion of especially unstable metabolites.

6.3 Protocol Text
1.) [Sample Extraction from Cells]
1.1) For a 10cm plate of cells: collect 1.5mL of lifted cell suspension in media into a prelabeled 10mL glass centrifuge tube. For adherent lines, cells should be lifted with gentle
scraping in 1.5mL of media kept on ice. Optional: If internal standards are used, add an
appropriate aliquot at this step.
Comment: Quenching of cellular metabolism is crucial for certain metabolites. For
analysis of time-sensitive metabolites, procedures such as cold methanol extraction
should be considered.(199)
1.2) Add 6mL of chloroform (CHCl3)/methanol (CH3OH) (2:1, v/v) to each of the 10mL
glass tubes containing the samples. Set the samples in a shaker or multi-vortexer on low
speed for 30 min. After shaking, the samples are centrifuged with a low
acceleration/deceleration setting at 1935 x g for 10 min at 4°C to completely separate
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the phases. Optional: To avoid using CHCl3, extractions can be conducted with
dichloromethane (CH2Cl2).(159,200)
1.3) Using a long stem Pasteur pipet, transfer the organic (bottom) layer to a new prelabeled 10mL glass centrifuge tube. Continue to 4.1.
1.4) Transfer the upper aqueous later into a clean plastic 2mL Eppendorf tube.
Evaporate the sample under nitrogen gas. Continue to 2.6.2 for aqueous phase
desalting or continue to 4.1.
2.) [Sample Extraction from Serum]
2.1) Transfer 20μL of serum into a plastic 2mL Eppendorf tube. Optional: If internal
standards are used, add an appropriate aliquot at this step.
2.2) Add 190μL of CH3OH and vortex for 10 sec.
2.3) Add 380μL of CHCl3 and vortex for 10 sec.
2.4) Add 120μL of H2O to induce phase separation. Vortex the samples for 10 sec and
allow to equilibrate at room temperature for 10 min.
2.5) Centrifuge the samples at 8000 x g for 10 min at 4°C to separate the phases.
2.6) Transfer the lower organic phase into a clean plastic 2mL Eppendorf tube. Continue
to 4.1.
2.6.1) Transfer the upper aqueous later into a clean plastic 2mL Eppendorf tube.
Evaporate the sample under nitrogen gas.
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2.6.2) Re-suspend the sample in 200L H2O. Acid or base reagents (0.1% Acetic acid,
formic acid or 0.1% ammonium hydroxide) may be used to preferentially extract pH
sensitive metabolites. Sonicate for 20 min on ice to re-suspend the sample completely.
2.6.3) Activate the C18 spin columns with 500L CH3OH.
2.6.4) Equilibrate the spin column with two washes of 500 H2O and then load the
sample. If acid/base reagents are used maintain this concentration in the wash steps.
2.6.5) Wash with 500L H2O to desalt the sample. Again, if acid/base reagents are used
maintain this concentration in the wash steps.
2.6.6) Elute with two volumes of 200L 80% CH3OH in H2O into a pre-labeled clean 2mL
Eppendorf tube. Again, if acid/base reagents are used maintain this concentration in
the wash steps. Continue to 4.1.
3.) [Sample Extraction from Tissue]
3.1.) Depending on the tissue, use between 10-100 mg of frozen tissue. Add the whole
piece of tissue to a pre-labeled 2mL low retention Eppendorf tube with 1mL of PBS (1M,
pH 6.8) in an ice bath. Optional: If internal standards are used, add it into the buffer,
before adding the tissue.
3.2.) Homogenize the tissue in ice with an electric tissue grinder for 30 sec in each
Eppendorf. Between samples, clean the tissue grinder in two separate tubes containing
CH3OH and H2O, respectively.
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3.3) Transfer the tissue homogenate with a plastic pipette into a pre-labeled 10mL glass
centrifuge tube. After the transfer, rinse each Eppendorf tube two times with 1mL of
CH3OH and add the washes to the tissue homogenate in the glass tubes.
3.5) Add 4mL of CHCl3 to each of the 10mL glass tubes containing the tissue
homogenate and CH3OH washes. Set the samples in a shaker or multi-vortexer on low
speed for 30 min.
3.6) After shaking, centrifuge the samples with a low acceleration/deceleration setting
at 1935 x g for 10 min to completely separate the phases. Optional: To avoid using
chloroform, extractions have been developed with CH2Cl2.
3.7) Using a long stem Pasteur pipette, transfer the organic (bottom) layer to a new prelabeled 10mL glass centrifuge tube. Continue to 4.1.
3.8) Using a long stem Pasteur pipette, transfer the aqueous layer to a new pre-labeled
10mL glass centrifuge tube. Go to 2.6.2 for desalting or continue to 4.1.
4.) [Re-suspension and filtration of samples for UPLC]
4.1) Evaporate the samples under nitrogen gas.
4.2) Reconstitute dried down samples in an appropriate volume of the starting solution
for the desired UPLC method (see Table 1). 50-100L is usually a desirable resuspension volume. Gently vortex and/or pipette the sample up and down to aid in
dissolving the analytes.
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4.3.) Transfer the sample into a 0.22m nylon tube filter and spin at up to 14000 x g
until the sample has completely passed through the filter (~5 min). Make sure that
there are no visible precipitates remaining in the sample.
4.4.) Transfer the supernatant of the filtered sample into a pre-labeled UPLC vial with
insert. Cap vial, then flick the vial to remove any bubbles from the bottom of the
sample vial. Place the sample in the chilled autosampler (4-5˚C).
5.) [UPLC Setup]
5.1.) Using the control software for the liquid chromatograph, create a run for the
organic sample based off of the conditions listed in Table 1. Then create a method for
the aqueous phase off the conditions listed in Table 1. Optional: If a known set of target
analytes are of high interest, optimize the UPLC conditions using the heavy labeled
analog of these compounds, and generate a method using these conditions.
5.3.) Allow the UPLC to adequately equilibrate. This should include a full priming of
solvents before attaching a column, and following the manufacturer’s directions for
equilibration volume of a new column (usually 3-5 column volumes). Maintain a log of
starting back pressures to help diagnose future problems.
6.) [Mass Spectrometer Setup]
6.1.) Using the control software for the high resolution mass spectrometer, create a
positive mode method using the conditions listed in Table 2. Then using the same
conditions, create a negative mode method. Optional: If a known set of target analytes
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are of high interest, optimize source and optics conditions using the heavy labeled
analog of these compounds, and generate a method using these conditions.
6.2) Clean and calibrate the instrument, establish a stable spray into the spectrometer,
and allow time for the calibration solution to adequately dissipate from the source and
optics. Acceptable stability of spray should give a 3-5% RSD of intensity over at least
100 scans with injection of calibration solution at the same slow rate as the LC method
being used.
6.3) Set up the sequence for all the samples, set appropriate injection volume, and run
a blank before the first sample. If carryover or matrix effects between samples are
suspected, run adequate blanks/washes. Samples should be setup in a randomized
manner using a random number generator and a key to avoid any batch effects
introduced by analysis.
Comment: Quality control samples including stable isotope standards or analytical
standards of likely targets can be extremely valuable in troubleshooting and assuring
reliable, reproducible, and valid results. A technical replicate of a standard only sample
followed by a solvent blank can be used to accesses deviation of signal intensity and
retention time, as well as carryover into the blank run.
6.4) Begin sequence and monitor periodically for problems including pressure
fluctuations, or loss of signal intensity across the run. If severe problems are detected,
stop the run, and repeat from 6.2.
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7.) [Differential Analysis]
7.1.) Two workflows are presented for this protocol. The first is through SIEVE 2.0,
proprietary label-free differential analysis software sold by Thermo Fisher. The second
workflow is through XCMS Online, a free platform through Scripps Research
Institute.(194) Before beginning differential analysis, manually check the TICs or look at
filtered chromatograms for any known compound in the sample to ensure
reproducibility of runs and injection/UPLC/spray stability throughout all the samples.
7.2.) SIEVE
7.2.1) Transfer the .raw data files from the mass spectrometer to the hard drive of the
workstation where SIEVE is installed. (Note: running SIEVE with data stored on a
networked or USB port connected drive is not advisable as it can limit the speed of
analysis)
7.2.2) Open SIEVE, and begin a new experiment.
7.2.3) Load the appropriate files into SIEVE.
7.2.4) Assign comparison groups and select a single reference file to allow SIEVE to
generate the parameters for analysis.
7.2.5) Follow the prompts and adjust any parameters per requirements of any individual
experiment. It is often advisable to start with stringent parameters and then go back
and loosen the parameters as more generous settings can lengthen analysis time.
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7.2.6) Load the correct adduct list for positive or negative mode in the parameters.
7.3.) XCMS Online
7.3.1) Convert files into an acceptable format for XCMS Online. In our case, we convert
to mzXML format.(201)
7.3.2) Open XCMS Online, and Create Job.
7.3.3) Upload and name datasets. Only two datasets (e.g. Control vs Treatment) can be
uploaded as XCMS stand-alone is limited to head-to-head comparisons.
7.3.4) Select desired settings from the drop-down list. Pre-populated parameters are
available for different instrumentation setups, and these can be further modified for
experimental needs. In our case, we use the HPLC-Orbi2 settings.
7.3.5) Submit and confirm job.
7.4) Data Analysis
7.4.1) For SIEVE and XCMS a list of frames and features, respectively, will be populated
once the analysis is finished. Ensure that the LC alignment overlays any landmark peaks.
If any of the unaligned LC runs show large deviation in landmark peaks this may indicate
a problem with the sample.
Optional: For SIEVE, if internal standards are used, locate the corresponding peak group
and normalize to the selected frame. For XCMS On-line, normalization can be done in a
spreadsheet after export.
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7.4.2) Plot the data by coefficient of variation (CV) within a like sample population (e.g.
control samples). Any large CV values may indicate a problem with one or more sample.
Sort the list based on desired traits (e.g. p-value<0.05, Fold Change>1.5, low standard
deviation within a group, etc.)
7.4.3) Examine each peak for appropriate peak alignment across groups, peak
integration, Gaussian peak shape, signal intensity, isotopes, and adduct assignment.
7.4.4) Export data as desired for further analysis or to generate targeted mass lists for
confirmation and MSn experiments.

6.4 Representative Results
The results presented show selected data from a 6-h treatment of SH-SY5Y
glioblastoma cells with the pesticide and mitochondrial complex I inhibitor rotenone.
For brevity, only the organic phase positive mode data is presented. The samples were
processed and analyzed as described above (Figure 1, Table 1, Table 2) and loaded onto
two differential analysis platforms for label-free quantification, SIEVE and XCMS online.
Although a large number of hits (Figure 2, Figure 3) are identified by the two programs
used for differential analysis these features include likely artifacts, poorly integrated
peaks, and other features of questionable analytical value (Figure 6). This can be judged
by screening the hits for appropriate signal intensity, low variation between samples of
the same group, background levels, and good chromatographic peak shapes (Figure 3).
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To demonstrate the downstream confirmation of initial hits, we isolate a feature
with a mass corresponding to our treatment compound rotenone within 3ppm (Figure
3, Figure 4). We confirm the identity of this analyte with UPLC-HR/tandem mass
spectrometry (MS/MS) of our sample and the pure compound (Figure 5). We also
identify a differentially abundant feature reduced in the rotenone treated group,
tentatively identified as D-pantethine by accurate mass database searching (Figure 4).

Tables and Figures:

Figure 6.1. General Experimental Outline for Sample Preparation and Analysis by
Microspray UPLC-HRMS.

A general outline of sample preparation, including the optional introduction of internal
standards and protein or lipid/protein content analysis. Phase separation, liquid
chromatography, and analysis by different ion modes in the mass spectrometer are
outlined.
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Table 6.1: [UPLC Conditions]

General and compound optimized UPLC conditions. For organic phase 1, constant flow
rate of 1.8L/min through a Waters nanoACQUITY C18 BEH130 column kept in a heater
at 35˚C was used. Solvent A: 99.5% water/0.5% acetonitrile with 0.1% formic acid,
Solvent B: 98% acetonitrile/2% water with 0.1% formic acid For organic phase 2,
constant flow rate of 3.4L/min through an Acentis Express C8 column kept in a heater
at 35˚C was used. Solvent A: 40% water/20% acetonitrile with 0.1% formic acid and
10mM ammonium formate, Solvent B: 90% isopropanol/10% acetonitrile with 0.1%
formic acid and 10mM ammonium formate For the aqueous phase, constant flow rate
of 1.2L/min through a Waters nanoACQUITY C18 BEH130 column kept in a heater at
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35˚C was used. Solvent A: 95% water/5% methanol with 0.1% ammonium hydroxide,
Solvent B: 95% methanol/5% water with 0.1% ammonium hydroxide.

Figure 6.2. Mirror Plot Generated with XCMS.

A mirror plot showing differentially abundant features as detected and quantified
through XCMS online from the organic phase positive mode UPLC-MS analysis. Each dot
represents a distinct “feature.” Green dots are features more abundant (larger
integrated area) in the control, whereas red dots are less abundant in the treatment.
Increasing size of the dot indicates increasing magnitude of fold change between the
groups, and the intensity of color indicates a decreasing p-value with increasing
saturation of color.
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Figure 6.3. Analyte Peaks.

Chromatograms showing the organic phase positive ion mode UPLC-MS analysis. A)
Corrected (aligned) Total ion current (TIC) from SIEVE 2.0. B) Extracted Ion
Chromatogram for the feature tentatively identified as D-pantethine through XCMS. C)
Extracted Ion Chromatogram for the feature later identified as rotenone from SIEVE. D)
XIC for the feature later identified as rotenone from SIEVE normalized to TIC.
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Figure 6.4. Database Search Results.

Database hits for A) Human Metabolome Database (http://www.hmdb.ca) and B)
ChemSpider/KEGG (via SIEVE) (ChemSpider alone can also be employed http://www.chemspider.com) using accurate mass determinations for the features
shown in Figures 3B, 3C, and 3D corresponding to the ions of m/z 555.2516 and
395.1481 based on the identification of these ions as [MH]+ species.

Figure 6.5. HR/MS/MS Structural Confirmation.

Confirmation of identification of the feature corresponding to the ion at 395.1481 m/z
with a retention time of 23.22 min as rotenone based on UPLC-MS/MS comparison to a
commercial standard with A) similar retention time and B) the same m/z (395.1481,
~0ppm error) with nearly identical fragmentation.
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Table 6.2: [MS Settings]

General and compound optimized mass spectrometer settings used for the LTQ XLOrbitrap with a Michrom Thermo Advance captive spray ESI source.

6.5 Discussion
Untargeted metabolomics offers a powerful tool for investigating endogenous or
xenobiotic biotransformations, or capturing a metabolic profile from a sample of
interest. The output of the technique scales with the resolution and sensitivity of the
technology used to separate and analyze the sample, the ability to deal with the large
datasets generated, and the ability to mine the dataset for useful information (e.g.
accurate mass database searching). Recently, this has been facilitated by advances in
high resolution mass spectrometers, and high- or ultra-performance liquid
chromatography. Differential analysis software has addressed the analysis bottleneck,
and can accomplish peak detection adjustment for retention time shifts, filtering, and
statistical analysis with high-throughput.(202-204) Selection of the proper informatics
pipeline should include considerations as to data centroiding algorithms, peak
detection, peak integration, alignment, ability to integrate MS/MS data, and ability to
deal with isotopes or adducts.(205) Selection of appropriate cheminformatics databases
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should also be considered.(206-209) The current inadequacy of any particular database
to comprehensively identify compounds and integrate accurate mass data, MS/MS data,
or LC data remains a major problem in the field.
The workflow presented here integrates liquid-liquid extraction, micro-flow
liquid chromatography, and high resolution mass spectrometry with two different
differential analysis software platforms demonstrated in a cell culture treatment model.
Additionally, extraction protocols are listed for serum and tissue, as these may serve as
useful samples for similar analysis.
Although any method used for untargeted metabolomics should be optimized
for repeatability, stable UPLC conditions, and source stability, some variation is
inevitable. Both SIEVE and XCMS allow correction for retention time shift, but special
attention should be paid to ensure that the parameters set in the experiment are
adequate to correct variation. Also, stable isotope labeled internal standard(s) can be
easily integrated into this procedure to reduce artifacts and inter-sample variation
caused by differences in sample extractions or LC-MS analysis.(159) As with all sensitive
LC-MS methodology, it is crucial to use high purity reagents, and ensure that the sample
preparation removes undesirable particulate matter or aggregate. Artifacts can be
generated by the normal variation in contaminants, and it may be desirable to confirm
that putative hits are not in fact ubiquitous contaminants of the extraction or analysis
process.
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Lastly, although the method is labeled as “untargeted” or “unbiased”
metabolomics, this is a partial misnomer. The nature of the extraction, separation, and
analysis will favor metabolites with certain characteristics including stability during
extraction, interaction with stationary and mobile phases during separation, and
ionization at the source of the mass spectrometer.(210-212) Depending on the
available instrumentation, this procedure can be adapted to different extractions, flow
rates, LC pressures, ion sources, or mass spectrometers. Therefore, we have included
notes in the procedure where certain conditions can be optimized based on general
knowledge or internal standards representative of a class of molecules of interest.
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Name of the
reagent
Phosphate
Buffered Saline
Water (H2O)
Acetonitrile
(CH3CN)
Methanol (CH3OH)
Isopropanol
Chloroform
(CH3Cl)
Dichloromethane
(CH2Cl2)

Company

Comments
(optional)

Mediatech

Catalogue
number
21-031-CM

Fisher Scientific
Fisher Scientific

W7-4
A996-4

(optima)
(optima)

Fisher Scientific
Fisher Scientific
Sigma-Aldrich

A454-4
A464-4
366927

(optima)
(optima)
Hazard

Acros Organics

61030-1000

To replace
chloroform
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Diethyl Ether

Sigma-Aldrich

346136

Formic Acid (FA)
NH4OH
Ammonium
formate
(HCOONH4)
MicroSpin C18
Columns
Pasteur Pipets
10mL Glass
Centrifuge Tubes
10mL Plastic
Centrifuge Tubes
LC Vials (glass)
LC Inserts (glass)
LC Vials (plastic)
0.22m Filters
2mL Eppendorf
Tubes

Fisher Scientific
Fisher Scientific
Sigma-Aldrich

A470-250
78314

Nest Group Inc

SS18V

Fisher Scientific
Kimble Chase

13-678-200
73785-10

CellTreat

CLS-4301-015

Waters
Waters
Waters
Corning
BioExpress

60000751CV
WAT094171
186002640
8169
C-3229-1

Name of
equipment
High Resolution
Mass
Spectrometer
HPLC/UPLC

Company

Catalogue
number
LTQ XL-Orbitrap

Thermo Scientific

Waters

Source

Michrom

Differential
Analysis Software
nanoACQUITY C18
BEH130

Thermo Scientific

nanoACQUITY
UPLC
Thermo Advance
Source
SIEVE 2.0

Waters

186003546

Acentis Express C8

Sigma-Aldrich

54262

To replace
chloroform
(optima)
(optima)

nylon
Low Retention

Comments
(optional)

1.7 μm particle
size, 150 mm x
100 μm
2.7 μm particle
size, 15 cm ×
200 μm
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Table 6.3. Specific reagents and equipment

Chapter 7. Saturation and Coenzyme A Thioester Formation of
11- and 15-oxo-eicosatetraenoic Acid

In preparation for submission as: Saturation and coenzyme A thioester formation of 11and 15-oxo-eicosatetraenoic acid. Nathaniel W. Snyder, Alejandro D. Arroyo,
Clementina A. Mesaros, Suhong Zhang, Xiaojing Liu, Ian A. Blair

Abstract
Arachidonic acid metabolism by cyclooxygenase-2 (COX-2) and 15hydroxyprostaglandin dehydrogenase (15-PGDH) results in the formation of 11-oxo- and
15-oxo-eicosatetraenoic acid (oxo-ETE). Both 11-oxo- and 15-oxo-ETE have been
found in human specimens; however their further metabolism remains unknown. This
lack of understanding limits the biological measurement of these metabolites, as well as
hindering elucidation of their function. In this study, we describe metabolic pathways for
both 11-oxo- and 15-oxo-ETE including reduction of double bonds and thioester
formation. Using an untargeted liquid chromatography mass spectrometry (LC-MS)
approach we identify a mono-saturated product of both 11-oxo- and 15-oxo-ETE. We
also identify a di-saturated product of 11-oxo-ETE. We confirm these findings using LCMS/MS and treatment with aracidonic acid, [13C20]-15-oxo-ETE, as well as the methylester of 11-oxo-ETE. Time course experiments show that these metabolites
accumulate after treatment with the parent compounds. Examination of the Michael
addition adducts of the parent compounds and metabolites showed that the -
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unsaturated ketone moiety was absent in the doubly saturated product. With a targeted
LC-MS/MS approach we also describe the formation of CoA thioesters of both 11-oxoand 15-oxo-ETE. Subsequently, we demonstrate that these acyl-CoA species undergo
up to 4 double bond reductions. These findings should facilitate the further study of polyunsaturated fatty acid metabolism in inflammatory diseases and cancer.

Introduction
Cyclooxygenases are major enzymes responsible for the generation of bioactive
lipids from the preferred precursor arachidonic acid (AA) (22). The resulting products
are responsible for a vast array of cellular responses through families of G-coupled
protein receptors (GPCRs) (6). Evidence for non-GPCR mediated signaling exists
(12,16,17,136,145,163), but is still controversial for some mediators (11). The diversity
of physiological responses therefore stems from relatively small alterations in the
structure of the parent molecule. Oxidation, reduction, cyclization, isomerization, and
conjugation can fundamentally alter the function of eicosanoids. Certain transformation
result in changing of the affinity for receptors, increasing clearance, or effectively
inactivating a functionality of a given molecule (40).
The AA oxidation product 11-oxo-eicosatetraenoic acid (11-oxo-ETE) is
generated by the sequential action of cyclooxygenases (COX), peroxidases, and 15hydroxyprostaglandin dehydrogenase (15-PGDH) on free AA (129). The known
intermediates of this pathway are the unstable 11-hydroperoxyeicosatetraenoic aicd (11HPETE) and the stable product 11- hydroxyeicosatetraenoic acid (11-HETE) (27). 15oxo-ETE can be generated by a COX/15-PGDH pathway from free AA or a 15-LOX/15-
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PGDH or 12/15-LOX/15-PGDH pathway from free or esterified AA (83,108). The further
metabolism of these molecules however remains poorly described.
In human cancers and inflammatory conditions, COX-2 and 15-PGDH are
counter-regulated, whereby COX-2 expression is increased and 15-PGDH levels are
reduced (42,88,142). Electrophilic -unsaturated ketone containing fatty acids derived
from -6 and -3 polyunsaturated fatty acids have anti-proliferative, anti-inflammatory,
and redox signaling properties (12,108,118,129,136). The involvement of oxidized
phospholipids in atherosclerosis and inflammation also warrant interest in the
metabolism of oxidized lipids (213).
A more complete understanding of the metabolism of these molecules is needed
to understand the roles such lipids may play in normal and pathological function.
Understanding the exact biotransformation will facilitate identification of the responsible
enzyme(s). A variety of distinct fatty acid metabolizing enzymes exist with varying
specificity for substrate and reaction (40). Furthermore, the lack of an identified GPCR
for either 11-oxo- or 15-oxo-ETE complicates the elucidation of their biological function.
The possibility that the terminal signaling metabolite generated through 11-oxo- or 15oxo-ETE is not in fact the oxo-eicosatetraenoic acid cannot yet be discounted.
Due to the involvement of endothelial cells in eicosanoid metabolism,
atherosclerosis, tumor angiogenesis, inflammatory responses, and relevance to redox
signaling we chose to study the metabolism of 11-oxo- and 15-oxo-ETE in human
umbilical vein endothelial cells (HUVECs). We also employ a COX-2/15-PGDH stably
expressing human colon adenocarcinoma cell line (LoVo) that was used in previous
studies of 11-oxo- and 15-oxo-ETE (129). Through a combination of targeted and
untargeted approaches, we examined 11-oxo- and 15-oxo-ETE metabolism.
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Specifically, we investigated the interdependent saturation and CoA thioester formation
of 11-oxo- and 15-oxo-ETE.

Materials and Methods
Reagents. 11-oxoeicosatetranoic acid (11-oxo-ETE), 15-oxoeicosatetranoic acid (15oxo-ETE), 11-oxo-eicosatetranoic acid methyl ester (11-oxo-ETE-ME), 15-oxoeicosatetranoic acid methyl ester (15-oxo-ETE-ME) and the [13C20]-labeled 15-oxo-ETE
internal standard were synthesized in-house as previously reported (129). Peroxide free
arachidonic acid (AA) was purchased from Cayman Chemical (Ann Arbor, MI). 5sulfosalicilic acid (SSA), ammonium formate solution, glacial acetic acid, and dimethyl
sulfoxide (DMSO) were purchased from Sigma-Aldrich (St. Louis, MO). HPLC grade
chloroform and ammonium acetate as well as Optima LC-MS grade methanol,
acetonitrile, water, isopropanol, ammonium acetate, ammonium formate, and formic acid
were purchased from Fisher Scientific (Pittsburgh, PA). 2-(2-pyridyl) ethyl functionalized
silica gel (100 mg/mL) tubes were obtained from Supelco Analytical (Bellefonte, PA). F12K media, medium 200, low serum growth supplement (LSGS) kit, human umbilical
vein endothelial cells (HUVECs), streptomycin, and penicillin were purchased from
Invitrogen (Carlsbad, CA). Fetal bovine serum (FBS) was from Gemini Bioproducts
(West Sacramento, CA). Human colorectal adenocarcinoma cells (LoVo and HCA-7)
were obtained from ATCC (Manassas, VA).
Untargeted discovery. HUVECs were grown until 80% confluence on Collagen IV
coated plates from Becton Dickinson (Bedford, MA), and maintained in medium 200
supplemented with low serum growth supplement (LSGS) kit (Invitrogen). Cells were
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treated with 10 M 11-oxo-ETE, 11-oxo-ETE-ME, 15-oxo-ETE, or 15-oxo-ETE-ME in
0.25% DMSO containing media. An initial treatment time of 90 minutes at 37˚C was
chosen based on previously published uptake data (129,214). Extraction was performed
as previously described with minor modifications (137). Cells were gently lifted, mixed,
and an aliquot of the resulting suspension was transferred to a glass tube. Folch
extractions were performed with 2:1 chloroform:methanol with 0.1% acetic acid. The
organic phase was evaporated to dryness under N2. The samples were dissolved in
70:30 water:acetonitrile with 0.1% formic acid then filtered using 0.22 m nylon
centrifuge filters (Costar) and transferred into HPLC vials for LC-HRMS analysis.
Metabolic time course. HUVECs were grown as above. Media containing 0.25%
DMSO with 10 M 11-oxo-ETE, 11-oxo-ETE-ME, 15-oxo-ETE, or 15-oxo-ETE-ME was
added. Cells were incubated at 37˚C for 5 min, 30 min, 1.5 h, 3 h, 6 h or 9 h. At each
time point, 450 L of the supernatant media was collected and transferred to a glass
tube. The cells were gently scraped in the remaining 450 L of media and transferred to
a glass tube. 2.5 ng of [13C20]-15-oxo-ETE was added as an internal standard and,
subsequently, Folch extractions were performed as previously described with minor
modifications (215). The organic phase was evaporated to dryness under N2. The
samples were dissolved in 100 M70:30 water:acetonitrile with 0.1% formic acid then
filtered using 0.22 m nylon centrifuge filters and transferred into HPLC vials for LCHRMS analysis.
Acyl-CoA analysis. Human colorectal adenocarcinoma cells (LoVo) were grown to
80% confluence in F-12K media with 2% FBS and 100,000 units/L penicillin and 100
mg/L streptomycin. HUVECs were grown as above. Extraction and analysis were
performed as previously described (177,180). Briefly, cells were gently lifted, and the
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resulting suspension was centrifuged at 500 x g at 4˚C. The supernatant was removed,
and the pellet was suspended in 750 L of 3:1 acetonitrile:isopropanol (ACN:IPA). The
suspension was sonicated with a probe tip sonicator to disrupt the cellular membranes.
250 L of 100 mM KH2PO4 (pH 6.7) was added, the suspension was vortexed, and then
centrifuged at 16000 x g at 4˚C. The resulting supernatant was transferred to a glass
tube and acidified with 125 L glacial acetic acid for solid phase extraction. 100 mg 2(2-pyridyl)ethyl-functionalized silica gel solid phase extraction columns (Sigma) were
equilibrated with 1 mL 9:3:4:4 ACN:IPA:H2O:acetic acid. Supernatants were transferred
to the column and filtrated. The columns were washed two times with 1 mL of the
9:3:4:4 mixture. The columns were eluted two times with 500 µL 4:1 methanol:250 mM
ammonium formate into glass tubes. Filtrate was evaporated to dryness under N2. The
dry samples were dissolved in 50 µL of 70:30 water:acetonitrile with 5% SSA (w/v) and
transferred to HPLC vials.
Liquid chromatography. For LC-HRMS analysis, LC separations were conducted as
previously described (215) using a Waters nano-ACQUITY UPLC system (Waters Corp.,
Milford, MA, USA). A Waters XBridge BEH130 C18 column (100 m × 150 mm, 1.7 m
pore size; Waters Corp) was employed for reversed phase separation (flow-rate 1.8
L/min) with a 3 L injection. For gradient 1, solvent A was 98/2 water/acetonitrile (v/v)
with 0.1% formic acid, and solvent B was 99.5/0.5 acetonitrile/water (v/v) with 0.1%
formic acid. The gradient was as follows: 2% B at 0 min, 2% B at 3 min, 3.6% B at 11
min, 8% B at 15 min, 8% B at 27 min, 50% B at 30 min, 50% at 35 min, and 2% B at 37
min. Separations were performed at 30 °C. For gradient 2, Solvent A was 4/6
water/acetonitrile (v/v) with 0.1% formic acid, 10 mM ammonium formate and solvent B
was 1/9 acetonitrile/isopropanol (v/v) with 0.1% formic acid, 10 mM ammonium formate.
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The gradient was as follows: 30% B at 0 min, 30% B at 6 min, 60% B at 11 min, 60% B
at 15 min, 80% B at 27 min, 80% B at 30 min, 85 % at 35 min, 85 % at 45 min, 30 % at
47 min, and 30% B at 55 min. Separations were performed at 50 °C.
For targeted acyl-CoA analysis, samples were maintained at 4°C in a Leap CTC
autosampler (CTC Analytics, Switzerland) during sample batch runs. 10 L injections
were used for LC-MS analysis. Chromatographic separation was performed using a
reversed phase Waters XBridge BEH130 C18 column (2.1 x 150 mm, 3.5 m pore size)
on an Agilent 1100 HPLC system using a three solvent system: (A) 5 mM ammonium
acetate in water, (B) 5 mM ammonium acetate in 95/5 acetonitrile/water (v/v), and (C)
80/20/0.1 (v/v/v) acetonitrile/water/formic acid, with a constant flow rate of 0.2 mL/min.
Solvent C was used after analysis to wash the column. The gradient was as follows: 2%
B at 0 min, 2% B at 1.5 min, 20% B at 5 min, 100% B at 5.5 min, 100% B at 13.5 min,
100% C at 14 min, 100% C at 19 min, 2% B at 20 min and 2% B at 25 min.
Mass spectrometry. For LC-HRMS analysis, an LTQ XL-Orbitrap hybrid mass
spectrometer (Thermo Fisher) was used in positive ion mode with a Michrom captive
spray ESI source as previously described (215). For gradient 1 from above, the
operating conditions were: spray voltage at 4 kV; capillary temperature at 250°C;
capillary voltage at 35 V, tube lens 60 V. For gradient 2, the operating conditions were:
spray voltage at 1.5 kV; capillary temperature at 200°C; capillary voltage at 0 V, tube
lens 80 V.
For targeted acyl-CoA analysis, samples were analyzed using an API 4000 triple
quadrupole mass spectrometer (Applied Biosystems, Foster City, CA) in the positive
electrospray ionization (ESI) mode and analyzed using Analyst software as previously
described (177). The column effluent was diverted to waste before 8 min and after 18
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min. The mass spectrometer operating conditions were as follows: ion spray voltage
(5.0 kV), compressed air as curtain gas (15 psi) and nitrogen as nebulizing gas (8 psi),
heater (15 psi), and collision-induced dissociation (CID) gas (5 psi). The ESI probe
temperature was 450°C, the declustering potential was 105 V, the entrance potential
was 10 V, the collision energy was 45 eV, and the collision exit potential was 15 V. CoA
thioesters were monitored using SRM (selected reaction monitoring mode) as previously
published (179).

Results
Untargeted discovery reveals distinctive patterns of biotransformation of the oxoETEs in HUVECs. To determine possible routes of biotransformation of 11-oxo-ETE
and 15-oxo-ETE, HUVECs were treated for 90 minutes with 10 M of the parent
compound in 0.25% DMSO. A biphasic Folch extraction was then performed on the
lifted cell suspension to capture a broad range of intra- and extra-cellular metabolites.
LC-HRMS was carried out in an untargeted manner on the extracted lipid and aqueous
fractions. Analysis of differential abundant features was carried out by SIEVE 2.0,
metaboanalyst 2.0, and XCMS (194,216). Metabolic discovery experiments conducted
in HUVEC cells revealed a diversity of differentially abundant features from the lipid
fraction, with markedly less features in the aqueous fraction as demonstrated by the
respective cloud plots generated with XCMS (S Fig. 1). A ranked list by fold change
versus control using a t-test (Welch’s unpaired) p-value cut-off of p < 0.01 was
generated. Top hits from both programs were manually inspected; chromatograms were
extracted from representative raw data samples (Fig. 1).
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Two sequential mass shifts of +2 amu and an increased retention time were
chosen for follow up targeted analysis for 11-oxo-ETE (Fig. 1A). Only one +2 amu shift
was observed for 15-oxo-ETE (Fig. 1B). Interestingly, the free acid of 11-oxo-ETE
demonstrated one major saturation and one minor second saturation, however, the
methyl-ester of 11-oxo-ETE showed only one +2 amu shift (Fig. 1D). These putative 15oxo-ETE metabolites were confirmed by treatment with [13C20]-15-oxo-ETE, and a
resulting heavy isotope labeled metabolite was found with the same pattern of mass and
retention time shift (Fig. 1C). This pattern of retention time and mass shift seems
logically indicative of a reduction in double bonds. Accurate mass and isotope patterns
matched predicted values for both parent and saturated compounds for 11-oxo-ETE and
15-oxo-ETE in positive and negative ion mode (Supplemental Figure 3 and data not
shown).
Time course studies reveal accumulation of reduced metabolites. To further
describe the dysregulated features, time course studies were carried out using a
targeted approach. Cells were treated as above, using 11-oxo-ETE, 15-oxo-ETE, and
their methyl esters. Extractions were done over a multi-hour time course to examine the
change in levels of targeted metabolites. [13C20]-15-oxo-ETE stable isotope standard
was spiked into all extractions to allow quantitation of the metabolites (Fig. 2). The
internal standard co-eluted with 15-oxo-ETE (Fig. 2). The area of the target peak was
integrated and quantified as a ratio over the area of the internal standard peak. Values
were expressed as a fold change log10 for each time point in order to cover the range of
observed change in signal (Fig. 3). The methyl-ester treated cells showed an order of
magnitude amplification in the accumulation of metabolites compared to cells treated
without the methyl ester derivatives of 11- and 15-oxo-ETE (Figs. 3B, 3D). This was in
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line with our previous work demonstrating that treatment with the methyl esters
increased the intracellular pool of the free acid (214).
MS/MS of parent oxo-ETEs and saturated metabolites. MS/MS experiments were
carried out in both positive and negative mode. (Supplemental Figure 3) Under negative
ESI conditions, both mono-saturated oxo-ETEs exhibited an intense parent ion at m/z
319.2270 (δ = 2.8ppm). (Supplemental Figure 3) The bis-saturated metabolite
corresponding to 11-oxo-ETE+4 amu showed m/z 321.2424 (δ = 3.4ppm). The 11-oxoETE MS/MS spectrum exhibited m/z 165.1283 (δ = 0.6ppm) that is formed by αcleavage to the carbonyl at position 11, and thus it retains the original double bonds from
C12 and C14. In the MS/MS spectrum of the mono-saturated 11-oxo-ETE, the fragment
corresponding to one double bond being reduced in the same fragment was found at
m/z 167.1442 (δ = 0.4ppm) (Supplemental Figure 3). This indicates that the first
saturation happens to positions C12 or C14. Consistent with this finding, the molecular
fragment m/z 167.1076 (δ = 0.4ppm)

from 11-oxo-ETE, that corresponds to the

fragment containing the initial double bonds at C 5 and C8, did not have a corresponding
ion in the MS/MS spectrum of the 11-oxo-ETE mono-unsaturated (m/z 169.1234). This
further indicated that the first reduction did not occur at the position C5 or C8. The
hypothesis that the first reduction happens to positions C12 or C14, was supported by
the MS/MS data in positive mode. The m/z 217.1587 fragment, that contained the two
double bonds at position C12 and C14, had a similar ion m/z 219.1742 in the monosaturated 11-oxo-ETE, indicating a similar first reduction at one of these positions.
The negative ion MS/MS spectrum of 15-oxoETE was identical with published
CID spectrum by Murphy, et. al (217). The MS/MS spectrum of the monosaturated 15oxoETE contained multiple different fragments that showed a mass increase of 2 amu.
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Unfortunately, the best described fragmentation of oxo-ETEs is due to the breaking of
the double bond allylic to the carbonyl moiety. This generates the fragments 113.0977,
corresponding to the part of the molecule without any double bond, and 219.1394,
corresponding to the part of the molecule containing all the double bonds. The MS/MS
spectrum of the mono-saturated 15-oxoETE showed the same fragment 113.0977
indicating that the first reduction did not occur at C13. The fragment corresponding to
219.1394 shifted to 221.1549 consistent with the first reduction taking place to one of the
initial double bonds at C5, C8 or C11. As discovered by the use of deuterium and
oxygen labeled compounds there are simultaneous mechanisms of ion formation in the
MS/MS spectra of oxo-ETEs, resulting in isobaric fragments derived from different
fragmentation (217). Even if different fragment ions from the MS/MS spectrum of 15oxo-ETE showed the corresponding ions + 2 amu in the monounsaturated spectrum
(Supplemental Figure 3), would be highly speculative to propose the place of the double
bond reduction just based on the MS/MS data.

Michael addition adducts of the parent and saturated products reveal position of
double bond reduction. In order to examine the position of the double bond reductions
in the metabolites, the formation of 1,4-Michael adducts was monitored by LC-HRMS.
Lipid extracts from treated HUVECs were treated overnight with 5% (v/v) BME at 37°C to
adduct any -unsaturated ketone containing compounds (Figs. 4B, 4D). Control
treated extracts were treated with 5% (v/v) water and treated identically overnight (Figs.
4A, 4C). Treatment of the 11-oxo-ETE containing extracts reduced the parent and
mono-saturated products by over one order of magnitude (Figs. 4A, 4B). In contrast, the
doubly saturated product gave a strong peak in both control and BME treated samples
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(Figs. 4B, 4D). These findings indicate that the parent and monosaturated product still
contain the -unsaturated ketone with the double bond at carbon 12. This is in
contrast to the disaturated product of 11-oxo-ETE where one of the two reduced double
bonds appears to occur at C12 resulting in the loss of the -unsaturated ketone
moiety.
The formation of GSH-adducts from treated HUVECs was also examined by LCHRMS. GSH-adducts were observed for the parent and monosaturated 11-oxo-ETE
(Figs. 5A), as well as the parent and monosaturated 15-oxo-ETE (Figs. 5B). The same
pattern was observed for the GSH-adduct of [13C20]-15-oxo-ETE (Figs. 5C). Agreeing
with the BME adduction, no GSH-adduct was observed for the doubly saturated 11-oxoETE metabolite (Figs. 5A). These data agree with the BME adduction results and
indicate a second reduction of a double bond in 11-oxo-ETE abolishes the unsaturated ketone.
Targeted acyl-CoA analysis reveals thioester formation and saturation. The
observation of a second reduction in 11-oxo-ETE prompted further experiments to
understand the nature of this biotransformation. A cytosolic prostaglandin reductase has
been described for prostanoids with a double bond between carbons 13 and 14.
However, description of a second saturation is to the author’s knowledge unknown. The
possibility of mitochondrial metabolism for the oxo-ETEs was therefore raised. Using a
previously described method for analysis of acyl-coenzyme A thioesters, we investigated
the possibility of a oxo-ETE-coenzyme A thioester as had been described for similar
oxidized fatty acids (166).

142
A proof-of-principle experiment was conducted using LoVo cells treated with
DMSO vehicle control or 25 M AA (Fig. 6). LC-MS experiments using the CoA
stereotypical neutral loss of 507 DA revealed an induction of acyl-CoA species. A strong
peak at 1054 m/z corresponding to arachidonoyl-CoA was induced in the treatment
versus the control. Interestingly, a peak at 1068 m/z was also observed, which would
correspond to a oxo-ETE-CoA thioester (Fig. 6B).
To confirm this initial observation and test if the saturated products previously
observed also formed CoA thioesters we treated LoVo cells with 25 M AA, 10 M 11oxo-ETE, 10 M 11-oxo-ETE-ME, or 10 M 15-oxo-ETE. Using our previously
described extraction methodology, we used LC-SRM/MS with transitions corresponding
to the distinct CoA neutral loss of 507 amu fragmentation for the oxo-ETE-thioester with
zero to four saturations (Fig. 7). In contrast to the free acid, we observed peaks in more
than two channels.
To further investigate the nature of the saturation, we treated two human colon
adenocarcinoma lines, LoVo and HCA-7, with 11-oxo-ETE and observed the saturation
of the 11-oxo-ETE-CoA thioesters over time. In order to provide a semi-quantitative
analysis, heavy labeled arachidonoyl-CoA was generated as previously described (179)
and used as an internal standard for normalization and spiked into the sample before
extraction. The patterns of saturation observed was different between the two cell lines,
where detectable amounts of all four saturations were seen in the LoVo cells, with only 2
saturations at maximum seen in the HCA-7 cells.
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Discussion
The study of metabolism of eicosanoids has mostly focused on the generation of
bioactive lipids. The transformation of the initial products remains less well described.
Existing literature on eicosanoid metabolism for COX/15-PGDH products has focused on
PGE2 and its 15-PGDH dependent product 15-keto-PGE2. A second level of
transformation via a double bond reduction forms the product 13,14-dihydro-15-ketoPGE2. However, the COX/PGDH pathway also produces 11-oxo- and 15-oxo-ETE. 15oxo-ETE can also be generated by 15-LOX/PGDH metabolism. Existing work on the
metabolism of 15-oxo-ETE has described the generation and signaling of complex lipids
integrating 15-oxo-ETE (218). In this work, we expand the knowledge of these pathways
to include additional downstream products.
Our untargeted metabolomics approach revealed a distinct pattern of limited
saturation for 11-oxo- and 15-oxo-ETE. The similar metabolism of [13C20]-15-oxo-ETE,
as well as time course studies support the identification of the metabolites are
derivatives of the parent oxo-ETEs. By examining the formation of Michael adducts,
including BME and GSH adducts, we were able to discern the status of the double bond
proximal to the carbonyl in the -unsaturated ketone moiety of the oxo-ETEs. The
parent and predominant first saturation of 11-oxo- and 15-oxo-ETE maintain the unsaturated ketone moiety. However, the second saturation of 11-oxo-ETE no longer
forms a BME or GSH adduct, indicating the double bond at C12 adjacent to the carbonyl
has been reduced. The enzymatic basis of this transformation warrants investigation as
the -unsaturated ketone moiety has been associated with bioactivity in related
molecules.
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Saturation of mono- or poly-unsaturated fatty acids has been described through
mitochondrial metabolism. However, description of eicosanoid thioesters is lacking in
the literature. Although we extended our discovery method to specifically look for CoA
thioesters of PGE2 and the proximal metabolites 15-keto-PGE2 and 13,14-dihydro-15keto-PGE2, we could not detect any of these products (Figure 6B and data not shown).
We also fail to detect the CoA thioester of the 11-oxo-ETE-methyl ester (data not
shown). This further supports the hypothesis that the identified product is in fact a
thioester via the carboxylic acid group. This distinction is important since the unsaturated ketone moiety could result in a 1,4-Michael addition product as identified in
our previous work on covalent adduction to a nucleophilic amino acid.
The limited saturation of free 11-oxo-ETE and 15-oxo-ETE and the pattern
observed for the CoA thioesters may be relevant to wider metabolism. For the
saturation of the CoA thioester we detect up to the full four possible saturation events,
which may indicate a difference in mitochondrial versus cytosolic enzyme activity or
substrate specificity for only the CoA thioester.
Ultimately, design of therapeutic interventions to modulate or mimic the effects of
these molecules could be enabled by a complete elucidation of the pathways of
metabolism. This could facilitate the discovery of inhibitors or for the design of stable
derivatives. As additional benefit, identification of these novel metabolites may
contribute to the ongoing efforts in untargeted metabolomics and an increased
appreciation of specificity in lipidomics experiments.
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Figure 7.1. Extracted ion chromatograms of LC-HRMS analysis of lipid extract
from oxo-ETE treated HUVECs. Mass spectral features from the discovery experiment
were extracted from representative chromatograms with a 5 ppm mass window from the
given m/z from positive ion mode LC-HRMS analysis of lipid extracts of HUVECs treated
with (A) 11-oxo-ETE, (B) 15-oxo-ETE, (C) [13C20]-15-oxo-ETE, or (D) 11-oxo-ETE-ME.
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Peaks putatively corresponding to reductions in double bonds (saturations) were
apparent for one and two saturations in 11-oxo-ETE. Only one saturation was
detectable for 15-oxo-ETE and [13C20]-15-oxo-ETE. 11-oxo-ETE-ME treatment revealed
a similar pattern of saturation as observed for 11-oxo-ETE, except the methyl ester itself
was only mono-saturated.

Figure 7.2. Representative stable isotope dilution-LC-HRMS chromatograms of
parent and putative metabolites. Co-elution of 15-oxo-ETE and [13C20]-15-oxo-ETE
was observed as well as baseline separation of 11-oxo-ETE from [13C20]-15-oxo-ETE.
Extracted ion chromatograms within a 5 ppm window of (A) 11-oxo-ETE and the
suspected monosaturated and disaturated products (B) 15-oxo-ETE and the suspected
monosaturated product.
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Figure 7.3. Time course of accumulation of free oxo-acid metabolites in lipid
extracts from HUVECs. Accumulation of putative metabolites after treatment with 10M
(A) 11-oxo-ETE, (B) 11-oxo-ETE-ME, (C) 15-oxo-ETE, or (D) 15-oxo-ETE-ME. Area
under the curve was calculated from XICs of metabolites. [13C20]-15-oxo-ETE was used
as the internal standard and to normalize for extraction and ionization efficiency for
relative quantitation. Values are expressed in Log Area under the peak for
(Analyte/ISTD) to capture the full range of values over the timecourse.
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Figure 7.4. LC-HRMS chromatograms of mock and BME treated oxo-ETE samples
for parent oxo-ETEs and metabolites. Lipid extracts of treated HUVECs were treated
with or without 5% volume/volume BME overnight at 37°C. (A) 11-oxo-ETE treated
samples without BME, (B) 11-oxo-ETE with BME, (C) 15-oxo-ETE without BME (D) 15oxo-ETE with BME. Panel (E) shows the reaction of 11-oxo-ETE with BME and the
resulting adduct.
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Figure 7.5. LC-HRMS chromatograms of GSH-adducts from parent and saturated
products of oxo-ETEs. Aqueous phase of Folch extraction from treated HUVECs were
analyzed by LC-HRMS after desalting. A 5 ppm mass window around the GSH-adduct
is shown for (A) 11-oxo-ETE and saturated products (B) 15-oxo-ETE and its
monosaturated product, (C) [13C20]-15-oxo-ETE and its monosaturated product.
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Figure 7.6. Neutral loss of 507 Da scans show inducible acyl-CoA species. Neutral
loss scans of 507 Da of (A) DMSO (B) 25 M AA treated LoVo cells.
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Figure 7.7. LC-MS/MS chromatograms for oxo-ETE-acyl-CoA species and reduced
metabolites. Extracted ion chromatograms of acyl-CoA LC-MS/SRM analysis from
LoVo Cells treated with (A) 25 M AA treated LoVo cells (B) 10 M 11-oxo-ETE (C) 10
M 15-oxo-ETE (D) 10 M 11-oxo-ETE-ME. The m/z transitions corresponding to the
reduction of 0-4 double bonds were monitored (1068561, 1070563, 1072565,
1074567, 1076569). Panel (E) shows the structures of 11-oxo-ETE-CoA and 15oxo-ETE-CoA.
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Figure 7.8. Time course of 11-oxo-ETE-CoA thioesters. Quantification over 4 h of the
parent and saturated products of 11-oxo-ETE-CoA in (A) LoVo cells (B) HCA-7 cells.
SID-LC-MS/SRM were performed using [13C3 15N1]-arachidonoyl-CoA as an internal
standard for quantitation. Values are expressed in Log Area under the peak for
(Analyte/ISTD) to capture the full range of values over the timecourse.
Supplemental Figures

S Fig
7.1. Mirror plots from XCMSonline differential analysis of untargeted LC-HRMS of
(A) organic phase and (B) aqueous phase from 11-oxo-ETE-ME treated HUVECs.
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S Fig 7.2. Background of LC-HRMS analysis of Folch extraction from HUVEC lipid
extract for DMSO treated cells. XICs for a 5 ppm mass window corresponding to the
parent and reduced oxo-ETEs are shown.
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S Fig 7.3. MS/MS determination of reduced double bond positions. (A) Negative ion
mode ESI fragmentation of 11-oxo-ETE. (B) Chromatograms of diagnostic product ions
for 11-oxo-ETE parent and metabolite structural elucidation. (C) Chromatograms of
diagnostic product ions for 11-oxo-ETE parent and metabolite structural elucidation
confirmed by a second LC gradient. (D) LC-CID-MS/HRMS negative ion product ion
scan of 11-oxo-ETE. (E) LC-CID-MS/HRMS negative ion product ion scan of
monosaturated 11-oxo-ETE. (F) LC-CID-MS/HRMS negative ion product ion scan of
disaturated 11-oxo-ETE. (G) LC-CID-MS/HRMS negative ion and LC-HCD-MS/HRMS
product ion scan of 15-oxo-ETE. (H) LC-CID-MS/HRMS negative ion and LC-HCDMS/HRMS product ion scan of monosaturated 15-oxo-ETE. (I) LC-CID-MS/HRMS
negative ion and LC-HCD-MS/HRMS product ion scan of disaturated 15-oxo-ETE.
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Chapter 8: Conclusion and future directions

8.1 Conclusions
The work presented above describes the discovery of a new set of lipid metabolites of
11-oxo-ETE as well as description of the bioactivity and possible mechanistic function of the
parent 11-oxo-ETE. The methodology used for metabolite characterization and quantification
was then applied to the specific public health problem of asbestos exposure. The metabolic
pathway under investigation in this work begins when COX-2 converts the substrate arachidonic
acid into PGG2, 11(R)-HPETE, 15(S)-HPETE and 15(R)-HPETE. The subsequent action of
POXs reduces the unstable hydroperoxide precursors to PGH2, 11(R)-HETE, 15(S)-HETE, and
15(R)-HETE, respectively. From these resulting metabolites, a plethora of other eicosanoids is
generated in an enzyme and/or context dependent manner.
In Chapter 2, the ability of 15-PGDH to oxidize 11(R)-HETE into anti-proliferative 11-oxoETE is described. The LoVo colon cancer adenocarcinoma cell model was used to clearly
demonstrate that 11-oxo-ETE was rapidly secreted or metabolized by the LoVo cells. Chapter 3
describes an elaboration of the initial findings of rapid export and anti-proliferative action of 11oxo-ETE by design of potent “pro-drug” methyl-ester forms of 11-oxo-ETE and 15-oxo-ETE that
showed increased concentration in the intracellular space and more potent anti-proliferative
effects. Furthermore, these effects were increased by pharmacological blockade of MRP
exporters, which further implicates these exporters in modulating the biological effects of 11-oxoETE. Using the tools described in Chapter 3, the signaling, bioactivity, and mechanistic cellular
action of 11-oxo-ETE on the NF-κB pathway were examined. The findings of these studies are
described in Chapter 4. Inhibition of NF-κB signaling was demonstrated in HUVECs and with a
luciferase reporter assay. A plausible mechanism was elucidated through the characterization of
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an 11-oxo-ETE adduct on the cysteine or histidine residue of the DNA binding domain of a NF-κB
transcription factor protein.
Chapter 5 describes a targeted approach to acyl-CoA analysis, whereby the novel 11oxo-ETE-CoA thioester was discovered. Chapter 6 describes the methodology used for
untargeted metabolomic analysis through nanoflow-ultraperformance liquid chromatography-high
resolution accurate mass-mass spectrometry. The methods described in Chapters 5 and 6 were
applied to the study of 11-oxo-ETE and 15-oxo-ETE metabolism to reveal distinct pathways of
biotransformation. The results of these metabolic studies are described in Chapter 7.
Overall, this thesis reports the evolution of studies that initially involved the specific
problem of understanding how an endogenous metabolite exerted its anti-proliferative effects on
cancer cells. When existing methodologies failed to further the understanding of the problem,
new methodologies were developed. Untargeted and targeted LC-MS based approaches for
sensitive discovery and rigorous quantitation of AA metabolites were developed. The power of
these methodologies was then realized in the elucidation of novel metabolism.
Initial studies involved the targeting a specific metabolite of AA, 11-oxo-ETE, together
with an investigation of its mechanism of formation. Although 11-oxo-ETE belongs to a
physiologically critical and pharmacological important pathway, little previous work had focused
on the specific metabolite itself. Through understanding of the exact enzymology of formation,
the relevance of 15-PGDH as a pharmacological target was supported. The initial kinetic
description of 11-oxo-ETE formation prompted further work to examine its disposition and
bioactivity. This required the generation and testing of specific chemical tools, which might be
useful to the study of related molecules, or for therapeutic uses. The chemical tools developed in
the initial study of 11-oxo-ETE then served as a useful probe in the examination the mechanistic
signaling of 11-oxo-ETE in an inflammatory context. This mechanistic understanding expanded a
broader scientific understanding of the electrophilic fatty acids, and will further the study of other
related molecules for therapeutic and biomarker use. Through use of the most rigorous SID-LC-
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MS/MS, the investigation of the formation and disposition of 11-oxo- and 15-oxo-ETE remained
internally consistent across studies, and externally consistent with existing literature.
In order to examine the further metabolism of 11-oxo-ETE, specific methodological tools
had to be developed. Both untargeted and targeted liquid chromatography-mass spectrometry
approaches were created to study pathways of 11-oxo-ETE metabolism. The application of these
approaches led to identification of novel metabolites. Pathways of biotransformation discovered
for 11-oxo- and 15-oxo-ETE may also play roles in the metabolism of a wide variety of important
lipid mediators.

8.2 Future directions
Considering the complexity of human metabolism, a major limitation of current
methodology is that it focuses on limited numbers of metabolites within a specific context without
consideration of the broader metabolic context (i.e. the other changes within the system). Mass
spectrometry platforms, such as LTQ-Orbitrap, Q-exactive, Tribrid, TripleTOF 5600, Synapt, and
12T FT-ICR all provide high resolution capacity that can facilitate good mass accuracy
(69,152,185,219-221). Expanded dynamic range, and increased sensitivity afforded by such
technological innovation will also drive metabolism research. Supplementing studies with
targeted analysis or complementary techniques such as NMR will also provide increased
coverage and validity to studies (222). The growth of metabolomics software (e.g. XCMS and
SIEVE), bioinformatics platforms with integrated statistical tools (e.g. R and metaboanalyst), and
metabolite databases (e.g. METLIN, ChemSpider, LipidMAPS, and HMDB), together with HRMS,
will make it possible to begin addressing these issues (190,193,194,207,209,216). Improvements
in LC systems, including 2D-LC, and retention time database matching with references standards
will also improve metabolomics.
For metabolic studies of lipids, the current small molecule metabolite databases provide
incomplete coverage (Chapter 8). Therefore, compared to proteomics studies (with more
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sophisticated databases), it is more challenging to assign specific structures to unknown features
observed in an LC-MS chromatogram (Chapter 7 and 8). This is an inherent property of the
enormous diversity of structures that can be encountered with small molecule metabolites
(Chapter 7 and 8), which is also paradoxically what makes global metabolite profiling
(metabolomics) such a necessary tool when confronted with such biochemical complexity.
HRMS based analysis of small molecule metabolites should not be expected to provide accurate
quantitation, complete specificity, or complete structural information in all cases and no single tool
that is currently available is applicable to every experimental design. Besides LC-MS, NMR is
also crucial for unknown metabolite structure elucidation, but suffers from limitations of sensitivity
and capital costs (223). Thus, more basic discovery research into human metabolism (Chapters
1-8) will be required to attain the goal of high confidence assignments from broad coverage
metabolomics data sets on a routine basis. Ultimately, validation with targeted analysis using
rigorous analytical methodology suited for the task (Chapter 5) will still be required (81).
Importantly, the integration of genomics, transcriptomics, and proteomics/posttranslational modifications experiments may provide the complex and enriched data necessary for
understanding feedback relationships and the fine tuning of metabolites in physiology and
disease. In this thesis research, no specific G-coupled protein receptors were identified for any
product along the 11-oxo-ETE or 15-oxo-ETE pathway. Although the first steps in this process
were laid in Chapter 1-7, assignment of an unknown receptor/ligand pair is still one of the most
difficult problems of pharmacology. The integration of multi-dimensional (gene, RNA, protein,
modification, metabolite) –omics data may facilitate this type of identification by virtue of providing
a systems biology approach to narrow down candidate receptors. Additionally, increasing power
of LC-MS platforms may facilitate better chemical probe approaches (224).
Ultimately, the future directions of the work in this thesis are two-fold: the top-down
approach informed from metabolomics driving identification of differentially abundant metabolites
from experimental studies and the bottom-up investigation of newly discovered pathways with
rigorous validation. Both approaches are complimentary, necessary, and scientifically valid when
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conducted with due acknowledgement of the inherent limitations. The historic and ongoing use of
metabolites as putative biomarkers, therapeutics in their own right, and receptor or enzyme drug
targets makes metabolism an attractive area of study for the betterment of human knowledge and
health.
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